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1 Summary 
Normal physiology is not given without immunological tolerance. Depending on the origin 
of induction, tolerance can be divided into central and peripheral tolerance. Central tolerance 
comprises depletion of autoreactive T cells in the thymus (i.e. negative selection), and with 
this prevents autoimmunity. Peripheral tolerance critically depends on regulatory T cells 
(Tregs) maintaining lymphocyte homeostasis. Hallmark features of CD4+ Tregs are the 
expression of high surface IL-2-Rα (CD25) and the transcription factor Forkhead box protein 
P3 (Foxp3). Expression of non-functional Foxp3 results in lethal multi-organ lymphocytic 
infiltrations and cytokine secretions. Numerous data agree on an indispensable role for Tregs 
enabling physiological immunity. Yet an understanding of how Tregs function at a cellular 
and molecular level has not been fully elucidated.  
 
In the first part of the thesis we made use of a RagKO TCR transgenic mouse expressing a 
Foxp3 transgene. This mouse provides a source of monoclonal CD4+, Foxp3+ T cells with a 
defined specificity. We show that monoclonal B3K506 Tregs are fully functional in vitro and 
in vivo and clearly require cognate antigen to be suppressive. We further show that the 
strength of Treg stimulation determines the strength of Treg mediated suppression. Finally 
we analysed various suppressive mechanisms used by monoclonal Tregs and found that 
Treg-Tconv proximity is an important parameter, which correlates with effective 
suppression. 
 
In the second part of the thesis we aimed to understand the molecular mechanism underlying 
the affinity threshold for negative selection. We quantified the amount of Lck coupled to 
CD8 or CD4 coreceptors. We found that CD4 co-receptors have higher Lck coupling ratios 
than do CD8 co-receptors. In addition we determined the absolute numbers of surface 
molecules (i.e. CD8α, CD4 and CD3ε) on double positive (DP) thymocytes in B6 and MHC-
class I restricted, TCR Tg mouse strains. A model, explaining how the TCR measures 
antigen affinity to initiate a negative selection signal, was generated. Here we show that the 
affinity threshold for different co-receptors depends on the probability that a peptide-MHC-
TCR complex will collide with a co-receptor carrying Lck during the time pMCH binds to 
the TCR (Stepanek, O. et al. Cell, 2014)  
 
Introduction 
 6 
2 Introduction 
2.1 Tolerance, resistance and immunity 
The every day challenge of our immune system is to fight unwanted pathogen invasion 
while maintaining tolerance to self and important commensals. Immunity is the balanced 
state between tolerance and resistance, which every healthy individual critically depends 
on. Affected immunity results in infections, autoimmune diseases and malignant 
conditions, which can ultimately lead to death.  
The gut represents an ideal example to illustrate immunity. Here, digestion and nutrient 
up take critically depend on immune tolerance promoting commensalism. Resistance to 
gut microbiota has devastating consequences for the host. Lymphocyte invasion and 
tissue damage by inflammatory mediators cause a breakdown of the gut mucosal barrier, 
leading to nutrient malabsorption and dangerous microbial invasion of former sterile 
tissues. Unless adequately treated, septic colitis usually kills the host.  
However, tolerating virulent pathogens also provokes severe damages. Exponential 
pathogen growth and loss of important resources or toxin secretion harms the host. 
Elimination of virulent pathogen induces short-term pain and swelling in the affected 
tissue. The benefit of resisting pathogen invasion and preventing parasitism results in 
survival. Nevertheless, establishing immune resistance fighting foreign 
antigens/pathogens can be a trigger for unwanted immune reactions toward self. Failed 
discrimination between self and foreign antigens, or breakdown of tolerance inducing 
mechanisms, can lead to allergic reactions and autoimmune diseases.  
 
 
2.2 Central tolerance 
Long-lasting protective immunity is provided through our adaptive immune system and 
mediated by specific B and T lymphocyte responses against antigens. T lymphocytes 
derive from a multi-potent hematopoietic stem cell in the bone marrow. T cell precursors 
migrate to the thymus where they further develop and differentiate into T cell receptor 
expressing, mature single positive CD8 or CD4 thymocytes. The T cell receptor (TCR) is 
a heterodimer of two protein chains. Most TCRs consist of an α and β chain, however 
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there is a small fraction (≈5%) of γ:δ chain TCRs. Each α:β T cell expresses a single TCR 
with unique antigen specificity. The generation of TCRs relies on a random 
rearrangement of antigen receptor genes (V, D, J) resulting in a broad TCR repertoire. 
This repertoire comprises a major part of TCRs incapable of binding to antigen and a 
small fraction of dangerous TCRs recognizing self-antigens from tissues of the body. 
These self-reactive T lymphocytes can cause autoimmunity and need to carefully be 
prevented from entering the pool of mature T cells in the periphery.  
Burnet first postulated the mechanism of central tolerance in the 1960’s1. Each 
developing thymocyte undergoes a selection process in the thymus. Double positive (DP) 
CD4+CD8+ thymocytes binding weakly to self-antigen MHC complexes presented by 
cortical thymic epithelial cells (cTEC), get positively selected and survive. They cease to 
express one of the co-receptors, becoming single positive (SP) CD8+ or CD4+ 
thymocytes, ready to leave the thymus and form the peripheral T cell repertoire.  
However, thymocytes binding strongly to self-antigen MHC complexes, presented by 
medullary thymic epithelial cells (mTECs), get negatively selected and die. MTECs 
express the autoimmune regulator gene (AIRE) which has an important role in the 
process of negative selection2: via the induction of peripheral-tissue antigen presentation 
on the surfaces of mTECs, AIRE contributes to clonal deletion, i.e. apoptotic cell death of 
auto-reactive thymocytes, and thus controls autoimmunity3. 
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Figure 2.2.1 Graphical abstract of thymic T cells selection 
In the thymus, 90% of thymocytes never interact with antigen and die by neglect (grey). 
5% of all thymocytes get negatively selected (red) and only a fraction get positively 
selected and home to the periphery where they homeostatically expand (blue) 
 
 
2.2.1 Negative selection 
Thymic negative selection results in the depletion of autoimmune T cells expressing 
TCRs with high affinity for self-antigens. It is therefore considered a key mechanism in 
the induction of tolerance. To negatively select a thymocyte, peptide affinity needs to 
generate a strong enough TCR signal to initiate thymocyte apoptosis4,5. The TCR can 
measure antigen affinity by the duration of TCR peptide-MHC complex interaction 
(antigen dwell-time)6-8. A ligand dissociation constant (KD) of 6uM and a half-life of ≈ 2 
seconds was proposed to define the affinity threshold for a MHC class I restricted double 
positive (DP) thymocyte to succumb to negative selection in the thymus6,8. Recent data 
from our lab measured that an antigen dwell time of ≈ 0.9 seconds defines the affinity 
threshold for MHC class I restricted, double positive thymocytes to succumb to negative 
selection in the thymus. For MHC class II restricted TCRs this threshold is lower (antigen 
dwell time of ≈ 0.2 seconds) and as a consequences leads to negative selection in 
response to weaker self-antigens9.  
Peptide-MHC driven TCR signaling initiates with co-receptor bound Lck, 
phosphorylating ITAMs within the TCR/CD3 complex. Not every co-receptor carries Lck 
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indicating that only some collisions between a TCR and a co-receptor are capable of 
triggering a TCR signaling (see results 5.2). Therefore not all co-receptor TCR collisions 
are productive. CD4 co-receptors carry more TCR-signal-inducing-kinase Lck than do 
CD8 co-receptors. A shorter antigen dwell time for MHC class II restricted thymocytes 
can elicit a strong enough TCR signal to initiate negative selection9.  
 
 
Figure 2.2.2 Co-receptor coupled Lck initiates TCR signalling  
 
2.3 Peripheral tolerance and Tregs 
Elimination of potentially self-reactive T cell clones in the thymus is an important 
process enabling immunological tolerance. However despite its efficiency, negative 
selection is not 100% complete. A small number of T cells, with potential to cause 
autoimmune diseases, escape negative selection. The periphery established additional 
control mechanism to prevent mature self-reactive T cells from unwanted responses 
toward self. Recessive peripheral tolerance or clonal T cell anergy, was described in the 
1980 when mature T cells were rendered unresponsive to antigen recall responses in the 
absence of co-stimulation10,11. 
The idea of a “suppressor T lymphocyte” controlling peripheral tolerance was first 
postulated in the 1960’s. Mice, thymectomized at day 3 of life, suffered from sever 
autoimmune ovary inflammation and autoimmune gastritis. It was suggested that 
“suppressor T lymphocytes” emerge from the thymus after day 3 of life to prevent 
immune responses against self-antigens12-14.  
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In 1995 Sakaguchi and colleagues described a small population (5-10%) of CD4+CD25+ 
T cells that appear in the periphery only after day 3 of life and upon depletion lead to 
lethal multiple autoimmune diseases in mice15,16. An x-linked syndrome of diarrhea, 
polyendocrinopathy and fatal infection in infancy (IPEX) has long been described in 
humans17. Male patients suffer from severe colitis, autoimmune endocrinopathies, food 
allergies, dermatitis and scarcely reach the age of 6 years. The equivalent phenotype in 
mice termed “scurfy” arose as a spontaneous mutation in radiation-exposed animals and 
was described by Godfrey and colleagues in 199118,19. In 2001 Brunkow and others20 
mapped the Forkhead box protein P3 (Foxp3) gene mutation and evidence was supplied 
that the scurfy disease in mice and the IPEX syndrome in humans resulted from a 
defective expression of the transcription factor Foxp321.  
 
 
Figure 2.3.1 Diagram of IPEX symptoms 
 
Work of Schubert et al. showing that Foxp3 acts as a repressor of transcription and 
regulator of T cell activity accounts for a major Treg breakthrough22. In subsequent steps 
diverse independent teams could identify Foxp3 as the master controller for the 
development and function of CD4+CD25+ regulatory T cells23-25.  
Today dominant peripheral tolerance refers to this population of Foxp3+CD4+CD25+ T 
cells. Regulatory T cells are believed to form a TCR repertoire skewed toward self-
recognition and exert key regulatory functions in the maintenance of peripheral T cell 
homeostasis.  
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2.4 Treg origins and nomenclature 
Tregs can be divided into two main subgroups based on their place of origin: thymic 
Tregs (tTregs) emerge from the thymus and peripheral Treg (pTregs) from the periphery. 
However du to the lack of defining selection markers, this classification has been revised 
(see 2.4.3-5)26 
 
2.4.1 Thymic Tregs 
Thymic Tregs (tTregs) are thought to arise during thymic selection and to be survivors of 
negative selection27-29. As mentioned above, negative selection is not a hundred percent 
complete. Along with the danger of high affinity self-reactive Tconvs escaping, there is 
the beneficial effect of generating Tregs expressing a TCR repertoire skewed towards 
self-recognition. TTregs are estimated to account for seventy to ninety percent of the Treg 
population26,30. Data suggest that tTregs express the transcription factor Helios (also 
known as IKZF2) and respond to high affinity self-peptides presented in the context of 
MHC class II molecules31. Expression of the surface marker neuropilin 1 was also 
associated with tTregs32. Up to date these markers provide the best tool to distinguish 
between thymic derived and peripherally induced Foxp3+ regulatory T cells30.  
Emerging tTregs are maintained in secondary lymphoid organs as a result of homeostatic 
proliferation due to self-peptide encounter in the periphery. They are critically involved 
in the prevention of autoimmune diseases and represent a key mechanism for induction 
and maintenance of peripheral tolerance. 
 
2.4.2 Peripheral Tregs  
It is well accepted that approximately ten to thirty percent of Treg cells are generated by 
conversion of T conventional cells (pTregs) in the periphery33. In vitro conversion of T 
conventional cells occurs in a milieu where TCR stimulation, IL-2 and the presence of 
tTregs, expressing surface coupled TGF-β, is provided34,35. In vivo experiments could 
show the emergence of pTregs as a subsequent wave of T effector differentiation during 
inflammation, resulting in resolution of the disease36. Importantly, a non-redundant role 
for peripherally generated Tregs could be shown, enabling TCR diversity for suppression 
of chronic inflammation and autoimmunity in Foxp3 deficient mice33 .  
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While pTregs express a big part of Treg signature genes, it is reasonable to assume that 
thymic and pTreg populations exhibit different TCR repertoires and functional profiles. 
However, owing to the lack of validated markers, a Treg nomenclature based on defining 
markers and functional properties rather than origin (i.e. thymic and peripheral Tregs) 
was proposed26 (i.e. central, effector and tissue-resident Tregs). 
 
2.4.3 Central Tregs 
Central Tregs mark the biggest population of Tregs. After Tregs emerge from their origin 
they circulate through secondary lymphoid organs. They highly express homing markers 
like CD62L and CCR7 and are low on activation markers like CD44 and CD25. Their 
phenotype resembles one of naïve or memory T conventional cells26.  
However upon TCR and co-stimulatory activation signals, they up regulate CD25 and 
exert suppressive functions. Central Tregs depend on IL-2. This allows homeostasis of 
the Treg and Tconv populations, since IL-2 production by Tconvs inversely correlates 
with Tconvs suppression 26,37. Their high basal proliferation rate is counterbalanced by a 
high apoptosis rate due to Foxp3 mediated phosphorylation of the pro-apoptotic marker 
Bim38. Bim on the other hand is antagonized by the pro-survival factor Mcl-1 that is up 
regulated in Tregs upon IL-2 signaling39.  
If the high turnover of central Tregs is due to constant TCR triggering or is a direct 
consequence of the Foxp3 transcriptional program (or both) needs yet to be examined. 
Importantly growing evidence suggests that Treg suppression and homeostasis in 
secondary lymphoid organs alone, cannot guarantee immunological tolerance. 
 
2.4.4 Effector Tregs 
Effector Tregs or “activated” Tregs mark a minor but important population of the Treg 
pool. Due to recent antigen encounter, their phenotype resembles one of activated 
conventional T cells. They are high on CD44, CD25, KLRG1, CD103 and low on CD62L 
and CCR740. This profile allows migration through non-lymphoid tissues in order to 
locate the site of need40.  
Effector Treg differentiation from central Tregs requires the transcription factor IRF4 and 
involves Blimp-1 up regulation41. Further polarization of effector Tregs takes place upon 
unknown stimuli and depends on the place of recruitment. Up regulation of transcription 
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factors like Tbet, STAT3, BCL-6 or PPARγ act together with Foxp3, inducing expression 
of required surface chemokine and homing receptors42.  
IL-2 is a minor player in the maintenance of polarized effector Tregs, leaving essential 
cues to cytokines like IL-7, IL-27, IL-10, IL-6 and IL-1. This observation implies that 
effector Tregs are tailored to match the type of T conventional cells, i.e. Th1, Th2 or 
Th17 that needs to be suppressed43. It is still unclear whether the change of phenotype 
from central to effector Treg is reversible or terminal.  
 
2.4.5 Tissue-resident Tregs 
Non-lymphoid tissues, that have been reported to harbor a substantial number of Treg, 
include gut, skin, lung, liver, adipose tissue, placenta, inflammatory tissues and tumors44.  
Tools for discrimination between residential tissue Tregs and migrating effector Tregs are 
still limited. However, new insights from the gut and adipose tissue lead to improved 
understanding of tissue resident Treg populations. The gut harbors the largest pool of 
tissue-resident Tregs. Especially in the colon, where bacterial colonization has a non-
redundant role in maintaining gastrointestinal physiology, it is of utter importance to 
control inflammatory immune responses at the intestinal barrier. Colonic tissue resident 
Treg cells are induced by indigenous clostridium species and respond to homeostatic 
mediators of microbial metabolites called SCAFs (short-chain fatty acids)45,46.  
Another important site of tissue-resident Tregs is the visceral adipose tissue (VAT). IL-33 
signaling via the ST-2 receptor represents an essential environmental cue for VAT Treg 
differentiation47. VAT Tregs express the transcription factor PPAR-γ and are critically 
involved in regulating metabolism related processes, i.e. prevention of obesity-associated 
inflammation, preservation of insulin sensitivity and glucose tolerance48,49.  
CCR4+CD103+ Tregs are found in the skin and after resolution of inflammatory 
responses, survive as memory Tregs with enhanced functional activity50,51. Regulation of 
humeral immunity relies on CXCR5+BCL-6+ T follicular regulatory cells (TFR), which 
are found in germinal centers of secondary lymphoid organs and limit the numbers of T 
follicular helper (TFH) and germinal B cells52,53. In mice a distinct Helios+NRP-1+ growth 
factor amphiregulin expressing Treg population is critically involved in the repair of 
dystrophic muscles54. Finally, pregnancy imprints protective memory by generating 
maternal Tregs with fetal specificity, persisting at elevated levels, and rapidly re-
accumulating in subsequent pregnancies55. 
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2.5 Tregs and Foxp3 
The transcription factor Foxp3 represents the master regulator and controller of Tregs56,57. 
Expression of a non-functional Foxp3 leads to lethal massive multi-organ lymphocytic 
infiltration and cytokine secretion, a condition termed “scurfy” in the mouse and IPEX in 
the human. 
 
2.5.1 Structure 
The transcription factor Foxp3 belongs to the forkhead/winged–helix family of 
transcriptional regulators. The protein consist of 431 aa encoded by 11 exons20.  
It contains a Forkhead domain at its carboxyl-terminal which is responsible for DNA 
binding and nuclear localization58. The proline rich N-terminal contains the repressor 
domain. Here epigenetic regulation via binding of histone acetyltransferases (HATs) and 
deacetylases (HDACs) is mediated. Also the transcription factors ROR-α and ROR-γt 
bind to this region of Foxp3. The leucine zipper in the middle allows Foxp3 dimerization. 
Runx1 binds to a region between the zipper and the Forkhead domain. Finally the 
Forkhead domain, besides mediating DNA binding and nuclear localization, binds the 
transcription factor NFAT (nuclear factor of activated Tcells) which inhibits the promoter 
of IL-259 
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Figure 2.5.1 Diagram of the transcription factor Foxp3 
 
 
2.5.2 Function 
Depending on its interaction partners, Foxp3 either acts as a transcriptional repressor or a 
transcriptional activator. The typical Treg phenotype results from transcriptional 
repression of the IL-2, IL-4 and INFγ genes and transcriptional activation of suppressor 
molecules like CTLA-4, GITR and CD25.   
Foxp3 competes against AP-1 (a dimer of c-FOS and c-JUN) for a cooperative binding 
with NFAT. The Foxp3/NFAT complex inhibits the IL-2 promoter. In Tconv (i.e. Foxp3 
negative) cells the AP-1/NFAT complex activates the IL-2 promoter. Foxp3 and RUNX1, 
RUNX2 and RUNX3 interactions inhibit the production of the cytokines Il-2 and INFγ.  
Depending on environmental TGF-β levels Foxp3 regulates Th17 deviation through 
interactions with ROR-γt. High levels of TGF-β lead to repression of ROR-γt mediated 
activities and keep Th17 cell numbers low. This allows for optimal Treg expansion.  
Epigenetic modifications are changes to chromatin packing and thus the accessibility of 
transcription factors to genes. An active role of Foxp3 in epigenetic chromatin 
remodeling of target genes is well established. Foxp3 accesses genes critical for Treg 
development and phenotype, i.e. IL-2, INFγ, CD25, GITR, CTLA-4, Foxp3. 
Modifications at histone levels involve methylation (inhibition) or acetylation (activation) 
of DNA. These processes are mediated through HAD7/9 and Tip60 bound to the Foxp3 
repressor domain. Sustained Foxp3 expression allows the de-methylation of the Treg-
specific-de-methylated region (TSDR), creating a positive-feedback pathway to further 
enhance Foxp3 expression and maintain stable Treg lineage60.  
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2.5.3 Regulation of Foxp3 
Foxp3 has three highly conserved non-coding sequence (CNS1-3) regions. These are 
important regarding the regulation of Foxp3 expression61.  
Their role has been described as follows: CNS1, containing a TGF-β–NFAT response 
element, is essential for the generation of peripheral Tregs involved in maternal-fetal 
tolerance of placental animals62. CNS1 deficient females suffer form peripheral Treg cell 
paucity and have increased spontaneous abortions62. CNS2 seems to be dispensable for 
Foxp3 induction but is important for maintaining its expression in dividing Treg cells.  
Via a CBFβ-RUNX1-Foxp3 complex, DNA is demethylated and induces the heritability 
of the activated Foxp3 locus and with this Treg lineage stability61. C-rel, a member of the 
NF-κB family, can directly bind to CNS3 and open the enhancer/promoter region of 
Foxp363,64. In c-rel deficient mice, thymic Treg cell numbers are markedly reduced. 
It could be shown that Foxp3 makes use of a pre-existent enhancer landscape established 
during T cell differentiation. Treg lineage specification emerges form a late-acting 
opportunistic transcriptional modification of T cell specific enhancers present in 
precursors from Foxp3- T cells65. Numerous transcription factors like Foxo-1, Helios, 
Eos, IRF4, Tbet, BLIMP-1 and GATA-1 help maintain a stable epigenetic landscape 
within a Treg cell66. Thus the epigenetic signature of a Treg seems to be set in a mostly 
Foxp3 independent manner. 
 
2.5.4 Differences in Mouse and human Foxp3 
Foxp3 is transiently induced upon TCR stimulation in human conventional CD4 T cells67. 
The functional consequences regarding pathogen-specific or autoimmune reactions are 
under investigation.  
However, this phenomenon is not seen in mouse CD4+ T conventional cells. Human 
Foxp3 has multiple isoforms generated by alternative splicing, i.e. FOXP3ΔEx2, 
FOXP3ΔEx7, FOXP3ΔEx2Ex768. In mice there is only a single Foxp3 isoform. Since 
exon 2 and 7 partially encode the proline rich and the leucine zipper domain, it is 
assumed that the lack leads to failure of Foxp3 dimerization and binding of ROR-γt and 
ROR-α. However the functional implications of these human isoforms and which Foxp3 
is expressed in which Treg cell population is still unclear.  
Finally, a new binding partner of human Foxp3 was identified which is not seen in the 
mouse. The Foxp3-interacting KRAB domain-containing protein (FIK) can bind to the 
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human Foxp3 splice variant of the zinc finger protein 90 and interact with TIF1β to form 
a repressive chromatin-remodeling complex69. 
 
 
2.6 Tregs and IL-2 
Interleukin 2 (IL-2) plays an important role as dominant regulator of homeostasis and 
growth of regulatory T cells70. Tregs continuously express the high affinity IL-2 receptor 
alpha chain (CD25) but are incapable of producing IL-2 them selves. Thus their survival 
is dependent on a consistent source of paracrine IL-2.  
 
2.6.1 Ligand 
IL-2 is a 15kDa small protein with T-cell stimulatory capacity. IL-2 has a short half live 
of 15-30 minutes71,72 and is cleared from the circulation via the kidneys. Under steady 
state conditions, CD4 conventional T cells are the main source of IL-2. CD8, NK, NKT 
and DC cells additionally produce low amounts of IL-2.  
Upon TCR and CD28 stimulation transcriptional induction of the IL-2 gene is induced 
and activated T cells rapidly secret IL-2. TCR signaling induces and activates 
transcription factors like AP-1, NFAT and NF-κB promoting their nuclear localization 
where they bind and transcribe the IL-2 gene73.  
IL-2 can inhibit its own production via an auto-regulatory negative feedback loop: upon 
IL-2 uptake, STAT5 (Signal transducer and activator of transcription) activation leads to 
Blimp-1 induction and ultimate repression of the IL-2 gene74,75. 
 
2.6.2 Receptor and signaling 
The trimeric IL-2 receptor expressed on activated T cells consists of CD25, CD122 and 
CD132 (or IL-2Rα, IL-2RΒ and the common γ chain). With a dissociation constant (Kd) 
of 10e-11 M it has a high affinity for IL-2. CD25 has no part in signaling but initially 
binds IL-2 on its own which leads to the assembly of CD122 and CD132. The dimeric IL-
2 receptor consisting of CD122 and CD132 has a lower affinity for IL-2 (Kd≈10e-9) and 
is only detectably expressed on CD8 and memory T cells.  
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Upon IL-2 binding the receptor-ligand complex is rapidly internalized (t1/2 10-20min)73. 
The signaling subunits CD122 and CD132 are degraded. CD25 gets recycled and 
reappears on the cell surface76. Binding of the IL-2 ligand by its receptor leads to 
phosphorylation of the Janus activated kinase 1 and 3 (JAK1, 3)77 associated with CD122 
and CD132. This in term leads to the activation and dimerization of STAT5. pSTAT5 
trans locates to the nucleus where it activates a number of genes involved in cell survival, 
growth and transcriptional regulation78.  
PSTAT5 also binds to the Foxp3 promoter amplifying the Treg’s suppressive capacity by 
maintaining high Foxp3 levels79. Together with Foxp3, STAT5 acts on CD25 to maintain 
high CD25 surface expression in Tregs.  
IL-2 signal transduction differs between CD4+Foxp3+ regulatory and CD4+ conventional 
T cells: apart form the JAK-STAT signaling pathway, phosphorylation of the IL-2 
receptor also leads to activation of the PI3K-mTOR and MAPK signaling pathways in 
CD4 T conventional cells. However Foxp3+ regulatory T cells express high levels of the 
negative regulator PTEN resulting in inhibition of the Akt-mTOR pathway80.  
 
2.6.3 Role in development and homeostasis 
It has been shown that IL-2, CD25 or CD122 deficient mice show rapid and lethal 
autoimmune syndromes81-83. These results suggest a non-redundant role for IL-2 in the 
development, maintenance and regulation of the immune system84,85. IL-2 influences 
terminal differentiation, effector responses or memory recall responses of CD8 and CD4 
T cells.  Importantly, IL-2 plays an essential part in thymic development, homeostasis and 
function of regulatory T cells38,70.  
CD122 deficient mice suffer form sever autoimmune diseases due to the lack of 
development and survival of regulatory T cells. In these mice, thymic-targeted expression 
of CD122 restored Treg numbers and prevented disease85 emphasizing an important role 
for IL-2 signaling in developing Tregs.  
Foxp3+ T cells are not detected until after the stage of positive selection. The thymus 
contains very few IL-2 producing cells that are mainly located in the cortical medullary 
junction. IL-2 is believed to induce a terminal developmental and survival signal, 
promoting maturation of precursor (Foxp3low, CD25low, Bimlow, Bcl-2high) Tregs into 
mature (Foxp3high, CD25high) Tregs. Deprivation of this niche-dependent and limiting γc 
signal results in a unique pro-apoptotic protein signature (PUMA++, p-BIM++, p-JNK++ 
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DUSP6-) that represses Bcl-2 survival signals and leads to Foxp3 induced cell death of 
Treg precursors38.  
Once CD4+CD25+Foxp3+ Tregs emerge from the thymus, in a first step they home to 
secondary lymphoid tissues (lymph nodes and spleen), where their homeostasis again 
relies on IL-2. Due to direct repression of the IL-2 promoter via Foxp3, Tregs cannot 
produce their own IL-2 and rely on a constant source of paracrine IL-2. Since IL-2 
secretion form T cells activated by foreign antigen may happen at a great distance to the 
Treg and is unpredictable, it seems unlikely that this is their main source of paracrine IL-
2. A more reliable source is a naïve CD4+ T cell encountering ubiquitously present self-
peptide in the periphery. Constant and high expression of surface CD25 on Tregs allows 
for uptake of excess paracrine IL-2 with beneficial effects for all players: consuming IL-2 
gives the Treg a survival signal; due to low amounts of paracrine IL-2 the Tconv is 
stopped from further activation and will not proliferate; physiological levels of IL-2 are 
restored in the system and homeostasis is preserved.  
That peripheral tolerance solely relies on the suppressive mechanism of passive IL-2 
consumption by Tregs seems unlikely. However tolerance may profit from IL-2 clearance 
by Tregs since potentially dangerous terminal effector development or memory 
generation gets interfered with72,73. 
 
2.6.4 IL-2 complexes 
Due to its potent immune regulatory function, IL-2 is a promising therapeutic candidate 
in clinical settings. However when used at high doses IL-2 toxicity causes dangerous 
vascular leak syndrome. Rapid renal clearance and a short half live poses yet another 
serious problem for IL-2 immunotherapy. Still, high-dose IL-2 applications induced 
activation of antitumor-lymphocytes and achieved positive results regarding the survival 
of patients suffering from metastatic renal or skin cancer86,87. Importantly low dose IL-2 
applications were shown to correlate with Treg expansion. First clinical trials 
administering low dose IL-2 in patients with autoimmune diseases like diabetes type 1 or 
graft-versus-host-disease (GVHD) describe beneficial effects on the induction of Treg 
numbers and/or function88.  
Apart from the serious adverse effects described above, an additional problem of 
injecting soluble IL-2 is the stimulation of both cytotoxic T and regulatory T cells.  
Coupling IL-2 to IL-2-specific, neutralizing, monoclonal antibodies like JES6-1A12 or 
S4B6 is a method to overcome this problem. Directing IL-2 to distinct T cell subsets 
Introduction 
 20 
results in either enhanced or suppressed immune responses. While injection of IL-2-S4B6 
complexes in mice lead to increased CD8 memory T and NK cell populations, injection 
of IL-2-JES6-1 complexes selectively expands CD25+Foxp3+ regulatory T cells. Similar 
effects were observed using human IL-2 coupled with the human IL-2 to the specific 
monoclonal antibody 534489-93.  
 
 
Figure 2.6.1 Effects of IL-2/JES6-1 mAb complex administration  
 
2.7 Tregs and TCR signalling 
The Treg TCR repertoire is described to be enriched in self-reactive cells specific for 
tissue-restricted antigens and TCRs expressed by Tregs are thought to be of higher 
affinity for self-antigens than conventional T cells94.  
The RAS/MAPK, NFκB as well as mTor signaling pathways are considered the driving 
pathways in controlling proliferation and activation of a conventional T cell. They are 
major components of TCR signaling, tightly regulating the transcription of the IL-2 gene 
via NFAT/AP-1 and thus controlling proliferation, activation and survival of the T cell59. 
How intracellular signaling events differ between Tregs and T effectors is still 
incompletely understood. 
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Figure 2.7.1 Diagram of TCR signalling pathways in CD4+ Tcell 
In green: Signalling intermediates that were described to be increased in Tregs 
In red: Signalling intermediates that were described to be decreased in Tregs 
 
 
TCR signaling initiates with co-receptor coupled Lck, phosphorylating the immune-
receptor tyrosine-based activation motives (ITAMS) within the CD3 complex95. 
Subsequent recruitment and phosphorylation of Zap-70 follows. Zap-70 phosphorylates 
the adaptor protein LAT, which then recruits SLP76, Grb2 and SOS to activate the MAP 
kinase ERK either via Raf-1 or via PLCγ and RAS8. Co-stimulatory signals are also 
important for T cell activation. CD28 recruits PKCθ to the synapse leading to activation 
of the NFκB signaling pathway96,97. CD28 signal transduction activates PI3 kinase, which 
activates Akt to induce signaling through the mTor pathway98.  
Despite the self-reactivity of Tregs, the role of TCR signalling in Treg biology has been 
controversial and is still not fully understood. Numerous reports support the idea that 
TCR signalling in Tregs is uncoupled from the signalling pathways described in 
conventional T cells99-101. Mechanisms that inhibit the onset of TCR signaling have been 
proposed. Among them is a negative feedback loop involving Dok-1 and 2. These 
proteins recruit the C-terminal Src kinase (Csk) to the plasma membrane102,103 and 
negatively regulate Lck, resulting in reduced phosphorylation of CD3ζ and of Zap-70104. 
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Recently it was demonstrated that the catalytic activation of Zap-70 is not required for the 
suppressive activity of Tregs100. It's been proposed that ZAP-70 has a scaffolding 
function, which is independent of its catalytic function, and contributes to the lymphocyte 
function-associated antigen 1 (LFA-1) mediated adhesion100. In terms of the RAS/MAPK 
pathway, Tregs have been shown to have decreased levels of PLCγ, DAG, RAS and 
ERK99. Furthermore many signaling intermediates are not activated by TCR signaling. 
For example Ca2+ mobilization seems to be impaired upon TCR engagement101. 
Decreased levels of PKCθ and thus hampered activity of NFκB have also been 
described105. Taken together the idea that TCR signaling in Tregs is blunted or deviated to 
maintain an anergic, suppressive Treg phenotype has received experimental support.  
However, recent data indicate that continuous expression and signalling of the TCR is 
required for effective suppression to occur in vivo106. Deletion of the TCR in peripheral 
Treg cells from Foxp3eGFP-Cre-ERT2 x TCRαFL/FL mice resulted in a marked loss of effector 
Tregs. These mice developed sever autoimmunity and died by day 13 of life. Interestingly 
loss of the TCR did not alter the amount of Foxp3, CD25 or GITR expression in these 
“Tregs”106. The role of downstream TCR signaling, together with its influence on Treg 
suppressive functions, was further addressed by Schmidt et al107. Their work revealed that 
TCR signals through SLP-76 and PLCγ1 (resulting in downstream signaling of DAG) 
play an essential role in Treg suppression but that Tregs lacking molecules involved in 
TCR-mediated integrin activation, displayed normal suppressive functions107.  
Overall these data suggest that proximal and distal TCR signals are required in Tregs 
(also see results), but that TCR mediated integrin activation has a non-essential role for 
effective Treg suppressive functions. 
 
 
2.8  Tregs and suppressive mechanisms 
Numerous work characterized Tregs and described their suppressive mechanisms. These 
mechanisms can be divided into two main groups, i.e. those that are dependent on cell-to-
cell contact and those that are not. 
 
2.8.1 Cell-contact dependent mechanisms  
In regard of contact dependent mechanisms, studies using transwell suppression assays, 
where a semipermeable membrane prevents Treg and Tconv contact, suggested a 
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predominate role for cell contact dependent suppressive mechanisms108,109. However, a 
failure to observe suppression in these experiments could be explained by the inability of 
diffusible suppressive molecules to function in the relatively large volume of the in vitro 
culture. Theoretically, suppression might utilize Treg secreted molecules but additionally 
require proximity between Tregs and Tconv cells110.  
The cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) is constitutively expressed 
on Tregs111. Mice with Treg specific CTLA-4 deficiency suffer from spontaneous 
development of systemic lymphoproliferation and fatal T cell autoimmunity112. It was 
proposed that Tregs initiate the catabolism of tryptophan in dendritic cells through a 
CD80/86-CTLA-4 dependent mechanism, generating metabolites, which convert naïve 
CD4 Tconv into tolerogenic Foxp3+ Tregs113-115. CTLA-4 has an additional function that 
down regulates co-stimulatory molecules CD80 and CD86 on antigen presenting cells 
(APCs) via trans-endocytosis116-118. By diminishing the APC’s capacity to efficiently 
present antigen, Tregs likely prevent priming of Tconvs119,120.  
High LFA-1 expression on Tregs was proposed to augment the physical interaction 
between Tregs and APCs121. In this way Tregs can out compete Tconv for space on the 
APC. Tregs expressing LAG-3 were shown to bind MHC-2 and block DC maturation122. 
Since LAG-3 deficient mice do not show autoimmune disorders the relevance of LAG-3 
for suppression remains to be established123.  
 
2.8.2 Cell-contact independent mechanisms  
Cell-contact independent mechanisms depend on the action of cytokines and chemokines. 
Tregs produce immunosuppressive cytokines like transforming growth factor β (TGFβ) 
and IL-10, which have been shown to control Tconv proliferation124,125. Treg cell-derived 
TGFβ was shown to convert naïve T cell precursors into suppressive Foxp3+ T cells34. 
However, the role of TGFβ in Treg suppression remains controversial since Tregs 
mediate suppression of Tconvs from TGFβRII KO and Smad3-/- mice126. In addition 
Tregs from neonatal TGFβKO mice retained their suppressive capacity126. Gut Tregs were 
shown to secrete IL-10, which was required for mucosal immune homeostasis and the 
control of colitis127-129. However, Treg-specific IL-10 deficient mice did not suffer from 
systemic autoimmunity per se but failed to control immune responses at mucosal, 
environmental interfaces (i.e. gut, lung)130. Further more, blockade of either IL-10 or 
TGF-β failed to abrogate Treg mediated suppression in vitro131.  
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Another possible suppressive mechanism is the Treg mediated release of granzymes A or 
B132-134. Tregs have been shown to disrupt Tconv metabolism through cyclic adenosine 
monophosphate (cAMP)135,136, or by scavenging cytokines137. Tregs constitutively express 
high levels of CD25, which could steal IL-2 from Tconvs preventing their full 
activation70. However two observations question the idea that Tregs function by 
consuming Tconv generated IL-2: (i) Tregs from CD25 KO mice are suppressive, in vitro 
and (ii) mice with specific peripheral abrogation of Treg CD122 (IL-2RΒ) expression 
don’t suffer from autoimmune disorders85. However more recent work mitigated these 
interpretations. CD122 deficient Tregs can still respond, albeit to a diminished extent138, 
to IL-2 signaling  and CD25 deficient Tregs were proposed to display compensatory up 
regulation of CD122 and CD132110,139, which renders them capable of responding to, and 
consuming IL-2. Finally another line of evidence for IL-2 consumption as a suppressive 
mechanism lies in the fact that addition of exogenous, IL-2 abrogates suppression (in 
vitro)108,109. 
 
 
2.9 Tregs and clinic 
Disruption of Treg homeostasis leads to dysfunctional immunity and devastating 
conditions in the host. Autoimmune diseases, chronic infections and tumorous illnesses140 
are the consequences. Although we lack a full understanding of how Tregs function at a 
cellular and molecular level, Tregs are being used in clinical trials. Three main 
approaches of Treg treatment are pursued;  
(i) Treg induction: i.e. increase and maintenance of Tregs in patients with autoimmune 
diseases like diabetes type 1141 via IL-2 complex treatment89, rapamycin administration142 
or monoclonal antibody treatment (i.e. anti-CD3, anti-thymocyte globulin, anti-CD52)143. 
After global T cell depletion, these antibodies possibly induce a shift in the Treg/non-
Treg re-population of the periphery, resulting in a functional enrichment of Tregs. 
Another approach of Treg induction therapy is the generation of antigen specific Tregs in 
the host. Nexvax2144-146 is a vaccine, comprising a dominant peptide epitope of the gluten 
protein. Upon oral gluten consummation, allergic T cell mediated reactions in the gut 
mucosa of celiac patients are suppressed by gluten-antigen specific Tregs144.  
(ii) Treg cell therapy includes in vitro expansion and autologous transfusion or over-
expression of Foxp3 in T cells using a vector system, which ensures continuous high 
expression levels of Foxp3147. In vitro expansion and transfusion of autologous Tregs was 
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shown to reduce the risk of GVHD after hematopoietic stem cell transplantation148-151. 
Recently this approach was also shown to suppress autoreactive T cells in Morbus Crohn 
patients152.  
(iii) Treg-depletion, i.e. depletion of Tregs using specific monoclonal anti-CTLA-4 or 
anti-PD1 antibodies in cancer patients153,154. Upon Treg depletion, cytotoxic, tumor-
reactive T cells can attack and clear the tumor without being suppressed. 
Using Tregs as cellular therapies entails safety concerns including the 
expansion/transfusion of un-pure Treg populations and the instability of Treg lineage 
commitment. A better understanding of Treg biology is still required, so Treg cell 
treatment can be administered safely and with a predictable outcome. 
 
 
Figure 2.9.1 Diagram of three main approaches in Treg cell therapy 
Examples of diseases where Treg-cell therapy is applied 
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3 Hypothesis  
 
3.1 Part A: Studies of suppression using monoclonal regulatory T cells  
In the first part of the thesis, we re-assessed the mechanisms of Treg mediated suppression 
and the TCRs contribution, making use of mice expressing a population of monoclonal, TCR 
transgenic Tregs (B3K506 Tregs). 
 
3.2 Part B: The importance of co-receptor Lck coupling ratios for negative 
selection 
In the second part of the thesis, we examined if the TCR affinity threshold is defined by the 
time it takes a TCR to collide with a co-receptor carrying Lck and if a difference in the co-
receptor Lck coupling ratios of CD8 and CD4 coreceptors explains the decrease in antigen 
affinity needed to initiated negative selection in class II restricted DP thymocytes. 
 !
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4 Material/methods  
4.1 Part A 
4.1.1 Mice 
Foxp3 Tg mice on a C57BL/6 background were described previously57 and kindly provided 
by S. F. Ziegler.  B3K506 TCR Tg Rag-/- mice on a C57BL/6 background were described 
previously155 and kindly provided by J. W. Kappler. B3K506 TCR Tg Foxp3 Tg mice were 
generated in our lab by crossing B3K506 TCR Tg Rag-/- to Foxp3 Tg animals.  Foxp3-EGFP 
reporter mice on a C57BL/6 background were described previously156 and kindly provided 
by B. Malissen.  ABM (anti-bm12) TCR Tg mice on a C57BL/6 background were described 
previously157 and generated by E. Palmer. IL-2-EGFP Reporter mice on a C57BL/6 
background were described previously158 and kindly provided by A. A. Freitas. OT-II TCR 
Tg Rag-/- IL-2-EGFP Reporter mice were generated in our lab by crossing OT-II TCR Tg Rag-/- 
to IL-2-EGFP Reporter animals. OT-II TCR Tg mice on a C57BL/6 background, C57BL/6 
Ly5.1, C57BL/6 Ly5.2, H2-Abm12 and BALB/c mice were purchased from The Jackson 
Laboratory (Bar Harbor, Maine, USA). CD3-/- mice on a C57BL/6 background were 
described previously159 and kindly provided by P. Marrack. HA TCR Tg mice on a BALB/c 
Ly5.1 background were previously160 described and kindly provided by A. Rolink. All adult 
mice were 6–12 weeks old and bred in our colony (University Hospital Basel) in accordance 
with the Cantonal and Federal laws of Switzerland. The Cantonal Veterinary Office of 
Basel-Stadt, Switzerland, approved the animal protocols. 
 
4.1.2 Media, antibodies and reagents 
All cells were grown in RPMI 1640 (Gibco /Lifetechnologies) supplemented with 10% heat-
inactivated FCS. Biotin-conjugated anti-CD3 (145-2C11), Biotin-conjugated anti-CD4 
(RM4-5), Biotin-conjugated anti-CD8 (53-6.7), PE-conjugated anti-CD45.2 (104), 
Alexa700-conjugated anti-IFNγ (XMG1.2), PerCP-conjugated anti-CD45.1 (A20), FITC-
conjugated anti-CD69 (H1.2F3), FITC-conjugated anti-CD44 (IM7), APC-conjugated anti-
CD19 (1D3), PE-conjugated anti-CD62L (Mel-14), PE-conjugated anti-CD5 (53-7.3), 
PerCP-conjugated anti-CD3 (145-2C11), Alexa700-conjugated anti-CD4 (RM4-5), APC-
conjugated anti-CD11a (M17/4), PE-conjugated anti-TCRValpha 2 (B20.1), PE-conjugated 
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anti-TCRVbeta 5 (MR9-4), PE-conjugated anti-p4G10, PE-conjugated anti-pCD3zeta, PE-
conjugated anti-pZap-70 and APC-conjugated anti-TCRVbeta 8 (MR5-2) were purchased 
from BD Pharmigen (www.bdbioscience.com). PerCP-conjugated anti-NRP-1 was 
purchased from R&D Systems Inc. (www.RnDSystems.com). PE-Cy7-conjugated anti-
GITR (DTA-1), PE-conjugated anti-TBET (4B10), PE-Cy7-conjugated anti-Foxp3 (FJK-
16a) and APC-conjugated anti-Helios (22F6) were purchased from eBioscience 
(www.eBioscience.com). Pacific blue-conjugated anti-CD4 (RM4-4), Alexa700-conjugated 
anti-CD86 (GL-1), APC-conjugated anti-LAP (TW7-16B4), Alexa700-conjugated anti-
CD25 (PC61) and APC-conjugated anti-CTLA-4 (UC10-4B9) were purchased from 
BioLegend (San Diego, CA, USA). Anti-pERK and anti-pc-JUN were purchased from Cell 
Signalling. EasySep Mouse CD4+ T cell Isolation Kit and EasySep Mouse B cell Isolation 
Kit, were purchased from Stemcell Technologies (www.stemcell.com). Recombinant Mouse 
IL-2 was purchased from BioLegend (San Diego, CA, USA). Cell Proliferation dye eFluor 
670 was purchased from eBioscience (www.eBioscience.com). BD Cytofix/Cytoperm Plus 
Fixation/Permeabilization Kit with GolgiStop and BD Cytometric Bead Array Mouse 
Th1/Th2/Th17 CBA Kit was purchased from BD Pharmigen (www.bdbioscience.com). 
Anti–IL-2 (JES6-1) and anti-CD3 (145-2C11) were produced in our lab. Protein G 
Sepharose 4 Fast Flow, was purchased from (www.gelifescience.com). Peptides 3K (FEA 
QKA KAN KAV), P8G (FEA QKA KAN GAV), P2A (FEA AKA KAN KAV), and OVA 
(323-339) (ISQ AVH AAH AEI NEA GR), were purchase from AnaSpec (Fremont, CA, 
USA). HA-Peptide (YPY DVP DYA) was kindly provided by L. Klein (LMU, Germany). 
Dynabeads Biotin Binder, Cell trace CFSE and LIVE/DEAD fixable Near-IR were 
purchased from Invitrogen (Eugene, Oregon, USA). PMA, Ionomycin, methanol, PFA and 
glycine were purchased from Sigma-Aldrich (www.sigmaaldrich.com). Streptavidin was 
purchased form Jackson Immunoresearch. I-Ab 3K monomers were kindly provided by Prof. 
E. Huseby. 
 
4.1.3 Generation of JES6-1 monoclonal Antibody 
JES6-1 hybridoma cells were grown at a density of 10e6/ml in RPMI media completed with 
2% low IgG FCS. FCS was carefully run over a Potein G column twice to reduce the amount 
of IgG protein. IgG protein levels were controlled for by western blot. Hybridoma cells were 
cultured in roller bottles at 37°C for 21 days until >80% of cells were dead. Culture media 
was centrifuged and decanted into fresh container to get rid of cell debris. In addition culture 
media was filtered through a 0,2 µm pore filter and 0.02% of sodium azide was added for 
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storage at 4°C until further processed. Culture supernatant was run over a 5ml protein G 
column at a speed of 60-120ml/hour. IgG was eluted with 0.1M gycine (pH 2.8) into 50µl of 
1M Tris (pH 9.0). High concentrated elution fractions were dialyzed against endotoxin free 
PBS for 48 hours. Antibody fractions were sterile filtered and concentration was determined 
by absorbance at 280 nm with a nanodrop system. 
 
4.1.4 IL-2 complex treatment 
B3K506 TCR Tg Foxp3 Tg Rag-/- and B3K506 TCR Tg Rag-/- (ctrl) mice were injected intra 
peritoneal (i.p.) with 7.5µg anti-IL-2 antibody (JES6-1) complexed to 2.5µg mouse 
recombinant IL-2 in 200µl PBS on three subsequent days. Complex formation was achieved 
by adding IL-2 and JES6-1 to PBS and letting it incubate for 30 min at 37°C. 
 
4.1.5 Preparation and sorting of lymphocytes 
LNs (axillary, inguinal, superficial cervical, mandibular, and mesenteric) were harvested 
from 6-12 week old mice. For single cell preparation they were mashed through a mesh into 
RPMI/10% FCS. B3K506 TCR Tg Foxp3 Tg cell suspensions were then incubated with 
Pacific Blue conjugated anti-CD4 and PE-Cy7 conjugated anti-GITR antibodies for 10 min 
at 4°C, washed, and then sorted for CD4+GITRhigh cells on a BD INFLUX Cell Sorter (purity 
≥96%) into RPMI/10%FCS. B6 Foxp3EGFP cell suspensions were sorted for GFP+ cells on a 
BD INFLUX Cell Sorter (purity ≥98%) into RPMI/10%FCS. Spleens were harvested from 
6-12 week old mice. For single cell preparation they were mashed through a mesh into 
Erytrocyte lysis buffer and incubated for 1 min. The cells were washed in RPMI/10% FCS. 
After incubating the cell suspension for 10 min with biotin-conjugated anti-CD4, biotin-
conjugated anti-CD8, biotin-conjugated anti-CD3 antibodies, T cell depletion was preformed 
with the EasySep Mouse B cell Isolation Kit from Stemcell technologies (according to 
manufacture’s protocol) or with Dynabeads Biotin Binder Kit (according to manufacture’s 
protocol, Invitrogen). 
 
4.1.6 In vitro suppression culture 
10e5 B3K506 Tregs, 10e5 B6 Foxp3-EGFP Tregs or 10e5 B3K506 Tconv (ctrl) were cultured 
in 96-well plates (0.2 ml) with 2.5x10e4 OT-II Tconv and 10e5 T cell–depleted splenocytes, 
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0.1 µg/ml anti-CD3 or 3K, P8G or P2A (at various concentrations, see figures). T cell 
depleted splenocytes were preloaded with 10e-7 M OVA (323-339) peptide for 4.5h at 37°C 
and carefully washed. OT-II Tconv were labelled with 5µM CFSE or 5µM eFlour 670 
according to manufacture’s protocols. Flow cytometric analysis of suppressive cultures was 
preformed after 24, 48 or 72h. 
 
4.1.7 Staining and flow cytometry 
Surface staining was preformed in PBS/3% FCS at 4°C for 10 min with various antibodies. 
For intracellular staining cells were fixed and permeabilized (according to manufacture’s 
protocol) using the Cytofix/Cytoperm Plus Fixation/Permeabilization Kit from BD. 
Intracellular Foxp3 staining was preformed at 4°C for 1h. For intracellular cytokine staining 
cultured cells were re-stimulated with 100ng/ml PMA, 1.5µM Ionomycin and 1.5µl/ml 
Monensin (BD Pharmigen) and left for 5h at 37°C. Flow cytometry was preformed with a 
FACSCanto II from BD Pharmigen (www.bdbioscience.com). 
 
4.1.8 In vivo graft transplantation 
Tail skin from B6.bm12 Rag-/- mice was isolated and transplanted onto the back of B6 Rag-/- 
mice and allowed to heal in for 7 days. The following day mice were injected with 2x10e4 
ABM (I-Abm12 specific) Tconvs along with 2x10e5 Foxp3-EGFP Tregs or 2x10e5 B3K506 
Tregs. In one group mice received 30µg 3K peptide/200µl PBS IP. injections every 2nd day 
until day 15. A control group was injected with 2x10e4 ABM Tconvs alone. Graft rejection 
was checked for every 2nd day. 
 
4.1.9 Cytokine assay 
Culture supernatants were stored at -80°C and thawed. The BD Cytometric bead array 
(CBA) system using antibody-coated capture beads was used to quantitate various cytokines 
in the culture supernatants (see manufacture’s protocol). Analysis was preformed with Excel 
software (version 14.4.3) calculating the unknown sample concentrations from a standard 
curve.  
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4.1.10 EC50 determination of B3K506 TCR APLs 
10e5 T cell depleted splenic B cells were isolated and loaded with varying amounts of 
peptide for 4.5 h at 37°C before addition of 2.5x10e4 B3K506 Tconvs or 2.5x10e4 OT-II 
Tconvs. Cells were cultured in 96-well plates (0.2ml) with RPMI/10% FCS for 24h at 37°C. 
T cells were then surface stained (described above) for CD3, CD4 and CD69 and flow 
cytometry was preformed. The EC50 values for CD69 up regulation were calculated using a 
nonlinear regression curve (log (agonist) vs. response (three parameters), Prism, version 
6.0b). 
 
4.1.11 Signalling assays 
For short time point stimulation assays (I.e. 30, 60, 90 and 150 seconds) 3K tetramers were 
used. T cells were rested at a concentration of 40x10e6 in RPMI/10% FCS for 20 minutes on 
a shaker at 37°C. Tetramers were added at a 2X concentration (i.e. 200nM). At time point, 
the tetramer-cell mix was re-suspended in 8% PFA. In addition cells were spun at 1000G for 
2 minutes and re-suspended in ice-cold methanol. After carefully washing with PBS, primary 
antibody in signaling buffer was applied and left over night at 4°C. After washing secondary 
antibody diluted in signaling buffer was applied and left for 1 hour on ice. 
For longer time point stimulation assays (i.e. 60 and 150 minutes) peptide pulsed splenocytes 
were used to stimulate T cells. To enhance conjugate formation, cells were spun at 1500 
RPM for 3 minutes. To break conjugates at indicated time points, 5mM EDTA in PBS was 
applied and cell suspension was pipetted up and down for 5 minutes. 
 
4.1.12 Tetramers 
Tetramers consist of four I-Ab monomers (30 kDa each) coupled to one molecule of 
streptavidin (53 kDa). Tetramers were generated by incubating biotinylated monomers with 
streptavidin at a ratio of 4:1 on ice. Streptavidin was added in two steps. After each 
streptavidin addition, mix was allowed to incubate for 60 minutes on ice. Tetramer stock was 
diluted in PBS to a final concentration of 2mM and could be stored for several weeks at 4°C. 
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4.1.13 Same/separate APC experiments 
For same APC cultures, 10e5 B3K506 Tregs (I-Ab restricted), 2.5x10e4 HA Tg Tconvs (I-Ed 
restricted) and 10e5 splenic B cells from F1 mice (BALB/c x B6, on a I-Ed x I-Ab 
background) were cultured in a 96-well plate (0.2ml) with RPMI/10%FCS at 37°C. For 
separate APC cultures, 10e5 B3K506 Tregs (I-Ab restricted), 2.5x10e4 HA Tg Tconvs (I-Ed 
restricted), 10e5 splenic B cells from B6 (I-Ab background) and 10e5 splenic B cells from 
BALB/c (I-Ed background) were cultured in a 96-well plate (0.2ml) with RPMI/10%FCS at 
37°C. 3K peptide (10e-7M) and HA peptide (10e-5M) was added to same and separate APC 
cultures. Cultures were analyzed using flow cytometry after 72 h. 
 
4.1.14 Statistics 
Cell proliferation Index (PI) was calculated using FlowJo software (version 9.7.7). % 
Suppression was calculated using the formula (100-(% proliferated Tconv from suppressed 
culture/% proliferated Tconv)*100). Curve fitting and statistical analysis was performed 
using Prism version 6.0b and Excel version 14.4.3. 
 
 
4.2 Part B 
4.2.1 Mice 
All adult mice were 6-12 weeks old and had a C57Bl/6 genetic background. OTI Rag-/-, OT-I 
Rag-/- β2m-/-, B3K508 Rag-/- mice were described previously8,155. CD8.4 OT-I Rag-/- β2m-/- 
strain was generated by crossing CD8.4 knock-in mouse161 with OT-I Rag-/- β2m-/-. B3K508 
Rag-/- I-A-/- mice were generated by breeding B3K508 Rag-/- with I-A-/- mice. Crossing the 
CD8.4 knock-in mouse with B3K508 Rag-/- generated the CD8.4 B3K5008 Rag-/- strain.  
 
4.2.2 Media, antibodies and reagents 
All cells suspension were made in RPMI 1640 (Gibco/ Lifetechnologies) supplemented with 
10% heat-inactivated FCS. Antibodies to following antigens were used: Lck (clone 3A5), 
were purchased from Santa Cruz Biotechnology. CD3ε (clone 145-2C11), CD8α (clone 53-
6.7), CD8β (clone 53-5.8), CD4 (clones RM4-5 and H129.19) and TCRβ (clone H57-597) 
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were purchase from BD Pharmingen. For flow cytometry, antibodies were conjugated to 
various fluorescent dyes by the manufacturers. For western blotting a secondary light-chain-
specifc goat-anti-mouse HRPO-conjugated antibody was purchased from Jackson 
Immunoresearch. Protein G sepharose beads and full-range rainbow molecular weight 
marker were purchased from GE Healthcare. Acrylamide mix (30%), Trans-blott 
nitrocellulose membrane, Milk powder, ECL western blotting reagents, ECL Hyperfilm and 
TEMED were purchased from BIO RAD. CML latex beads were purchased from Invitrogen. 
Laemmli sample buffer, MES hydrate, Tris Base, Glycine, SDS and EDAC (Ethyl-3-(3-
dimethylaminopropyl)carbodiimid) were purchased from Sigma-Aldrich. Halt Protease and 
Phosphatase Inhibitor Cocktail was purchased from Thermo scientific. RCP-30-5A 
calibration beads were purchased from Spherotech Inc.  
 
4.2.3 Immunoprecipitation and Western blotting 
10e7 thymocytes from OT-1 WT or OT-1 CD8.4 mice were lysed in 50µl lysis buffer and 
incubated for 15 minutes on ice. Cell lysates were cleared by centrifugation at 14000 rpm for 
10 minutes at 4 °C. Immunoprecipitation was preformed in 400µl lysis buffer with 2µg 
monoclonal antibody and 20µl of 50 % protein G sepharose for 1.5 hours on a rotation wheel 
at 4°C. Upon washing sample and beads were boiled for 5 miuntes at 95 °C in 20µl Laemmli 
buffer. SDS-PAGE and western blotting was preformed. After proetein transfer, 
nitrocellulose membrane was blocked for 1hour in blocking buffer. Primary antibody (anti-
LCK clone 3A5) was applied in blocking buffer and incubated over night at 4 °C. Upon 
washing, HRPO-conjugated light-chain specific goat-anti-mouse antibody was applied for 1 
hour at room temperature. Nitrocellulose membrane was developed in 2ml of ECL western 
blotting detection reagents for 3 minutes at room temperature. The luminescence of HRPO-
mediated conversion of the ECL detection reagent was captured by exposing the membrane 
to ECL hyperfilms for appropriate periods of time and developing the films on a Curix80 
developer. 
 
4.2.4 CML bead antibody coating162 
18x10e6 CML beads were washed twice in MES buffer, and re-suspended in 50µl MES 
buffer. 20µl of EDAC/MES buffer (50µg/µl) was applied and incubated for 15 minutes at 25 
°C. Beads were then washed 3 times in PBS and 50µl of monoclonal antibody (0.2mg/ml) 
was applied and incubated overnight at room temperature. Beads were carefully washed 3 
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times in PBS. For quenching, beads were re-suspended at a concentration of 25x10e6/ml in 
storage buffer and stored at 4°C. 
 
4.2.5 IP-FCM  
10e6 cells were lysed in 50 µl lysis buffer for 30 minutes on ice. 75,000 CML beads coupled 
to anti-CD4 (clone RM4.4), anti-CD8α (clone 53-6.7), or anti-MHCI (clone Y3.8) 
antibodies, as described above, were added to the lysate and incubated for 3 hours at 4°C. 
Beads were washed 3x in lysis buffer and stained with different PE-conjugated antibodies to 
CD4 (clone H129.19), CD8β (clone 53-5.8), or Lck (clone 3A5) at saturating concentrations 
(40 min, on ice) and analyzed by flow cytometry. The geometric mean fluorescence 
intensities (gMFI) were taken as the measure of the antibody binding. The CD8, CD8.4 or 
CD4-Lck coupling ratio was calculated as Lck signal to CD8 or CD4 signal (after 
subtracting respective background signal calculated from control anti-MHCI beads) and 
adjusted for the PE/antibody ratio. 
 
4.2.6 Determination of surface molecule numbers 
Saturating concentrations of PE–conjugated antibodies were determined (0.04 mg/ml for 
CD3ε, CD8α and 0.01 mg/ml for CD4). 25,000 cells were stained in 25 µl of staining buffer 
(PBS/2% FCS) for 40 min on ice, washed, and analyzed along with PE calibration beads by 
flow cytometry. A calibration curve was generated based on the fluorescence signal from 
calibration beads to transform the geometric mean of fluorescence intensity (after subtraction 
of background signal from antibody stained peripheral B cells) into mean equivalent of PE 
intensity (MEPE) values. The actual number of surface molecules was calculated by 
adjusting the MEPE values to the PE/antibody ratio (determined by absorbance at 560 nm 
using soluble PE as a standard). Number of antigens captured by one molecule of antibody 
(assumed as 2163), except for TCR, where the results were further corrected for the presence 
of 2 molecules of CD3ε per TCR/CD3 complex. 
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4.2.7 Buffers and gels 
 
Lysis buffer 1% NP-40, 10 mM Tris pH 7.4, 140 mM NaCl, 2 
mM EDTA, Protease Inhibitor Cocktail (Sigma-
Aldrich).  
 
IP-FCM staining/washing buffer 50mM Tris ph 7.4, 100mM NaCl, 0.02% NaN3, 5% 
FBS or 1% BSA, 1% Np-40. 
 
Storage buffer 1% BSA, 0.02% NaN3 in PBS. 
 
SDS resolving gel (12%), 20ml 6.6ml H2O, 8ml 30% acrylamide mix (4°C), 5ml 
TRIS 1.5 M (pH 8.8), 200ul 10% SDS, 200ul of 10% 
freshly prepared ammonium persulfate, 8ul TEMED.  
 
SDS stacking gel (5%), 6ml 4.1ml H2O, 1ml 30% acrylamide mix (4°C), 750ul 
TRIS 1 M (ph 6.8), 60ul 10% SDS, 60ul 10% freshly 
prepared ammonium persulfate, 6ul TEMED. 
 
SDS Running buffer, 20L 60g Tris Base, 288g Glycine, 20g SDS in 20L H2O.  
 
Transfer buffer, 1L 100ml Towlin (10x), 100ml Methanol, 800ml H2O.  
 
Blocking buffer, 50ml 2.5g milk powder dissolved in 50 ml of 1% Tween.  
 
Washing buffer, 2L 200ml TBS (10x), 1800ml H2O, 2ml Tween.  
 
Tris buffer 1M (pH 6.8), 500ml 60.6 g TRIS in 200ml H2O, adjust pH with 12N 
HCL. 
 
Tris buffer 1,5M (pH 8.8), 500ml 90.8g TRIS in 400ml H2O, adjust pH with 12N HCL. 
 
Tris-buffered Saline 10x, 1L 24 g Tris base (Formula weight: 121.1 g), 88 g NaCl 
(Formula weight: 58.4 g) dissolve in 900 ml distilled 
water, adjust pH to 7.6 with 12N HCL. Add distilled 
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water for final volume of 1 liter. 
Erythrocyte lysis Buffer (10X) 8,26 g of NH4Cl, 1,19 g of NaHCO3, 200 µL EDTA 
(0,5 M, pH8) add distilled water until 100 mL. Adjust 
pH to 7.3 and filter sterile  
Signalling buffer PBS, 3% FCS, 0.3% Triton X , 5% Goat serum 
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5 Results  
5.1 Part A 
A Foxp3 transgene was backcrossed to TCR transgenic B3K506 Rag-/- mice to generate 
B3K506 Tg Foxp3 Tg “Treg” mice. Forty-50 % of T cells in the B3K506 Tg Foxp3 Tg 
strain are Foxp3+. This contrasts with T cells from B3K506 Rag-/- animals, where almost all 
T cells are Foxp3- (Tconvs) (Figure 5.1.1) 
 
 
Figure 5.1.1 Foxp3 distribution 
Representative flow cytometry plots of live, CD4+ LN T cells from B3K506 TCR Tg Foxp3 
Tg Rag-/- (B3K506 Treg) and B3K506TCR Tg Rag-/- (B3K506 Tconv) mice are shown. 
Numbers in plots depict % of cells in the quadrant. 
 
Compared to polyclonal B6 Tregs, monoclonal B3K506 Tregs expressed slightly reduced 
levels of CD25, GITR and LFA-1 and clearly decreased amounts of CTLA-4. B3K506 Tregs 
neither expressed Helios nor NRP-1 (Figure 5.1.2).  
 
 
Figure 5.1.2 B3K506 Treg phenotype 
Surface marker expression on monoclonal LN B3K506Tregs, polyclonal B6 Foxp3EGFP Tregs 
and monoclonal LN B3K506 Tconvs. Expression (MFI) for each marker was normalized to 
that expressed on CD4+ B6 Tconvs. Data show fold increase +/- SD, n=4. 
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B3K506 Tg Foxp3 Tg mice are lymphopenic. IL-2 coupled to JES6-1 monoclonal antibody 
was reported to specifically enrich Tregs91,92. We administered injections of IL-2/JES6-1 
mAb complexes (IL-2C) to B3K506 Tg Foxp3 Tg mice on three subsequent days (Figure 
5.1.3 A). Total cell numbers in the lymph nodes were increased compared to PBS treatment 
(Figure 5.1.3 B, C). However a specific enrichment of the Foxp3+ population was not 
observed (Figure 5.1.3 D). 
 
 
Figure 5.1.3 IL-2/JES6-1 mAb treatment 
A) IL-2/mAb injection scheme. B) Inguinal lymph nodes from PBS injected or IL-2 complex 
injected B3K506TCR Tg, Rag-/- mice. C) Bar graph shows mean number +/- SEM of LN cells 
isolated from PBS injected (black bar) or IL-2 complex injected (white bar) B3K506TCR Tg, 
Rag-/-, Foxp3 Tg mice, n=3. D) Bar graph and representative flow cytometry plots show mean 
% +/- SEM of Foxp3+ LN T cells isolated from mice described in A, n=3. Numbers in the 
plots depict % of cells in gate. 
 
 
Treatment with IL-2/mAb complexes might have increased the number of NK T cells in 
B3K506 Treg mice. By staining for NK1.1 and CD49b surface markers one can follow the 
enrichment of NK Tcells in IL-2/JES6-1 mAb treated B3K506 Tg Rag-/- mice. Comparing Il-
2/JES6-1 mAb treated B3K506 Tg Rag-/- to PBS treated B3K506 Tg Rag-/- and B6 mice, 
there was a slight increase in total number of CD3+ cells. However we did not observe an 
increase of CD3+NK1.1+ or CD3+CD49b+ cells (Figure 5.1.4 A).  
 
Compared to polyclonal B6 and untreated B3K506 Tg Foxp3 Tg Rag-/- mice, IL-2/JES6-1 
mAb treated B3K506 Tg Foxp3 Tg Rag-/- animals showed a significant decrease in CD122 
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and increase in GITR expression but no differences in CD25, CTLA-4, LFA-1, Helios and 
NRP-1 expression (Figure 5.1.4 B). 
 
 
Figure 5.1.4 Effect of IL-2/mAb treatment on CD3+ T cells and B3K506 Treg 
phenotype  
A) IL-2/mAb treated B3K506 Tg Rag-/- compared to PBS treated B3K506 Tg Rag-/- and B6 
mice. Histograms of IL-2/mAb treated animals show slightly increased CD3+ cell numbers. 
Flow cytometry plots show CD3+ LN cells of mice described. Number in the plots depict % of 
cells in the quadrant. B) Comparison of IL-2/mAb treated B3K506 Tg Foxp3 Tg Rag-/- mice 
(white bars) to PBS treated B3K506 Tg Foxp3 Tg Rag-/- (black bars) and B6 mice (green 
bars). Expression (MFI) for each marker was normalized to that expressed on CD4+ B6 
Tconvs, Data show mean fold increase +/- SD, n=4. Statistical significance was calculated 
using a two-tailed t-test. NS=p>0.05, *=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001 
 
Expression of the glucocorticoid-induced TNFR-related protein (GITR) was significantly 
increased on IL-2/JES6-1 mAb treated B3K506 Tregs. Of this we made use to optimally sort 
the Foxp3+ population in the B3K506 Tg Foxp3 Tg mouse. Sorting CD4+ GITRhigh cells 
resulted in a >95% pure monoclonal B3K506 Treg population (Figure 5.1.5). We used this 
approach for all experiments to reduce the amount of mice needed for one experiment. 
 
Results 
 40 
 
Figure 5.1.5 Sorting strategy 
Representative flow cytometry plots of B3K506 Tregs pre- and post-cell sorting, which was 
carried out based on CD4high and GITRhigh expression. Numbers in the plots depict % of cells 
in gate/quadrant. 
 
 
We examined the suppressive capacity of sorted monoclonal B3K506 Tregs in a 
conventional suppression assay using soluble anti-CD3ε antibody. No significant difference 
between the suppressive capacity of monoclonal B3K506 and polyclonal B6 Tregs was 
observed. As expected B3K506 Tconv cells are not suppressive (Figure 5.1.6).  
 
 
Figure 5.1.6 Conventional anti-CD3 suppression assay 
A) Representative proliferation of polyclonal B6 CD4+ Tconvs co-cultured with polyclonal 
B6 Foxp3-EGFP Tregs (black), monoclonal B3K506 Tregs (red) or B3K506 Tconv (blue). Grey 
histograms indicate proliferation of B6 CD4+ Tconvs cultured without Tregs. Number in 
histograms depict  % proliferated cells. Graph shows mean % suppression +/- SD at 72h, n=5. 
B) In vitro anti-CD3ε suppression assays. Capacity of monoclonal B3K506 Tregs (red), 
polyclonal B6 Foxp3-EGFP Tregs (black) and monoclonal B3K506 Tconv (negative control; 
blue) to suppress proliferation of polyclonal B6 CD4+ T cells at varying Treg/Tconv ratios. 
Data show mean % suppression +/- SD, n=3. Statistical significance was calculated using a 
two-tailed t-test. NS=p>0.05, *=p≤0.05, **=p≤0.01, ***=p≤0.001, ****=p≤0.0001 
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A peptide specific suppression assay where monoclonal B3K506 Tregs and monoclonal OT-
II CD4 Tconvs received specific peptide stimulation (i.e., 3K and OVA peptide, 
respectively) was established. Tregs needed to be stimulated via their TCR in order to be 
suppressive. Depriving B3K506 Tregs from their cognate peptide stimulus clearly abrogated 
suppression (Figure 5.1.7). From these results, we conclude that monoclonal B3K506 Tregs 
are functional Tregs, which require cognate peptide stimulation for effective suppression, in 
vitro. 
 
 
Figure 5.1.7 Peptide specific suppression assay 
Monoclonal B3K506 Tregs lacking their cognate peptide antigen are not suppressive. Left: 
CFSE labelled OT-II Tconvs were co-cultured with B3K506 Tregs with 3K (red histogram) 
and without 3K (dotted red histogram) peptide or B3K506 Tconvs with 3K peptide (blue 
histogram). OVA peptide was added to all cultures. OT-II proliferation in the absence of 
Tregs is shown (grey histograms). Numbers in histograms represent  % proliferated cells. 
Right: OT-II proliferation index and % suppression in co-cultures described in above. 
Monoclonal B3K506 Tregs + 3K peptide (red triangles); monoclonal B3K506 Tregs -3K 
peptide (empty red triangles); monoclonal B3K506 Tconv (blue circles); OT-II Tconv alone 
(grey squares). Data show mean proliferation index and mean % suppression +/- SD, n=7-13. 
Statistical significance was calculated using an one-way ANOVA and subsequently 
Bonferroni's multiple comparisons test. NS=p>0.05, *=p≤0.05, **=p≤0.01, ***=p≤0.001, 
****=p≤0.0001  
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B3K506 Tregs require TCR stimulation to be suppressive in vitro. This led us to examine 
how TCR signalling between B3K506 Tregs and B3K506 Tconvs might differ. Peptide-
MHC driven TCR signaling initiates with co-receptor bound Lck phosphorylating ITAMs 
within the TCR/CD3 complex. First we determined the Lck co-receptor coupling ratios of 
polyclonal B6 Tregs (red) and Tconvs (blue). No significant difference was detected (Figure 
5.1.8 A). Comparing surface expression of CD4 and TCRVβ8 on monoclonal B3K506 Tregs 
(red) and B3K506 Tconvs (blue) we detected a twofold increase of CD4 co-receptor 
expression on B3K506 Tconvs. TCR Vβ8 were similar on both cells (Figure 5.1.8 B). 
 
 
Figure 5.1.8 Lck-coupling ratios and expression levels of CD4 and TCR Vβ8 
A) Bar graphs show Lck co-receptor coupling ratio of polyclonal B6 Tregs (red) and Tconv 
(blue). Data show mean Lck co-receptor coupling ratio (%) +/- SD, n=3. Statistical 
significance was calculated using a two-tailed t-test. NS=p>0.05, *=p≤0.05, **=p≤0.01, 
***=p≤0.001, ****=p≤0.0001. B) Representative histograms of monoclonal B3K506 Tregs 
(red) and B3K Tconvs are shown. Histograms depict CD4 (left) and TCR Vβ8 (right) 
overlays of cells described. 
 
 
Baseline levels of pERK, p4G10, pZAP-70, pCD3ζ and pcJUN in un-stimulated, resting 
B3K506 Tregs were examined. Expression levels were normalized to resting B3K506 
Tconvs (Figure 5.1.9, A). PCD3ζ, accounting as a very proximal TCR signaling molecule, 
was slightly reduced. At the same time distal mediators of TCR signaling (i.e. pERK and 
pcJUN) showed a modest increase (Figure 5.1.9 A). Using 3K:I-Ab tetramers we performed 
short-term stimulation assays with monoclonal B3K506 Tregs (red) and monoclonal 
B3K506 Tconv (blue) comparing the total phosphorylation status (p4G10) and proximal 
TCR signaling (pCD3ζ) in these cells (Figure 5.1.9, B). B3K506 Tregs showed decreased 
levels of proximal TCR signaling (i.e. CD3ζ) and decreased levels of total cell 
phosphorylation (measured by p4G10, Figure 5.1.9 B).  
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Figure 5.1.9 Signaling molecules; Treg baseline and short-term stimulation 
A) Bar graph shows mean expression levels of indicated signaling molecules in resting, 
monoclonal B3K506 Tregs. Expression level of each signaling molecule was normalized to 
that of resting monoclonal B3K506 Tregs. Data show mean fold increase, +/- SD, n=3. B) 
Short-term stimulation (seconds) assays were performed with 3K:I-Ab tetramers. Lines depict 
increase of p4G10 or pCD3ζ over time (seconds) +/- SD, n=2-5. Blue line; B3K506 Tconvs, 
red line; B3K506 Tregs. 
 
 
For longer-term stimulation assay (i.e. 60-150 minutes) we used 3K peptide pulsed 
splenocytes APCs (Figure 5.1.10). To increase conjugate formation APCs and Tcells were 
spun down. We detected a slight reduction (≈15%) in B3K506 Treg ERK phosphorylation 
(Figure 5.1.10, first panel, left and histograms right). However phosphorylation of c-JUN, 
which is critically involved in cell cycle progression, is regulated in a similar way in 
B3K506 Tregs and Tconvs (Figure 5.1.10, lower left panel).  
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Figure 5.1.10 TCR induced pERK and pc-JUN up-regulation 
Monoclonal B3K506 Tregs (red) and monoclonal B3K506 Tconvs (blue) were stimulated 
with 3K pulsed splenocytes for indicated time (minutes). Left: Lines in top panel show altered 
up-regulation of pERK in Tregs and Tconv. Data show % pERK positive cells +/-SD, n=3. 
Lower panel shows similar up-regulation of pc-JUN in Tregs and Tconv. Data show mean 
fold increase of pc-JUN over time, +/-SD n=2. Expression levels were normalized to 
unstimulated cells. Right: Histograms depict % positive pERK cells at 60 and 150 minutes in 
stimulation assay described above. Blue; B3K506 Tconvs, red; B3K506 Tregs and grey; 
unstimulated ctrl. 
 
 
B3K506 Tregs require TCR signaling to be suppressive in vitro, however proximal TCR 
signaling (measured by pCD3ζ) and overall phosphorylation (measured by p4G10) of 
B3K506 Tregs is reduced compared to B3K506 Tconvs. Similar regulation of TCR induced 
c-JUN phosphorylation might indicate that the Treg’s capacity to proliferate is not 
diminished compared to that of Tconvs.  
 
Unfortunately we did not have the time to investigate this finding any further. To make a 
concluding statement, we should have preformed more experiments and examined additional 
signaling pathways.  
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Next we wondered whether B3K506 Tregs required antigen stimulation for suppressive 
activity in vivo. Therefore skin grafts from B6.bm12 Rag-/- donor mice were transplanted on 
to B6 Rag-/- mice and challenged with a combination of adoptively transferred ABM (I-
Abm12 specific) Tconvs and B3K506 Tregs in the presence or absence of cognate 3K 
peptide (Figure 5.1.11 A, B). By administering 3K peptide until day 15, we could induce 
50% graft survival lasting ≥ 75 days.  
 
 
Figure 5.1.11 In vivo suppression assay 
A) Experimental design of in vivo suppression assay. B) Skin from B6.bm12 Rag-/- donor 
mouse was transplanted onto B6 Rag-/- mice and allowed to heal for 7 days. The following 
day mice were injected with 2x10e4 ABM (I-Abm12 specific) Tconvs along with polyclonal 
B6 Foxp3-EGFP Tregs (green line) or monoclonal B3K506 Tregs (solid red and dashed lines). 
An additional group (grey line) was injected with ABM Tconvs alone. One group (solid red 
line) received 3K (30 µg per mouse, IP every second day until day 15. Graph shows mean % 
graft survival +/- SD vs. time. Each group contains 5 to 8 mice and results are pooled from 2 
individual experiments.  
 
 
A few animals from both groups (receiving or not receiving 3K peptide) were sacrificed and 
analysed on day 21 (Figure 5.1.12 A, B). Graft acceptance correlated with extensive B3K506 
Treg survival and Foxp3 expression. In mice tolerating their graft, there were >70 % 
B3K506 Tregs and very few ABM Tconvs remaining in the draining LN (Figure 5.1.12 A). 
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From these results we conclude that TCR signalling is crucial for Treg suppression both in 
vitro and in vivo. 
 
 
Figure 5.1.12 Draining LN’s from grafted mice 
A) Representative flow cytometry plots show ABM Tconvs and B3K506 Tregs from the 
draining LN of skin-grafted mice. Cells in upper plots are from a mouse which received 3K 
peptide and accepted the skin graft, while cells in the lower plots are from a mouse which 
rejected it’s graft, despite receiving the Treg cognate peptide, 3K. Number in the plots depict 
% of cells in each gate/quadrant. B) Representative flow cytometry plot showing ABM 
Tconvs and B3K506 Tregs from the draining LN of skin-grafted mice, which did not receive 
3K peptide treatment and rejected their graft. Numbers in the plot depict % of cells in each 
gate/quadrant. 
 
 
We wondered how antigen recognition by Tregs influences the survival/expansion and 
functional profile of co-cultured CD4+ OT-II Tconvs. Therefore live cell numbers of 
B3K506 Tregs and OT-II Tconvs along with the up-regulation of activation markers and 
cytokine concentrations in supernatants of suppressive (+3K peptide) and non-suppressive (-
3K peptide) cultures were analysed over time (Figure 5.1.13 A, B).  
 
Results 
 47 
 
Figure 5.1.13 Functional profile of suppressed OT-II Tconvs 
A) B3K506 Tregs outcompete OT-II Tconvs, in vitro. Representative flow cytometry plots 
show % of OT-II Tconvs and B3K506 Tregs in suppressive (with 3K peptide) and non-
suppressive (without 3K peptide) co-cultures at 72h. Numbers in the plots represent % of live 
cells in gate. Graphs show mean numbers +/- SD of live OT-II Tconvs (grey) and B3K506 
Tregs (red) from co-cultures described in A), n=3. B) Representative histograms show CD44, 
CD62L, CD69, Tbet, CD5 and CD25 expression on OT-II Tconvs in suppressive (with 3K 
peptide, red) vs. non-suppressive (without 3K peptide, black) co-cultures at 72h. 
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In suppressive cultures, OT-II Tconvs are not only prevented form proliferating but they also 
secrete reduced amounts IFNγ and IL-2 (Figure 5.1.14 A, B). This is consistent with the 
observation that suppressed OT-II Tconvs are less activated and express lower levels of 
CD25 and CD69 than do non-suppressed OT-II Tconvs (Figure 5.1.14 C, D).  
 
 
Figure 5.1.14 Cytokine production and activation status of suppressed OT-II 
Tconvs 
A) Left: Graph depicts mean IFNγ (pg/ml) +/- SD in supernatants of suppressive (red) and 
non-suppressive (black) co-cultures, n=3. Right: Representative flow cytometry plots show 
intracellular IFNγ staining of OT-II Tconvs in suppressive (red) vs. non-suppressive (black) 
co-cultures. B) Left: Graph depicts mean IL-2 (pg/ml) +/- SD in supernatants of suppressive 
(red) and non-suppressive (black) co-cultures, n=3. Right: Representative flow cytometry 
plots show GFP expression from eFluor labelled OT-II IL-2-GFP reporter Tconvs in 
suppressive (red) vs. non-suppressive (black) co-cultures. C) Representative flow cytometry 
plots show CD69 expression on CFSE labelled OT-II Tconvs from suppressive (red) and non-
suppressive (black) cultures at 72h, n=3-5. Numbers in the plots represent % of cells in each 
quadrant. D) Representative flow cytometry plots show CD25 expression on CFSE labelled 
OT-II Tconvs from suppressive (red) and non-suppressive (black) cultures at 72h, n=3-5. 
Numbers in the plots represent % of cells in each quadrant. 
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To further investigate the role of TCR signalling in suppression, we stimulated co-cultures 
with various altered peptide ligands for B3K506 Tregs at various concentrations and 
analysed them. All three peptides induced suppression when used at their EC50 
concentration for CD69 (Figure 5.1.15).  
 
 
Figure 5.1.15 EC50 peptide concentrations 
Left: Graph shows mean % of CD69+ B3K506 Tconvs +/-SEM in response to various peptide 
antigens used at various concentrations. Cells were cultured for 24 hours, n=3. Right: Bar 
graph shows mean OT-II proliferation index +/-SD from suppressive co-cultures at 72h where 
B3K506 Tregs were stimulated with various altered peptide ligands at their EC50 
concentration, n=8. 
 
 
In cultures stimulated with various altered peptide ligands at various concentrations, live, 
CD4high, Foxp3high B3K506 Tregs were assessed for frequency, absolute cell numbers (Figure 
5.1.16 A), CD25 expression (Figure 5.1.16 B) and suppressive capacity (Figure 5.1.16 C). 
Independent of concentration, stimulation with the high affinity ligand 3K resulted in high 
numbers of surviving/expanding B3K506 Tregs and induction of significant OT-II Tconv 
suppression. However, the intermediate affinity ligand, P8G only led to Treg survival and 
significant suppression when added at a high concentration (Figure 5.1.16 A, C). B3K506 
Treg survival decreased even more when stimulated with the threshold affinity ligand, P2A 
(Figure 5.1.16 A). However, significant suppression could still be achieved in co-cultures 
with high P2A peptide concentrations (Figure 5.1.16 C).  
 
 
Results 
 50 
 
Figure 5.1.16 Suppression assays using altered peptide ligands for B3K506 
Tregs 
A) Representative flow cytometry plots show live B3K506 Tregs from suppressive co-
cultures at 72h stimulated with various B3K506 altered peptide ligands used at 10e-5  peptide 
concentration. Numbers in the plots depict % of cells in each quadrant. Bar graph shows mean 
number of live B3K506 Tregs +/-SD from these cultures at 72h, n=5. B) Representative 
histograms show CD25 expression (MFI) on CD4high Foxp3high B3K506 Tregs from 
suppressive co-cultures stimulated with various altered peptide ligands or no peptide at 72h. 
C) Representative histograms depict proliferation of CFSE labelled live OT-II Tconvs form 
suppressive co-cultures described in A).  Bar graph shows OT-II mean proliferation index +/-
SD at 72h, n=4-8. A,C) Statistical significance was calculated using an one-way ANOVA and 
subsequently Bonferroni's multiple comparisons test. Ns=p>0.05, *=p≤0.05, **=p≤0.01, 
***=p≤0.001, ****=p≤0.0001 
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To further deconstruct the role of TCR signalling in Treg suppression, we plotted the 
suppressive capacity of B3K506 Tregs against surviving B3K506 Treg numbers (Figure 
5.1.17 C) or B3K506 Treg CD25 expression (Figure 5.1.17 D). Suppression clearly 
correlated with pMHC affinity and concentration (Figure 5.1.17 A, B), surviving Treg 
numbers and the amount of CD25 expression on surviving Tregs. High Treg cell numbers 
can compensate for low CD25 expression (3K 10e-7M, compare red triangle in C and D) and 
vice versa (3K 10e-5 compare red circle in C and 3D). There is a clear threshold below 
which low Treg cell numbers and CD25 expression fail to induce suppression.  
 
 
Figure 5.1.17 Suppression correlates with Treg cell number, CD25 expression 
and peptide affinity 
A) Curve shows correlation between peptide-MHC affinity (1/KD) for the B3K506 TCR and 
OT-II proliferation index from suppressive co-cultures described in Figure 5.1.16. APCs were 
pulsed with 10e-8M peptides (squares) or 10e-5M peptides (circles). B) Curve shows 
correlation between B3K506 TCR stimulus strength (defined as pMHC affinity [1/KD x 
peptide conc. (µM)] and OT-II proliferation index from suppressive co-cultures described in 
Figure 5.1.16. Curve is a nonlinear fit with variable slope (4 parameters). C) Correlation 
between OT-II proliferation index and number of surviving Tregs from suppressive co-
cultures described in Figure 5.1.16. Curve is a nonlinear fit with variable slope (4 parameters). 
D) Correlation between OT-II proliferation index and CD25 levels on surviving Tregs from 
suppressive co-cultures described in Figure 5.1.16. Curve is a nonlinear fit with variable slope 
(4 parameters). 
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From these results we conclude that Treg TCR stimulation strength drives suppression 
through maintenance and induction of Treg cell survival/expansion and CD25 expression.  
With extent to the fact that suppression correlates with the numbers of Tregs, we further 
aimed to understand suppression on a cellular, mechanistic level. By stimulating OT-II 
Tconvs with peptide loaded APCs in the presence of culture supernatants form antigen 
stimulated B3K506 Treg cultures, no evidence for a soluble suppressive molecule was 
observed (Figure 5.1.18) 
 
 
Figure 5.1.18 B3K 506 Treg culture supernatant 
Supernatants from stimulated Treg cultures are not suppressive. Graph depicts mean 
proliferation index +/- SEM of OT-II T convs cultured in various concentrations of 
supernatant from stimulated B3K506 Treg cultures, n=3. Representative histograms depict 
proliferation of OT-II Tconvs cultured in media containing 50% Treg supernatant (red) or in 
media alone (grey). 
 
 
In suppressive (with 3K peptide) and non-suppressive (without 3K peptide) co-cultures, 
expression of CD86 on splenic B cell APCs and surviving splenic B cell numbers was 
similar (Figure 5.1.19). This argues that a Treg-induced decrease of CD86 on APCs (i.e. 
trans endocytosis) or a Treg-mediated killing of APCs was not obviously required for 
suppression in our cultures.  
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Figure 5.1.19 Tregs do not affect CD86 expression on APCs or APC cell 
numbers 
Left: Bar graph depicts % of CD86+ splenic B cell APCs from suppressive (with 3K peptide, 
red) and non-suppressive (without 3K peptide, black) co-cultures. Middle: Representative 
flow cytometry plots show CD86 expression on live, CD19+CD4- splenic B cell APCs at 72h 
from these cultures. Numbers in the plots depict % of cells in each quadrant. Right: Graph 
shows mean number of live splenic B cell APCs +/- SD vs. time in suppressive vs. non-
suppressive co-cultures, n=3. 
 
 
Even though B3K506 Tregs from suppressive co-cultures expressed surface latency 
associated peptide of TGFβ (LAP) (Figure 5.1.20 A) we didn’t observe conversion of OT-II 
Tconvs into iTregs (Figure 5.1.20 B). This mechanism of suppression is not evident in our 
experimental system. 
 
 
Figure 5.1.20 B3K506 Tregs do not convert OT-II Tconvs into iTregs 
A) Representative flow cytometry plots show Foxp3 and LAP expression on OT-II Tconvs 
and B3K506 Tregs from suppressive cultures at 72 hours. Numbers in the plots represent % of 
cells in each gate. B) B3K506 Tregs do not convert OT-II Tconvs into induced Tregs (iTregs). 
Representative flow cytometry plots show Foxp3 and CD4 expression on OT-IIs from 
suppressive co-cultures at 72h. Numbers in the plots depict % of cells in each quadrant or 
gate. 
 
 
Finally we wondered if Tregs and Tconvs needed to encounter their cognate peptide on the 
same APC for effective suppression to occur. To avoid cross-presentation, we used I-Ed 
restricted HA transgenic Tconvs. In this system, peptide cross presentation and alloreactions 
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did not occur (Figure 5.1.21 B). We co-cultured I-Ab restricted B3K506 Tregs and I-Ed 
restricted HA Tconvs on the same APCs (i.e. F1, B6xBalb/c splenic B cells with 3K and HA 
peptides) or on separate APCs (i.e. B6 splenic B cells loaded with 3K peptide only and 
BALB/c splenic B cells loaded with HA peptide only). The results show that suppression is 
more complete when both antigens are presented on the same APC (Figure 5.1.21 A) 
 
 
Figure 5.1.21 Peptide encounter on same vs. separate APCs 
A) Suppression is enhanced when Treg and Tconv antigens are presented on the same APC. 
Left: Representative histograms show proliferation of CFSE labelled HA Tconv co-cultured 
with B3K506 Tregs. HA Tconvs and 506 Tregs encounter their cognate ligand either on the 
same (left) or on separate (right) splenic B cell APCs (see diagram). Both conditions were 
compared to non-suppressive cultures where 3K peptide was omitted (black). Right: Graph 
shows mean % suppression and proliferation index +/-SD of HA-Tconvs co-cultured in the 
different conditions described above, n=4-5. B) Representative histogram shows CFSE-
labelled HA Tconv on an I-Ed background in culture with B6 splenic B cells on an I-Ab 
background after 72 hours. Gated on live, CD45.1+CD4+ cells (HA-Tconvs). 
 
 
However, antigens presented on separate APCs were able to support some degree of 
suppression, as up regulation of CD25 on HA Tconvs was suppressed in these separate APC 
co-cultures (Figure 5.1.22).  
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Figure 5.1.22 Suppression of CD25 on HA-Tconvs 
Representative flow cytometry plots show CD25 expression on live HA Tconvs in cultures 
described in 4.1.21. Numbers in the plots represent % of cells in each quadrant. Bar graph 
depicts mean % CD25+ HA-Tconvs +/-SD in these cultures at 72h, n=4. 
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5.2 Part B 
To quantify the amount of Lck coupled to CD8 or CD4 coreceptors we made use of a 
method where multiprotein complexes are analyzed via immunoprecipitation and 
quantitative flow cytometry (IP-FCM162 Figure 5.2.1).  
 
 
Figure 5.2.1 IP-FCM principle 
Scheme of immunoprecipitation and quantitative flow cytometry 
 
 
Sorting TCRβ low B6 thymocytes resulted in a 96.3 % pure population of DP thymocytes 
(Figure 5.2.3 A). In this sorted population, 0.6% of CD8 co-receptor were coupled to Lck 
where as 6.7% of CD4 co-receptors carried Lck (Figure 5.2.3 C: black bars and A: 
black/grey histograms) To further investigate this difference between CD8 and CD4 co-
receptor-Lck coupling ratios, OT-1 TCR transgenic mice were bred to a CD8.4 co-receptor 
chimera knock-in strain. In this mouse, thymocytes express a co-receptor consisting of the 
extracellular CD8α chain and the intracellular CD4 tail carrying Lck (Figure 5.2.2). 
 
 
Figure 5.2.2 Chimeric CD8.4 receptor 
A. Singer et al. JI, 2006 
 
In DP thymocytes from OT-1 CD8.4 mice, 6% of CD8.4 molecules were loaded with Lck 
compared to 1.1% in OT-1 WT mice (Figure 5.2.3 C compare light blue and dark blue bars 
and Figure 5.2.3 B compare light blue and dark blue histograms).  
Interestingly, CD4 co-receptors in CD8.4 mice carried less Lck than CD4 co-receptors from 
OT-1 WT mice (Figure 5.2.3 C compare light blue bars and dark blue bars). These 
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differences were also apparent in co-immunoprecipitations of CD8 and CD4 co-receptors in 
DP thymocytes from these mice (Figure 5.2.3 D).  
 
Figure 5.2.3 Co-receptor Lck coupling ratios in WT and CD8.4 OT-I DP 
thymocytes compared to B6 DP thymocytes 
A) Left: representative histogram and flow cytometry blot show TCRβ high (SP) and low 
(DP) thymocytes from B6 mice. TCRβ low cells were sorted to exclude contamination with 
single positive thymocytes. Number in the plot depicts % of cells in the gate. Right: Cell 
lysates were incubated with beads coated with antibodies to CD4, CD8β or isotype controls. 
Beads were probed with PE-conjugated antibodies to Lck, CD8α or CD4 and analyzed by 
flow cytometry. Histograms show PE-signal intensity of immunoprecipitated proteins from 
sorted TCRβ low B6 thymocytes. B) Thymocytes from OT-I WT (dark blue) and OT-I CD8.4 
(light blue) were analyzed. Histograms show PE-signal intensity of immunoprecipitated 
proteins. Number in the plots depict % of cells in each gate. C) Bar graph show mean % Lck 
co-receptor coupling rations, +/- SD of DP thymocytes from B6 (black), OT-1 WT (dark blue) 
and OT-I CD8.4 (light blue) mice, n=3-5. D) Thymocyte lysates were immunoprecipitated 
with protein G beads coated with antibodies to CD4, CD8α or isotype controls and analyzed 
by western blotting. Membrane was probed with anti-Lck antibody, n=2. 
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We examined if there was a competition for Lck between the intracellular CD4 tail of the 
CD8.4 chimeric co-receptor and the wild type CD4 co-receptor. Therefore MHC class II 
restricted B3K508 TCR transgenic mice were bred to the CD8.4 co-receptor chimera knock-
in strain. While CD8.4 co-receptors from these mice had increased Lck coupling ratios, they 
also showed increased CD4 co-receptor Lck coupling ratios (16.4% vs. 9.9%, Figure 5.2.4). 
This argued against a competition for Lck between the intracellular CD4 WT tail and the 
CD8.4 chimeric co-receptor tail. 
 
 
Figure 5.2.4 Co-receptor coupling rations in MHC class II restricted 
B3K508 WT and B3K508 CD8.4 mice 
Cell lysates were incubated with beads coated with antibodies to CD4, CD8β or isotype 
controls. Beads were probed with PE-conjugated antibodies to Lck, CD8α or CD4 and 
analyzed by flow cytometry. Bar graph show mean % Lck co-receptor coupling rations, +/- 
SD of DP thymocytes from B3K508 WT (red) and B3K508 CD8.4 (yellow) mice compared 
to B6 (black), OT-1 WT (dark blue) and OT-I CD8.4 (light blue) mice, n=3-5 
 
 
Next we wondered if mature, single positive T cells showed increased CD8 and CD4 co-
receptor Lck coupling ratios compared to immature DP thymocytes (Figure 5.2.5). No 
significant difference was seen comparing CD4-coupled Lck ratios from peripheral T cells 
and CD4 Lck coupling ratios from DP thymocytes (Figure 5.2.5 and Figure 5.2.4, compare 
black and red bars). However there was a difference in CD8 coupled Lck ratios; while co-
receptors from peripheral B6 CD8+ T cells carried 9.5% of Lck, only 0.6% of CD8 
coreceptors in DP thymocytes form these mice carried Lck (Figure 5.2.5 and Figure 5.2.4, 
compare black bars). The same was true in the OT-1 WT strain: 8.9% of CD8 co-receptors 
from peripheral CD8+ T cells were coupled to Lck, but only 1.1% of CD8 co-receptors in DP 
thymocytes were coupled to Lck (Figure 5.2.4 and Figure 5.2.4, compare blue bars). A 
possible explanation for this finding might be the sialyation of the CD8β co-receptor chain 
following positive selection in the thymus7. To compensate for decreased binding capacity of 
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the sialylated CD8β chain to peptide–MHC complexes, peripheral CD8 co-receptor Lck 
coupling ratios might therefore be increased,.  
 
 
Figure 5.2.5 Co-receptor Lck coupling ratios in mature peripheral T cells  
Bar graph show mean % Lck co-receptor coupling rations, +/- SD of mature T lymphocytes 
from B6 (black bars) OT-I WT (blue) and B3K508 WT (red) mice, n=4-5 
 
 
Finally, to calculate the exact Lck molecule numbers, we determined the absolute amount of 
TCR, CD4 and CD8 surface molecules on DP thymocytes of B6, OT-1 WT and OT-1 CD8.4 
mice. By generating a standard curve based on the fluorescence signal of calibration beads, 
the mean fluorescence intensity of surface staining, i.e. CD3ε, CD4 and CD8, could be 
transformed into absolute numbers of surface molecules (Figure 5.2.6).  
 
 
Figure 5.2.6 Mean equivalent soluble PE molecules (MEPE) for B6 DP 
thymocytes 
DP TCRβ low B6 thymocytes were stained with saturating concentrations of PE-conjugated 
antibodies to CD4, CD8α or CD3 and analyzed by flow cytometry together with PE 
calibration beads. Florescence signals from stained thymocytes and calibration beads (grey 
histograms) are shown (i.e. CD4 (pink), CD8α (purple), CD3 (turquoise) and negative B cell 
control (dotted black)). Left: number in the plot depict % of cells in the gate. Right: number of 
mean equivalent soluble PE molecules (MEPE) is shown for each peak. 
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We counted approximately 2500 TCR molecules on the surface of a DP B6 thymocyte 
(Figure 5.2.7 A). The same cell expressed approximately 1.15x10e5 CD4 and 2.8x10e5 CD8 
co-receptors (Figure 5.2.7 B, C). A 50 to 100-fold increase of TCR expression was observed 
on peripheral T lymphocytes compared to DP thymocytes, indicating that TCR expression 
increased after successful thymic selection (Figure 5.2.7 A).  
Compared to DP thymocytes, there is a twofold increase of CD4 co-receptors expressed by 
peripheral CD4+ T cells (Figure 5.2.7 B). However no such increase was seen in the 
expression levels of CD8 co-receptors. DP and SP thymocytes from B6, OT-1 WT and OT-1 
CD8.4 mice expressed similar levels of CD8 co-receptors and no significant increase was 
seen in CD8+ peripheral T cells  (Figure 5.2.7 C).  
 
 
Figure 5.2.7 Surface molecules 
A) Bar graph show mean number of CD3 surface molecules on DP, SP thymocytes (left) and 
T lymphocytes (right). Cells from B6 (black), OT-1 WT (dark blue) and OT-1 CD8.4 (light 
blue) were analyzed. B) Bar graph show mean number of CD4 surface molecules on DP, SP 
thymocytes (left) and T lymphocytes (right). Cells from B6 (black), OT-1 WT (dark blue) and 
OT-1 CD8.4 (light blue) were analyzed. C) Bar graph show mean number of CD8α surface 
molecules on DP, SP thymocytes (left) and T lymphocytes (right). Cells from B6 (black), OT-
1 WT (dark blue) and OT-1 CD8.4 (light blue) were analyzed. Data show mean numbers +/- 
SEM, n=3-6. 
 
 
Taken together, we show that in DP thymocytes, CD4 co-receptors carry more Lck than CD8 
co-receptors. In a system where MHC class I restricted thymocytes express a chimeric 
CD8.4 co-receptor, Lck coupling ratios are increased. In addition, DP thymocytes express 
more CD8 than CD4 surface co-receptors. These data add to the idea that the affinity 
threshold for MHC class I and II restricted thymocytes depend on the probability of a 
peptide-MHC-TCR complex colliding with a co-receptor coupled to Lck to during the time 
pMHC occupies the TCR. We therefor believe co-receptor Lck coupling ratios have an 
important role in setting the affinity threshold for negative selection. 
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6 Discussion 
6.1 Studies of suppression using monoclonal regulatory T cells  
In the first part of the thesis we examined the role of various Treg suppressive mechanisms 
using a source of monoclonal TCR and Foxp3 transgenic Tregs (i.e. B3K506 Tregs). Here 
we show that monoclonal B3K506 Tregs are functional in vitro and in vivo and clearly 
require cognate peptide stimulation through their TCR to be suppressive. Our data show that 
the strength of Treg TCR stimulation correlates with the extent of Treg mediated 
suppression. Increasing the affinity and/or concentration of Treg antigen drives Treg 
proliferation and CD25 expression, which is likely related to the extent of suppression in the 
system.  
B3K506 (monoclonal) Tregs differed from polyclonal, thymus derived Tregs observed in B6 
mice in that B3K506 monoclonal Tregs express neither Helios nor NRP-1. Thymic Tregs in 
polyclonal mice are normally generated through antigen selection28,29; they likely acquire 
Helios and NRP1 expression following a high affinity encounter with self-antigen31. In 
contrast, thymocytes bearing the B3K506 TCR are normally positively selected but are 
directed into the Treg lineage due to the presence of the Foxp3 transgene. Since B3K506 
monoclonal Tregs did not encounter a high affinity self-antigen during their development, 
they are Helios- and NRP1- negative32. 
B3K506TCR Tg Foxp3 Tg mice are lymphopenic and only 40-50 % of CD4 T cells are 
Foxp3+. To increase Treg numbers, we injected mice with Il-2 complexed to the monoclonal 
antibody JES6-1164. Although CD4+ T cells expanded in treated mice the proportion of 
CD4+Foxp3+ cells did not alter. Treatment with IL-2/mAb complexes did not increase the 
number of NK Tcells in these mice. Sorting a CD4+GITRhigh population from the B3K506 
Foxp3 Tg mouse, resulted in >96% pure monoclonal Treg population. Previous work 
describing the ablation of Treg suppression after application of anti-GITR antibodies was not 
observed in our system, as GITR sorted Tregs were suppressive in vitro and in vivo165. 
B3K506 Tregs are suppressive in vitro upon cognate antigen encounter. This led us to 
examine how TCR signalling between B3K506 Tregs and B3K506 Tconvs might differ. 
Proximal TCR signalling (measured by pCD3ζ and pZap-70) seems to be reduced in Tregs. 
Previous work, stating that Tregs maintain a hypo-responsive state by suppressing the 
induction of TCR initiated signals support these findings99,100. However, we measured a 
similar increase of pc-JUN levels in pMHC stimulated B3K506 Tregs and B3KTconvs over 
time (0-150 minutes). C-JUN is critically involved in the cycle progression process of a T 
cell, indicating that the Treg’s capacity to proliferate upon TCR signalling is not diminished. 
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Recent data using a model where the TCR can be depleted in peripheral Tregs, show that 
continuous expression and signalling of the TRC is required for effective suppression to 
occur106. This supports our observation that monoclonal B3K506 Tregs clearly require 
cognate peptide stimulation through their TCR in order to be suppressive.  
Using a skin-graft-transplantation model we observed that B3K506 monoclonal Tregs 
receiving cognate peptide 3K, are less suppressive than polyclonal Tregs (50% vs. 100% 
graft survival). This might be explained by a short half-life of 3K peptide in vivo, leading to 
suboptimal priming in the host. However, recipient mice that had accepted their skin graft 
achieved stable (75d) tolerance and did not require peptide administration past day 15. 
In the presence of cognate antigen B3K506 Tregs expanded between 48 and 72h. This 
contradicts previous work describing a requirement for Treg anergy to achieve effective 
suppression108. There is data showing that Tconv proliferation is limited in suppressed 
cultures and cytokine production (IFNγ and IL-2) is inhibited at a level of RNA 
transcription109. Similar to what is reported, we observed decreased IFNγ and IL-2 cytokine 
levels in culture supernatants from suppressive co-cultures. Although suppressed OT-II 
Tconv produced very little IFNγ (as measured by intracellular staining) using an IL-2EGFP 
reporter, suppression of measured IL-2 production was incomplete.  
To investigate the role of TCR signal strength in B3K506 Treg suppression we used three 
altered peptide ligands (i.e. 3K, P8G, P2A). Although they display an affinity hierarchy for 
the B3K506 TCR (3K>P8G>P2A) all three peptides are above the affinity threshold for 
negative selection9. All three peptides induced suppression when used at their EC50 
concentration for CD69. However, low affinity peptides were more suppressive when used at 
increased concentrations. Peptide concentration could compensate decreased affinity to some 
extent. Overall suppressive capacity correlates with pMHC affinity, peptide concentration, 
TCR signal strength, B3K506 Treg proliferation and CD25 expression. 
In accordance with published data166, we did not detect a soluble suppressive molecule in 
culture supernatants from antigen stimulated B3K506 Tregs. However suppressive cytokines 
like IL-10, IL-35 and TGFβ or tryptophan metabolites, granzymes A or B and adenosine 
may be too diluted or unstable to be suppressive in a relatively large culture volume (200µl). 
In this experimental system, CTLA-4 mediated trans-endocytosis of CD86 was not 
observed116-118. CD86 expression on APCs (splenic B cells) from suppressive vs. non-
suppressive co-cultures was similar. Suppressive mechanisms involving the induction of 
APC apoptosis can also be excluded due to the fact that the numbers of surviving APCs in 
suppressive and non-suppressive co-cultures are similar and previous work showing that 
Discussion 
 63 
paraformaldehyde fixation of APCs had no significant effect on the degree of Treg mediated 
suppression108.  
Furthermore as polyclonal Tregs express higher amounts of LFA-1 than Tconvs121, 
suppression was suggested to work through the physical interference of Tregs with the 
interaction between APCs and Tconvs. However B3K506 monoclonal Tregs express lower 
levels of LFA-1 compared to B3K506 Tconvs. Therefor it does not seem likely that LFA-1 
by itself accounts for suppression in our system. Finally we didn’t observe conversion of 
OT-II Tconv into iTregs, although B3K506 Tregs from suppressive co-cultures expressed 
surface latency associated peptide of TGFβ (LAP).  
Experiments using transwell culture settings failed to observe suppression108,109. The authors 
concluded that Treg-to-Tconv-cell-contact has a predominant role in mediating suppression. 
Along this line we designed an experiment where I-Ab restricted B3K506 Tregs and I-Ed 
restricted HA Tconvs were either co-cultured on B6xBALB/c F1 APCs presenting Treg and 
Tconv peptides or on separate B6 and BALB/c APCs each presenting the Treg and Tconv 
peptides respectively. In this system, peptide cross presentation and alloreactions of the two 
MHC class 2 types did not occur. Suppression is more complete when Tregs and Tconvs 
received antigen stimulation from F1 APCs presenting both peptides. However, a partial 
suppression was detected when cells were cultured on separate APCs: using separate APCs 
for each antigen, HA Tconv were able to proliferate but did not up regulate CD25.  
Taken together we conclude that suppression requires high Treg numbers with high CD25 
surface expression and close proximity between Tregs and Tconvs. These results, along with 
the observation that addition of exogenous IL-2 abrogates suppression (in vitro)108,109, are 
consistent with the idea for a model of suppression, where Tregs scavenge IL-2 produced by 
Tconvs. Tregs continuously, and upon TCR signalling even more so, express high affinity 
CD25. Due to the direct repression of the IL-2 promoter via the transcription factor Foxp3 
they are unable to produce autocrine IL-259. A potential, reliable source of paracrine IL-2 
could be a naïve neighbouring CD4+ T cell encountering ubiquitously present self-peptide in 
the periphery. The uptake of excess paracrine IL-2 by Tregs has beneficial effects on the 
maintenance of immune homeostasis155: (i) consuming IL-2 gives the Treg a survival signal 
and maintains elevated CD25 expression and (ii) by decreasing the amounts of IL-2 
available to Tconvs, Tregs limit the ability of Tconvs to respond to self-antigens. 
There are few reports in the literature arguing against IL-2 scavenging as a major mechanism 
of suppression. CD25 KO mice are suppressive in vitro and mice with specific deletion of 
peripheral CD122 in Tregs do not suffer from autoimmune disorders85. However these 
arguments have been mitigated by work showing that CD122 deficient Tregs still respond, 
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albeit to a diminished extent, to IL-2 signalling138 and Tregs from CD25 KO mice failed to 
prevent spontaneous encephalomyelitis in vivo167.  
We show here that proximity imposed by Treg and Tconv peptide recognition on the same 
(F1) APC renders suppression more complete. This mechanism may be partially active in 
cultures using two separate APC’s due to the high density of Tregs. However, in vivo it 
seems unlikely that Tregs and Tconvs responding to separate APCs will achieve sufficient 
proximity to induce suppression. In the lymph node there is a large excess of bystander CD4 
and CD8 T cells, which decrease the proximity of Tregs and self-reactive Tconvs. In this 
light, the most efficient mechanism to achieve Treg-Tconv proximity is for the Treg and 
Tconv to be stimulated by the same APC. Recent data using a two-photon microscopy for 
LN-live imaging showed that Tregs migrate at high velocities and engage both Tconvs and 
DCs in brief but frequent contacts. The authors conclude that, under non-inflammatory 
conditions, a LN-resident DC is in contact with at least one Treg for 36-47% of the time168. 
The Treg TCR receptor repertoire is skewed towards self-antigen recognition and TCR 
expressed by Tregs are thought to be of higher affinity for self-antigens than conventional T 
cells169,170. Resident LN DCs constitutively present self-peptides. Accordingly if a Treg in 
the LN often occupies a DC, this provides an ideal platform for a Treg and a potentially self-
reactive Tconv to encounter (self)-peptide in close proximity (i.e. on the same APC). This 
might create a localized “IL-2-sink” which abrogates further activation and proliferation of 
self-reactive Tconvs.  
Even though we favour IL-2 steeling as the starring mechanism among all others proposed, 
this thesis couldn’t exclude a role for cell-to-cell contact suppressive mechanisms. It is well 
possible that Tregs, in addition to scavenging IL-2, physically interact with Tconv and 
mediate suppression, for example, through gap-junction formation, shunting high levels of 
inhibitory cyclic adenosine monophosphate (cAMP) from Tregs to Tconv135. In addition a 
requirement for Treg-Tconv proximity is also compatible with the Treg secreting 
suppressive mediators which are only effective (i.e. at sufficiently high concentrations) at 
short distance from the Treg. Additional work is needed to fully characterize the multiple 
mechanism of Treg-mediated suppression and monoclonal Tregs may be a useful tool for the 
future. 
 
6.2 The importance of co-receptor Lck coupling ratios for negative selection  
In the second part of the thesis we examined the importance of co-receptor Lck coupling 
ratios for negative selection. Here we show, that unequal proportions of CD8 and CD4 co-
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receptors from DP thymocytes carry the tyrosine kinase Lck (i.e. 0.6% vs. 6.7%, 
respectively). Further analysis showed that only 25-28% of coupled Lck is active. This 
implies that ~0.16% of CD8 and ~1.8% of CD4 molecules in B6 DP thymocytes are actually 
capable of initiating a TCR signal. 
Using a chimeric CD8.4 co-receptor, consisting of an extracellular CD8α chain and an 
intracellular CD4 tail, we measured an increase in the co-receptor Lck coupling ratio (i.e. 
1.1% for the CD8 WT and 6% for the CD8.4 co-receptor). Additional experiments making 
use of TCR Tg OT-I WT and OT-I CD8.4 DP thymocytes, revealed that a difference in co-
receptor Lck coupling ratios results in a shift of the affinity threshold for negative selection. 
In OT-I CD8.4 mice, below threshold ligands, with decreased affinity for the OT-I TCR, 
were able to induce negative selection (Fig. 3A, Stepanek, O. et al. Cell, 2014). 
Upon recruitment, active Lck phosphorylates the ITAMs in the CD3 complex and activates 
the tyrosines on Zap-70. Since TCR-pMHC complexes scan up to hundreds of co-receptors 
before colliding with one that carries active Lck, we measured the time an antigen needed to 
occupy the TCR (i.e. antigen dwell time) to induce a negative selection signal. A MHC class 
I-restricted TCR required antigens with a median dwell time (i.e. half life) > 0.9s to induce 
negative selection, while the negative selection threshold for MHCII-restricted TCRs is  > 
0.2s9.  
Modeling studies revealed that the co-receptor Lck coupling ratio is a critical parameter for 
the establishment of the affinity threshold for negative selection. The decrease in antigen 
dwell time threshold of negative selection seen in MHC-II restricted TCRs compared to 
MHC-I restricted TCRs is a direct consequence of the CD4’s increased Lck coupling ratio.  
With our experimental results and additional mathematical calculations the ‘Lck come and 
stay/signal duration’ model based on the principle of kinetic proofreading171 was generated. 
The model assumes that transient CD4-MHCII or CD8-MHCI interactions allow the TCR-
pMHC complex to scan multiple coreceptors via co-receptor exchange before finding a co-
receptor carrying catalytically active Lck. This model can explain how the TCR actually 
measures antigen affinity to initiate a negative selection signal; long lasting antigen binding 
events are more likely to be converted into a signaling event and trigger negative selection. 
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Figure 6.2.1 Graphical abstract of co-receptor scanning 
Stepanek, O. et al. Cell, 2014 
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8 Abbreviations 
Ab Antibody 
Ag Antigen 
AIRE Human autoimmune regulator protein 
Akt Also known as PKB, Protein kinase B 
APC Allophycocyanin 
APC Antigen-presenting cell 
AP-1 Activator protein 1 
B6 C57BL/6 
β2m Beta two microglobulin 
BCL B cell lymphoma  
Bim BCL2L11 protein 
Blimp-1 Domain zinc finger protein 1, also know as PRDM1 
BSA Bovine serum albumin 
Ca2+ Calcium 
cAMP Cyclic adenosine monophosphate 
CBA Cytometric bead array 
CBFβ Core-binding factor subunit beta 
CCR Chemokine receptor 
CD Cluster of differentiation 
CD25 IL-2 receptor alpha chain 
CD122 IL-2 receptor beta chain 
CD132 Common gamma chain 
CFSE Carboxyfluorescein diacetatsuccinimidyl ester 
CML Carboxylate modified latex 
CNS Conserved non-coding regions 
Cre Cyclization recombination 
C-rel Protoncogene 
Csk C-terminal Scr kinase 
cTEC Cortical thymic epithelial cell 
CTLA-4 Cytotoxic T-lymphocyte antigen 4 
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CXCR5 C-X-C chemokine receptor type 5 
DC Dendritic cell 
DMEM Dulbecco’s modified eagle medium 
DNA Desoxyribonucleinacid 
DP Double positive 
EC50 Half maximal effect concentration 
EDTA Ethylenediaminetetraacetic acid 
ERK Extracellular signal-regulated kinase 
FACS  Fluorescent activated cell scanning/sorting 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanat 
FIK Foxp3-interacting KRAB domain containing protein 
Foxp3 Forkhead box protein 3 
Foxo-1 Forkhead box protein O1 
GITR Glucocorticoid-induced TNFR-related protein 
GFP Green fluorescent protein 
GVHD Graft versus host disease 
HATs Histone acetyltransferases 
HCS Hematopoietic stem cell 
HDACcs Histone deacetyltransferases 
HRPO Horseradish peroxidase 
IFNγ Interferon gamma 
Ig Immuneglobulin 
IL Interleukine 
i.p.  Intraperitoneal 
IPEX Immunodysregulation polyendocrinopathy enteropathy X-linked 
syndrome 
IP-FCM Immunoprecipitation and quantitative flow cytometry 
IRF-4 Interferon regulatory factor 4 
ITAM Immunoreceptor tyrosine activator motif 
i.v.  Intravenous 
JAK Janus activated kinase 
kDa Kilodalton 
KD Dissociation constant 
KLRG1 Killer cell lectin-like receptor subfamily G member 1 
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KO Knock out 
KRAB Krüppel associated box 
LAG-3 Lymphocyte-activation gene 3 
LAP Surface latency associated peptide of TGFβ 
LAT Linker of activated T cells 
Lck Lymphocyte-specific protein tyrosine kinase 
LFA-1 Lymphocyte-function-associated antigen 1 
M Molar 
mAb Monoclonal antibody 
MAPK Mitogen-activated protein kinases 
Mcl-1 Induced myeloid leukemia cell differentiation protein 
MFI Mean fluorescent intensity 
MHC Major histocompatibility complex 
MEPE Mean equivalent soluble PE molecules 
mTECs Medullary Thymic epithelial cells 
mTOR Mammalian target of rapamycin 
NFAT Nuclear factor of activated T-cells 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NK Natural killer  
NRP-1 Neuropilin 1 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PB Pacific blue 
PD-1 Programmed cell death protein 1 
PE Phycoerithrine 
PE-Cy7 Phycoerythrin-cyanine dye 7 
PerCp Peridinin Chlorophyll protein 
PFA Paraformaldehyde 
PI Proliferation index 
PI3K Phosphatidylinositol 3-kinase 
PKC Protein kinase C 
PLCγ Phosphoinositide phospholipase C gamma 
pMHC Peptide-major histocomatibiliy complex 
PMA Phorbol myrisate acetate 
PPARγ Peroxisome proliferator-activated receptor gamma 
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PTEN Phosphate and tensin homolog 
Rag Recombinant activating gene 
ROR RAR-related orphan receptor 
RPM Revolutions per minute 
RPMI Roswell park memorial institute 1640 medium 
RT Room temperature 
RUNX Runt-related transcription factor 
SA Streptavidin 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SLP-76 Lymphocyte cytosolic protein 2 
SP Single positive 
STAT Signal transducer and activator of transcription 
Tbet T-box transcription factor 
TCR T cell receptor 
TCRα TCR alpha chain 
TCRβ TCR beta chain 
Tconv T conventional cell 
TEMED Tetramethylethylendiamin 
TFH T follicular helper cells 
TFR T follicular regulatory cells 
TGF-β Transforming growth factor beta 
Tg Transgenic 
Th T helper cells 
TNFα Tumor necrosis factor alpha 
TNFR Tumor necrosis factor receptor 
Treg T regulatory cell 
TSDR Treg-specific-de-methylated region 
WT Wild type 
Zap-70 
 
Zeta-chain-associated protein kinase 70 
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9.1.1 WIRM 2014, Davos 
 
 
  
Studying suppression using monoclonal regulatory T cells 
C. Osswald, B. Hausmann, R. Lang, E. Palmer 
Department of Biomedicine, University Hospital Basel & University Basel, Switzerland, c.osswald@unibas.ch 
Monoclonal 
506 Tregs and 
polyclonal B6 
Tregs similarly 
suppress 
Tconv.  
Importantly in the 
absence of TCR signalling, 
suppression is abrogated 
in both monoclonal 506 
and polyclonal Tregs. As 
expected 506 Tconv 
(iden&cal*TCR*as*506*Tregs)*
do*not*induce*suppression.*
Comparing 506 to B6 polyclonal Tregs Treg suppression depends on TCR signalling 
We utilized a panel 
of peptide variants 
with different TCR 
binding affinities. 
Interestingly low 
affinity APLs induce 
weaker CD69 
responses in 506 
Tregs compared to 
506  Tconv. 
Altered peptide ligands (APLs) 
Upon TCR triggering 
with high affinity 3K/I-
Ab tetramers, we 
observed  decreased 
pCD3z, pERK and  
decreased total  
tyrosine 
phosphorylation in 
506 Tregs compared 
to 506 Tconv.**
Decreased TCR signalling in Tregs 
We are investigating whether Tregs and Tconv differ in their ability to occupy and /or modify the APC through adhesion or co-stimulatory molecules. Monoclonal 
Tregs of defined antigen specificity should allow us to better characterize TCR mediated signaling in Tregs and better understand the cellular mechanisms of Treg 
mediated suppression. 
Outlook 
Mice 
We make use of B3K506 TCR Rag KO mice expressing a Foxp3 transgene to 
generate monoclonal Tregs with a defined specificity (506 Tregs). We compared 
the activity of these Tregs to 506 Tconv cells derived from B3K506 TCR Rag KO 
mice lacking the Foxp3 transgene.  
The presence 
of Tregs in 
these cultures 
also led to 
CD25 down 
regulation on 
conventional 
OT-IIs.  
**
The suppressive features of 
506 Tregs in the presence and 
absence of cognate antigen 
were assessed in vitro. Higher 
affinity Treg antigens lead to 
better suppression. 
Interestingly, co-culturing 506 
Tconv with OT-II Tconv led to 
strong responses from both 
conventional T cells. Therefore 
the presence of a second 
Tconv by itself did not lead to 
APC blockade or suppression.**
Suppression depends on Treg affinity 
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Affinity'Threshold'for'T'cell'tolerance'depends'on'co4receptor/Lck'coupling!
!
C.!Osswald,!C.!King,!O.!Stepanek,!V.!Gala6,!B.!Hausmann,!D.!Naeher!and!E.!Palmer!
Department)of)Biomedicine)and)Nephrology,)University)Hospital)Basel)
Methods)
Pep6de AMHC! d r i ven! TCR!
signaling! ini6ates! with! coA
r e c e p t o r ! b o u n d ! L c k!
phosphoryla6ng! ITAMs! within!
the!TCR/CD3!complex.!However,!
every! coAreceptor! carries! Lck!
indica6ng! that! only! some!
collisions! between! a! TCR! and! a!
coAreceptor! are! capable! of!
t r i g ger ing! TCR! s i gna l ing .!
Therefore! not! all! coAreceptor!
TCR!collisions!are!produc6ve.!
Thymic! nega6ve! selec6on! results! in! the! deple6on!
of! autoimmune! T! cells! expressing! TCRs! with! high!
affinity!for!selfAan6gens.!It!is!therefore!considered!a!
key!mechanism!in!the!induc6on!of!tolerance.!!
1.!T!cell!selec6on!
A!ligand!dissocia6on!constant!(KD)!of!6uM!and!a!halfA
life!of!≈!2!seconds!define!the!affinity!threshold!for!a!
class! I! MHC! restricted! double! posi6ve! (DP)!
thymocyte! to! succumb! to! nega6ve! selec6on! in! the!
thymus.!!
2.!What!is!affinity?!
For! class! II! restricted! TCRs! this! threshold! is! much!
lower! (KD300! uM,! t1/20.04! seconds)! and! leads! to!
nega6ve! selec6on! in! response! to! much! lower!
affinity!self!an6gen.!
3.!Threshold!for!thymocytes!
Background)
Results)
Using! a!method!where!
mul6protein!complexes!
a r e! a n a l y z e d! v i a!
immunoprecipita6on!
and! quan6ta6ve! flow!
cytometry!(IPAFCM),!we!
d e t e r m i n e d ! t h e!!
percentage!of!CD4!and!
CD8! c o A r e c e p t o r s!
c a r r y i n g! a n! L C K!
molecule! in! various!
t h y m o c y t e ! a n d!
p e r i p h e ra l! T! c e l l!
popula6ons.!!
5.!LCK!measurement!4.!Signaling!machinery!
6.!In!vivo!model! 8.!CD8.4!lowers!the!threshold!
(fetal!thymic!organ!cultures)!
OTA1! TCR! transgenic! mice! were! bred! to! a! CD8.4! coA
receptor! chimera! knockAin! strain! where! thymocytes!
express! a! coAreceptor! consis6ng! of! the! extracellular!
CD8α! chain! and! the! intracellular! CD4! tail! carrying! Lck.!
9.8%! of! CD8.4! molecules! are! loaded! with! Lck! in! DP!
thymocytes!from!these!mice.!!
7.!The!threshold!
The!threshold!affinity! for!nega6ve!selec6on!
inversely! correlates! with! the! LCK! /coA
receptor!coupling.!
Refernces 
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SUMMARY
In the thymus, high-affinity, self-reactive thymocytes
are eliminated from the pool of developing T cells,
generating central tolerance. Here, we investigate
how developing T cells measure self-antigen affinity.
We show that very few CD4 or CD8 coreceptor mole-
cules are coupled with the signal-initiating kinase,
Lck. To initiate signaling, an antigen-engaged T cell
receptor (TCR) scans multiple coreceptor molecules
to find one that is coupled to Lck; this is the first
and rate-limiting step in a kinetic proofreading chain
of events that eventually leads to TCR triggering and
negative selection. MHCII-restricted TCRs require a
shorter antigen dwell time (0.2 s) to initiate negative
selection compared to MHCI-restricted TCRs (0.9 s)
because more CD4 coreceptors are Lck-loaded
compared to CD8. We generated a model (Lck co-
me&stay/signal duration) that accurately predicts
the observed differences in antigen dwell-time thres-
holds used by MHCI- and MHCII-restricted thymo-
cytes to initiate negative selection and generate
self-tolerance.
INTRODUCTION
T cells regulate adaptive immune responses to pathogens and
tumors but can also drive autoimmune diseases. The T cell anti-
gen receptor (TCR) on conventional abT cells recognizes peptide
fragments bound to class I or class II major histocompatibility
complexes (pMHCI or pMHCII). Each developing T cell ex-
presses a unique TCR and generation of a self-MHC restricted
and self-tolerant T cell repertoire results from a multistep se-
lection process in the thymus. Thymocytes expressing a TCR
weakly reactive to the host’s self-antigens receive a maturation
signal to generate the functional T cell repertoire in the periphery
(positive selection). In contrast, thymocytes with strongly self-
reactive TCRs receive a death signal (negative selection). A fail-
ure to prevent strongly self-reactive T cells from entering the
peripheral T cell pool is one of the main causes of autoimmune
diseases (Yin et al., 2013). How thymocytes discriminate be-
tween positive- and negative-selecting antigens in the thymus
is incompletely understood. Another open question is how a
thymocyte balances the high sensitivity required to recognize
just a few molecules of strong antigens (Ebert et al., 2008; Peter-
son et al., 1999) with the selectivity needed to discriminate
between positive- and negative-selecting antigens even at rela-
tively high densities (Daniels et al., 2006; Naeher et al., 2007).
Engagement of a TCR by its cognate ligand leads to phos-
phorylation of TCR-associated ITAM-containing TCRz and CD3
chains by a Src family kinase, Lck (Straus and Weiss, 1992). An-
tigen discrimination might already occur at this step, because
positive selecting antigens poorly induce phosphorylation of
TCRz chain (Kersh et al., 1998). Doubly phosphorylated ITAMs
recruit ZAP70, a kinase that is subsequently activated by a sec-
ond round of Lck-mediated phosphorylation (Straus and Weiss,
1993). ZAP70 relays the signal downstream by phosphorylating
LAT and SLP76 (Smith-Garvin et al., 2009).
The CD4 and CD8 coreceptors bind to MHCII and MHCI,
respectively. It has been suggested that the principal role of cor-
eceptors is to enhance TCR signaling by delivering Lck to an
engaged TCR (Artyomov et al., 2010; Veillette et al., 1988).
CD8 additionally stabilizes TCR-pMHC interaction (Stone et al.,
2009). Although signaling can be induced by very strong ago-
nists or anti-TCR antibodies in the absence of coreceptors
(van der Merwe and Dushek, 2011), CD4 or CD8 are required
for signaling induced by most ligands (Kerry et al., 2003; Vidal
et al., 1999). Moreover, coreceptors are vitally important for se-
lecting T cells that recognize pMHCI and pMHCII antigens (Van
Laethem et al., 2013). Along these lines, increasing Lck coupling
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to CD8 enhances the efficiency of positive selection of MHCI-
restricted thymocytes (Erman et al., 2006).
The strength of a self-antigen-TCR interaction dictates whether
a developing thymocyte undergoes negative selection (Daniels
et al., 2006; Hogquist et al., 1994; Williams et al., 1999). The
main parameters describing the interaction between a TCR and
its ligand are association rate (kon), dissociation rate (koff), and
equilibrium dissociation constant (KD). Whereas koff determines
the median dwell time of the antigen-TCR interaction (t1/2 = ln2/
koff), kon (that is concentration-dependent) determines the rate
of TCR-pMHC complex formation. KD ( = koff/kon) indicates the
concentration-dependent occupancy of the TCR under equilib-
rium conditions. Although there are conflicting data whether
kon, koff, KD, or aggregate dwell time better describes the biolog-
ical response induced by particular antigens, koff predicts the
magnitude of TCR responsiveness in most studies (Bridgeman
et al., 2012; Govern et al., 2010; Huang et al., 2010; Kersh et al.,
1998; Tian et al., 2007). Moreover, mathematical modeling and
experimentswith TCR-induced IFNg production showed that bio-
logical potency correlated with an antigen’s KD, but that maximal
response was determined by its koff (Dushek et al., 2011).
T cells expressing a monoclonal TCR together with a set of
altered peptide ligands (APL) are commonly used to address the
issue of antigen discrimination by TCRs. OT-I is a murine TCR
recognizing MHCI (H2-Kb) loaded with OVA peptide (SIINFEKL)
or OVA-derived APLs. We previously showed that transgenic
OT-I thymocytes discriminate between positive- and negative-se-
lecting APLs in a manner that was largely dependent on antigen
affinity and less dependent on a ligand concentration (Daniels
et al., 2006). Two other MHCI-restricted TCRs could similarly
discriminate between negative- and positive-selecting ligands.
Threshold antigens were estimated to have on-cell KD !6 mM
and t1/2 !1 s (Naeher et al., 2007; Palmer and Naeher, 2009).
Moreover, negative, but not positive, selectors provoked a suffi-
ciently strong response inmature CD8OT-I T cells to induce auto-
immunity in an experimental model of type I diabetes (King et al.,
2012). These results indicate that T lineage cells sense an intrinsic
binding parameter of their antigens. One plausible explanation in-
cludes the ability of a TCR to measure the duration of TCR-pMHC
interactions (antigen dwell time), as suggested by a kinetic proof-
reading model of TCR triggering (McKeithan, 1995). However, the
mechanism used by the TCR to sense antigen dwell time is largely
unknown.
In this study, we show that an antigen-engaged TCR scans
multiple coreceptors to find one that is coupled to Lck; this is
the first and rate-limiting step in signal initiation. Based on exper-
imental data and mathematical modeling, we propose a mecha-
nism of TCR signaling (Lck come&stay/signal duration), where
the kinetics of Lck delivery by coreceptors underlies a kinetic
proofreading process that establishes a dwell-time threshold
for negative selection.
RESULTS
Dwell-Time Threshold for Negative Selection by pMHCI
versus pMHCII Ligands
To identify positive- and negative-selecting ligands for MHCII-
restricted TCRs, we analyzed the development of I-Ab- restricted,
peptide-specific B3K506 and B3K508 TCR transgenic Rag1"/"
thymocytesexposed toa variety ofAPLswithknownaffinities (Hu-
sebyetal., 2005,2006).Using the frequencyofCD4singlepositive
(SP) cells as an indicator of negative selection in B3K508 fetal
thymic organ cultures (FTOCs), we identified ligands behaving
as negative selectors (3K, P5R, and P2A), one partial negative
selector (threshold selector) (P-1A), and two ligands unable to
negatively select (P3A, P-1K) (Figures 1A and 1B). Interestingly,
negative- and positive-selecting ligands also affected the devel-
opment of the CD8 SP compartment. Previous work showed
that developing MHCII-restricted thymocytes undergoing nega-
tive selection generate a population of CD8aa innate-like T cells,
while the same cells undergoing positive selection paradoxically
select a minor population of CD8ab SP cells (Yamagata et al.,
2004). Similarly, in B3K508 FTOCs, only negative-selecting li-
gands generated a population of CD8aa SP cells, while CD8ab
SP thymocytes were present in FTOCs exposed to threshold
and positive-selecting ligands (Figure S1A available online).
Nevertheless, negative selection can be followed by the disap-
pearance of the CD4 SP population. We also identified negative
and threshold selectors using FTOCs from B3K506 Rag1"/"
mice (Figure1C). Threshold selectors forB3K508andB3K506 thy-
mocytes exhibited similar KD values (263 mMand 319 mM, respec-
tively) (Huseby et al., 2006), indicating thatMHCII-restricted TCRs
use a fixed affinity threshold (KD !300 mM) for negative selection.
To compare the affinities of threshold antigens mediating
MHCI- and MHCII-restricted negative selection, we determined
the affinities of several antigens for MHC-I restricted OT-I TCR
using surface plasmon resonance (SPR) (Figures 1D and S1B–
S1D). The threshold selector for OT-I thymocytes (Kb-T4) had a
KD value of 444 mM (Figure 1D) (Daniels et al., 2006). Taken
together, results from our FTOC and SPR experiments argue
that MHCI- and MHCII-restricted TCRs use a similar ligand affin-
ity threshold to initiate negative selection. However, SPR affinity
measurements neglect the roles of CD4 and CD8 coreceptors
that bind to pMHCII and pMHCI antigens, respectively. Impor-
tantly, CD8, but not CD4, stabilizes the TCR-pMHC complex
and prolongs a ligand’s dwell time on the cell surface (Huppa
et al., 2010; Naeher et al., 2007; Stone et al., 2009).
To directly determine the length of TCR-pMHC interactions in
the presence of coreceptors, we measured the dwell times of
Qdot-labeled-pMHC monomers on their respective peripheral
T cells or double positive (DP) thymocytes by direct observation
using single molecule microscopy (Movies S1 and S2). The
observed dwell times could be fitted to a one-phase exponential
decay curve (Figure 1E). For OT-I, an MHCI-restricted TCR, the
t1/2 of the various APLs on mature T cells range from 1 s to
16 s and the t1/2 correlates well with antigenic potency (Daniels
et al., 2006). The t1/2 of the threshold selector, K
b-T4, is 1.3 s.
Interestingly, the t1/2s of strong negative selectors for the
B3K506 (3K) and B3K508 (P1-A) MHCII-restricted TCRs are
1.3 s and 1.4 s, respectively.
We could not directly measure the dwell-time distribution of
pMHCII threshold ligands, due to the speed of image acquisition.
To estimate the t1/2 for an MHCII-restricted threshold selector,
we made some additional measurements.
We determined the t1/2s of several ligands binding to their
respective DP thymocytes (Figures 1E, panels 2 and 8, and
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Figure 1. Thresholds for Negative Selection by pMHCII and pMHCI Ligands Show Similar SPR Affinities but Different On-Cell Dwell Times
(A–D) Fetal thymi from B3K508 Rag1!/! (A and B), B3K506 Rag1!/! (C), and OTI Rag2!/! b2 m!/!mice (D) were cultured with different APLs (20 mM) for 7 days
and stained for CD4 and CD8. (A) Effects of 3K, P1-A, and P3A on the B3K508 Rag1!/! thymocyte development. Each panel is a representative plot from two
thymi. (B–D) Percentage of CD4 or CD8b single positive cells versus KD of APLs. Mean ± range, n = 2–5. Square symbol shows percentage of single positive cells
without peptide (mean ± SEM, n = 5–11).
(E) Distribution of dwell times of pMHCI and pMHCII ligands on TCR transgenic CD4 or CD8 peripheral T cells, or preselection DP thymocytes. Data were fitted
using one phase exponential decay curve.
(F) t1/2 on preselection thymocytes versus t1/2 on peripheral cells were plotted and fitted using linear regression with a fixed [0;0] point.
(G) koff, calculated from on-cell t1/2 on peripheral T cells versus KD determined by SPR was plotted for pMHCI and pMHCII ligands and fitted with a linear
regression with fixed [0;0] point.
See also Figure S1 and Table S1.
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1F). The t1/2s on DP thymocytes and peripheral T cells are in
good agreement but the t1/2s of a ligand binding to a thymocyte
is approximately one-third shorter (Figure 1F). As peripheral
T cells have substantially more TCR, the calculated t1/2s on
these cells may be slightly extended due to occasional rebinding
to a second TCR. In any event, the threshold t1/2s for negative
selection of MHCI restricted thymocytes is !0.9 s (Table S1).
We also observed that the on-cell koff and SPR KD are highly
correlated, indicating that differences in KD could be largely ex-
plained by differences in koff (Figure 1G). Therefore, the extrapo-
lated t1/2 on thymocytes for pMHCII threshold antigens (KD
!300 mM) is !0.2 s (Table S1).
Thus, MHCI-restricted thymocytes use a longer dwell-time
threshold for negative selection than MHCII-restricted thymo-
cytes (0.9 versus 0.2 s). This raises the question, why MHCII-
restricted thymocytes initiate negative selection with a shorter
dwell time.
Extent of Coreceptor-Lck Coupling Determines the
Threshold for Negative Selection
CD4 binds Lck better than CD8 (Wiest et al., 1993), which could
explain the shorter dwell-time threshold for MHCII- versus
MHCI-restricted thymocytes. We measured the CD4-Lck and
CD8-Lck coupling ratios in polyclonal preselection DP thymo-
cytes (B6) using immunoprecipitation followed by quantitative
Figure 2. Quantitative Determination of Lck
Coupling to CD4, CD8, and CD8.4 Corecep-
tors
Cell lysates were incubated with beads coated
with antibodies to CD4, CD8b, or isotype controls.
Beads were probed with PE-conjugated anti-
bodies to Lck, CD8a, or CD4 and analyzed by flow
cytometry.
(A–D) Sorted DP CD3low thymocytes from WT
mice were analyzed (A and B). Thymocytes from
CD8WT and CD8.4 OTI Rag2"/"b2 m"/" mice
were analyzed (C and D). Representative histo-
grams (A and C) and aggregate data (B and D)
(mean ± SD, n = 3–5) are shown. The p values were
calculated using Student’s t test (two-tailed, un-
equal variance). See also Figure S2.
(E) Lck was immunoprecipitated from lysates from
nontreated (NT), pervanadate (PV), or 20 mM PP2-
treated CD8WT and CD8.4 OTI Rag2"/" b2 m"/"
thymocytes. Phosphorylation of Lck was analyzed
by western blotting using simultaneous staining
with Abs specific for phosphorylated or nonphos-
phorylated Y394. The membrane was reprobed
with Ab to total Lck. Percentage of phosphorylated
Lck molecules in resting CD8WT or CD8.4 DP
thymocytes was calculated. CD8WT: n = 4; CD8.4:
n = 5.
flow cytometric analysis (FC-IP). While
only 0.6% of CD8ab coreceptors bound
Lck, 6.8% of CD4 molecules were Lck
coupled (Figures 2A, 2B, and S2A). The
CD4-Lck coupling in B3K508 and
B3K506 preselection DP thymocytes
was similar to that seen in polyclonal DPs from B6 mice
(Figure S2B).
To further study the impact of coreceptor-Lck coupling on
negative selection, we used homozygous CD8.4 knock-in mice
(Erman et al., 2006), which are unable to express endogenous
CD8a, and express instead only the chimeric CD8.4a chain,
which consists of the extracellular part of CD8a and a cyto-
plasmic CD4 tail, which binds Lck. In OT-I DP thymocytes ex-
pressing CD8WT or CD8.4, coreceptor-Lck coupling is 1.1%
and 5.8%, respectively (Figures 2C and 2D). It was important to
know the percentage of coreceptors coupled with catalytically
active Lck. For this reason,we usedpair of antibodies recognizing
active (pY394) and nonactive (non-pY394) Lck, respectively
(Nika et al., 2010). This analysis indicated that the percentage of
active Lck in the preselection DP thymocytes is 25%–28% (Fig-
ure 2E). Because the majority of Lck molecules are coreceptor-
coupled (Van Laethem et al., 2007), the fraction of CD4 and
CD8 coreceptors loaded with catalytically active Lck in DP thy-
mocytes is 1.8% and 0.16%, respectively. Thus, the majority of
coreceptors in DP thymocytes cannot initiate a TCR signal.
Expression of the CD8.4 coreceptor had no impact on the
developmental arrest at the DP stage or surface TCR levels in
the OT-I DP thymocytes (Figure S2C). Moreover, CD8.4 does
not significantly affect antigen binding because Kb-Q4R7 binds
to CD8WT and CD8.4 OT-I DP thymocytes with a similar t1/2
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(Figures 1E and S2D). Despite these similarities, the threshold for
negative selection was strikingly reduced in CD8.4 thymocytes,
converting threshold and partial negative selectors (T4, Q4R7)
into pure negative selectors and some positive selectors
(Q4H7, Q7) into threshold selectors (Figure 3A). The effect of
increasing CD8-Lck coupling cannot be mimicked by increasing
the antigen concentration in CD8WT OT-I FTOCs (Figure 3B).
Ten-fold higher concentrations (20 mM) of the APLs in CD8WT
OT-I FTOCs do not generate the same degree of negative selec-
tion as 2 mM peptides used in CD8.4 OT-I FTOCs. Therefore, the
increased Lck coupling to the CD8.4 coreceptor leads to a
shorter dwell-time threshold for negative selection that is largely
concentration insensitive. The impact of Lck-coupling on the
development of thymocytes is summarized in Table S1.
Increased CD8-Lck Coupling Enhances Proximal
Signaling and Cellular Responses
We further focused on the role of Lck coupling in the initiation of
TCR signaling by analyzing the response of CD8WT and CD8.4
OT-I DP thymocytes to stimulation with various Kb-peptide tetra-
mers (strong negative selector, Kb-OVA; just above threshold
selector, Kb-Q4R7; positive selector, Kb-Q4H7). In CD8WT OT-I
DP thymocytes, ligand-induced phosphorylation was modest
for TCRz and ZAP70 but downstream signaling proteins LAT,
SLP76, VAV, and Erk1 exhibited more extensive phosphorylation
upon stimulation (Figures 4A–4G and S3A–S3C). The data indi-
cate an amplification step between ZAP70 activation and LAT
phosphorylation. Importantly, CD8.4 thymocytes exhibited
enhanced phosphorylation of TCRz, ZAP70, LAT, SLP76, VAV,
and Erk1 following TCR stimulation (Figures 4A–4G and S3A–
S3C). The CD8.4 coreceptor increased overall TCR proximal
signaling by 1.4, 3.7, and 5.8 following stimulation with Kb-OVA,
Kb-Q4R7, and Kb-Q4H7, respectively (Figure S3D). Enhanced
coreceptor-Lck coupling augments the proximal TCR signaling
especially for lower affinity ligands.
Tetramer-stimulated CD8.4 thymocytes exhibited substan-
tially increased calcium influx compared to CD8WT thymocytes
(Figure 4H). In fact, CD8.4 thymocytes stimulated with below
threshold Kb-Q4H7 tetramers exhibited a comparable level of
calcium signaling as CD8WT thymocytes stimulated with high-
affinity Kb-OVA tetramers, indicating a substantial shift in the
signaling threshold induced by the chimeric coreceptor (com-
pare purple and red curves in Figure 4H, upper left panel).
To address the role of CD8-Lck coupling in response to a
broader range of APLs, CD8WT and CD8.4 OTI DP thymocytes
were stimulated with antigen presenting cells (APCs) loaded
with various peptide variants. Wemonitored induced expression
of CD69, an activationmarker that is upregulated both upon pos-
itive and negative selection (Figure S4). While CD8WT andCD8.4
thymocytes responded similarly to the strongest peptide, OVA,
CD8.4 thymocytes were more sensitive to weaker antigens (Fig-
ures 5A–5C). The impact of enhanced Lck delivery mediated by
the CD8.4 coreceptor inversely correlated with potency of the
ligand (Figure 5D), consistent with the effects of CD8.4 on prox-
imal signaling (Figure S3D).
Frequency of Coreceptor-Lck Coupling Determines
the Kinetics of Lck Delivery to the TCR
The overall experimental data implied that Lck delivery is a limiting
factor in signal initiation and potentially sets the dwell-time
threshold to initiate negative selection. To better understand
why coreceptor-Lck coupling is so important in this process, we
generated a mathematical model that calculates the probability
of recruiting an Lck-coupled coreceptor to an established
TCR:pMHC pair as a function of time, when the CD4, CD8, or
CD8.4 coreceptor is involved. The model is based on a Markov
chain that describes the behavior of coreceptor and TCR-pMHC
in the plasma membrane. A TCR-pMHC can form a pair (close
proximity) or a complex (binding) with an empty or Lck-coupled
coreceptor (Figure 6A). Because Lck-coupled coreceptors are
relatively rare, a TCR-pMHC usually has to scan a large number
of empty coreceptors before encountering an Lck-coupled one.
The average time to recruit an Lck-loaded coreceptor to the
TCR-pMHC is determined by the rate of coreceptor:TCR-pMHC
complex formation, the duration of empty coreceptor:TCR-MHC
interaction, and importantly, the percentage of Lck-coupled
coreceptors (see Extended Experimental Procedures). The pa-
rameters used to construct the model were based on our mea-
surements or published data (Figures S5A–S5C; Table S2). The
model shows that Lck delivery is very fast in case of TCR-pMHCII
interactions (CD4), but substantially slower upon TCR-pMHCI
engagement (CD8). CD8.4 shows faster Lck recruitment than
CD8WT (Figure 6B). When only active (pY394) Lck delivery is
considered, the delivery of the Lck is delayed but the hierarchy
of the coreceptors ismaintained (dashed line in Figure 6B). Impor-
tantly, the model predicts that the probability of Lck recruitment is
Figure 3. Enhanced Lck Coupling Lowers
the Threshold for Negative Selection
Fetal thymi from CD8WT and CD8.4 OT-I
Rag2!/!b2 m!/! mice were exposed to OVA-
derived APLs at the indicated concentrations Per-
centage of CD8b+ single positive cells versus 1/
potency of the ligands (Daniels et al., 2006) is
shown (mean ± SEM, n = 2–7). The squares show
percentage of single positive cells generated with
no peptide (mean ± SD, n = 11–12). The threshold
for negative selection is marked by dashed vertical
lines. Student’s t test (two-tailed, unequal vari-
ance): *p < 0.05, **p < 0.01, *** < 0.001.
See also Table S1.
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highly dependent on the extent of coreceptor-Lck coupling (Fig-
ure 6C), underscoring its importance for setting the dwell-time
threshold. Other parameters (number of CD8molecules, diffusion
coefficient of membrane anchored receptors, coreceptor-TCR
interaction kinetics, and lattice spacing) play less important roles
(Figure 6D).
To provide experimental evidence that a single TCR-pMHC
complex serially engages large number of coreceptors, we car-
ried out the following experiment. Qdot-labeled Kb-OVA or Kb-
Q4R7 monomers were bound to OT-I DP thymocytes allowing
the coengagement of the TCR and CD8 with the labeled antigen.
After reaching equilibrium binding, the cells were diluted in pres-
ence or absence of an anti-CD8bmAb. Blocking the unengaged
CD8 molecules accelerated the off-rate of pMHC dissociation
(Figures S5E andS5F). This is consistent with the idea that during
the life time of a pMHC-engaged TCR, there is significant
Figure 4. CD8.4 Enhances Proximal Signaling in OT-I Thymocytes
(A–G) Thymocytes from CD8WT or CD8.4 OT-I Rag2!/!b2 m!/!mice were stimulated with 100 nM Kb-OVA, Kb-Q4R7, or Kb-Q4H7 tetramers or left unstimulated
(ns). Results were normalized to the average of signal from unstimulated CD8WT or CD8.4 cells in each experiment. (A) Phosphorylation of TCRz (Y142) was
analyzed by flow cytometry on CD4+CD8+ population. Mean ± SEM, n = 6. (B, C, and G) Phosphorylation of LAT, ZAP70, and Erk was analyzed using phospho-
specific Abs. Reprobing the membranes for total ZAP70, LAT, and Erk served as respective loading controls. (D–F) Phosphorylation of LAT, SLP76, and VAV in
whole cell lysates was determined using anti-pTyr Ab and anti-actin Ab. as a loading control by western blotting. Mean ± SEM, n = 4. Statistical significance was
tested using Student’s t test (one-tailed, unequal variance): *p% 0.05, **p < 0.01. See also Figure S3.
(H) CD8WT or CD8.4 OT-I DP thymocytes were loaded with Indo-1 and stimulated with 200 nM Kb-OVA, -Q4R7, or -Q4H7 tetramers or 1.5 mM ionomycine.
Calciummobilization was analyzed by flow cytometry. Ca2+ response index is shown (see Extended Experimental Procedures). A representative experiment from
a total of three is shown.
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turnover of CD8 molecules, which only transiently bind to the
pMHC. This coreceptor exchange would allow the engaged
TCR to eventually find an Lck coupled coreceptor if the pMHC
engagement is sufficiently long.
Lck Delivery Is the Initial Step during
Kinetic Proofreading
The Markov chain model explained the importance of the pro-
portion of Lck-coupled coreceptors and coreceptor exchange
in determining the speed of the signal initiation.We subsequently
generated four different models that extended the Markov chain
model by combining Lck delivery together with its kinase activity.
Comparison of the models’ predictions with the experimental
data should indicate the actual molecular mechanism that initi-
ates TCR triggering and sets the antigen dwell-time threshold
for negative selection.
For all four models, we assumed that the recruited Lck has to
minimally phosphorylate four tyrosines (two ITAM tyrosines and
Y315 and Y319 in ZAP70) to obtain ZAP70 activation and signal
propagation. The actual number of tyrosine phosphorylations is
likely higher because phosphatase activity can counteract the
Lck activity and Lck might phosphorylate tyrosines in separate
ITAMs. Thus, we set five phosphorylations by an Lck molecule
as a criterion for TCR triggering to make it more than the minimal
number.
Our preferred model, ‘‘Lck come&stay/signal duration,’’ com-
bines the Lck recruitment calculated from the Markov chain
model with the classical TCR kinetic proofreadingmodel (McKei-
than, 1995). In this model, we assumed the following scenario.
A newly formed TCR-pMHC pair eventually interacts with a
coreceptor coupled to active Lck (pLck). The coreceptor-pLck
remains attached to the TCR-pMHC complex due to the interac-
tions of Lck’s SH2 domains with partially phosphorylated TCR
(and/or ZAP70) and stabilization via the pMHC:coreceptor inter-
action (Jiang et al., 2011; Straus et al., 1996). Lck triggers TCR
signaling by phosphorylating ITAM tyrosines and a subsequently
recruited ZAP70. Active ZAP70 continuously generates down-
stream signals by phosphorylating LAT, SPL76, and other sig-
naling molecules. When antigen disengages from the TCR,
coreceptor-Lck is released as well, leading to a massive
decrease in kinase activity. This shifts the kinase/phosphatase
equilibrium toward phosphatase activity and sets the TCR and
ZAP-70 back into a less phosphorylated state. ‘‘‘Lck come&s-
tay/signal duration’’ model assumes that the TCR-pMHC inter-
action has to last long enough to recruit and activate ZAP70.
Once the ZAP70 is activated, further antigen occupancy of the
already triggered TCR determines the strength of the TCR signal.
The overall TCR signal induced in a thymocyte is determined by
the number of triggered TCRs and the amount of time they
remain occupied by pMHC subsequent to TCR triggering
(Extended Experimental Procedures; Table S3). The model cal-
culates total TCR signal as a function of number of antigen mol-
ecules available in the thymocyte/APC interface and their t1/2
(Figures 7A and S6A). In contrast to a pure TCR occupancy
model (Figure 7B) that predicts little discrimination between
ligands with different dwell times, the ‘‘Lck come&stay/signal
duration’’ model displays the kinetic proofreading principle.
Our data clearly show that antigens with t1/2 !10 s (Kb-OVA)
can negatively select at low concentrations; antigens with t1/2
!1–2 s (Kb-T4 and Kb-Q4R7) negatively select at higher concen-
trations; and antigens with t1/2%0.6 s (Kb-Q4H7) are incapable
of negative selection even when present at very high concentra-
tions in the synapse (i.e., 250 cognate pMHC, which is !5%–
10% of the pMHCI pool at the interface). The model assumes
that as few as two to four triggered and occupied TCRs can
initiate negative selection, which has previous experimental sup-
port (Ebert et al., 2008; Peterson et al., 1999).
Themodel predicts a shift of the dwell-time threshold for nega-
tive selection in CD8.4 cells (Figures 7A and 7C), which in good
agreement with the experimental data (Figures 1 and 3; Table
S1). Moreover, this model predicts that the shorter the t1/2 of a
TCR ligand is, the more pronounced is the difference between
Figure 5. CD8.4 Preferentially Enhances
Response to Weak Ligands
(A–C) Thymocytes from CD8WT and CD8.4 OT-I
Rag2"/"b2 m"/" mice were incubated with APCs
loaded with varying concentrations of different
peptides. After 24 hr, the percentage of CD69+
thymocytes was measured by flow cytometry.
Response to OVA (A), T4 (B), and G4 (C) is shown.
Mean ± SEM, n = 4. Statistical significance was
tested using Student’s t test (one-tailed, unequal
variance): *p < 0.05, **p < 0.01.
(D) CD69 response of CD8WT and CD8.4 OT-I DP
thymocytes to different antigens was examined
and EC50 values were calculated. Ratio of EC50
CD8WT/EC50 CD8.4 was plotted versus EC50
CD8WT. Results show that CD8.4 thymocytes are
preferentially more sensitive to weaker ligands,
compared to CD8WT thymocytes. Red line shows
the log-log line fit and the black lines represent
95% confidence intervals.
See also Figure S4.
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CD8.4 and CD8WT signaling (Figure 7D). This is essentially in
agreement with the experimental data (Figures 4 and 5). The
‘‘Lck come&stay/signal duration’’ model predicts the dwell-
time thresholds used by polyclonal pMHCI- and pMHCII-
restricted thymocytes (!1 s for MHCI and !0.2 for MHCII
antigens) (Figure 7E). The model also reveals that antigens with
t1/2 at or just above the dwell-time threshold must be presented
at a relatively high copy number to induce negative selection
(e.g., 50 molecules of pMHCI antigens with t1/2 !2 s). If such
peri-threshold ligands are presented at low numbers in the
thymus, but at higher levels in peripheral tissues, the generation
of central self-tolerance may be defective.
The serial triggering (productive hit) model assumes that
once a TCR is triggered, continued pMHC binding does not
further increase the TCR signal (Dushek et al., 2011; Valitutti,
2012). We also constructed a combined ‘‘Lck come&stay/serial
triggering’’ model that assumes that the total TCR signal is deter-
mined by the number of triggered TCRs. However, the ‘‘Lck
Figure 6. Markov Chain Model for Lck Delivery to the TCR-pMHC Pair
(A) Scheme of the Markov chain model describing kinetics of protein interactions in the plasma membrane. TM is a TCR-pMHC pair, C is an empty coreceptor,
and LC is an Lck coupled coreceptor. TM+C and TM+LC represent coreceptor and TCR-pMHCpairs (in close proximity), TM:C and TM:LC represent coreceptor-
TCR-pMHC complexes (binding). The complex of Lck-coupled coreceptor and TCR-pMHC (TM:LC) is an absorbing end state. KD, kb, ku, kf0, kf1 represent kinetic
rates (Table S2). The rates that depend on the extent of coreceptor-Lck coupling are shown in red.
(B) Numerical solution of Markov chain model. The probability of TM:LC complex formation as a function of time was calculated for CD4 (pMHCII), CD8WT
(pMHCI), and CD8.4 (pMHCI). Both the probability of recruitment of any Lck-coupled coreceptor (solid line) or a coreceptor coupled to active Lck (pY394) is
shown (dashed line).
(C) Probability of TM:LC pair formation as a function of CD8-Lck coupling for MHCI ligand. The values for CD8WT (blue dot) and CD8.4 (red dot) aremarked. Other
parameters remained fixed.
(D) The probabilities of TM:LC formation as a function of lattice spacing, coreceptors number, CD8 and TCR diffusion coefficient and CD8:MHC unbinding ku
(when ku/kb ratio was fixed) for MHCI ligand and CD8 coreceptor. The original parameters are marked (black dot).
See also Extended Experimental Procedures, Figure S5, and Table S2.
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come&stay/serial triggering’’ model does not predict the exper-
imentally observed hierarchy of the ligands, arguing that serial
triggering cannot explain the negative selection threshold
(Figure S6B).
We also generated two additional models requiring multiple
visits of Lck to trigger the TCR (Figure S6C). In these models,
we assumed that Lck is not stabilized at the TCR-pMHC and
phosphorylates only one tyrosine upon a single interaction be-
tween a coreceptor-Lck molecule and the TCR-pMHC. Thus,
coreceptor-Lck has to be repeatedly recruited to the TCR-
pMHC to trigger the TCR. These models predict very strong
discrimination between ligands based on their t1/2, but displays
very low sensitivity to ligands, just over the dwell-time threshold;
this is not compatible with our experimental data. Given the poor
predictive power of these last three models, the ‘‘Lck come&s-
tay/signal duration’’ model clearly provides the best explanation
of our experimental data.
DISCUSSION
Here, we describe a mechanism that allows thymocytes to
discriminate antigens of differing median dwell times and estab-
lish an antigen dwell-time threshold for negative selection. Dur-
ing the time that a TCR binds a pMHC antigen, the TCR-pMHC
Figure 7. Model of Lck Recruitment Com-
bined with Kinetic Proofreading Predicts
Experimental Data
Graphs show TCR signal intensity as a function of
number of cognate ligands at the thymocyte/APC
interface for different ligands (kon = 0.1 mm
2 s!1, t1/2
variable). Horizontal green dashed line shows the
likely threshold when two TCRs are triggered and
still occupied.
(A) ‘‘Lck come&stay/signal duration’’ model for
CD8WT OT-I Rag2!/! b2 m!/! thymocytes. N,
negative selectors; T, threshold ligands (partial
negative selectors); P, positive selectors.
(B) Pure TCR occupancy model for OT-I Rag2!/!
b2 m!/! thymocytes.
(C) ‘‘Lck come&stay/signal duration’’ model for
CD8.4 OT-I Rag2!/! b2 m!/! thymocytes.
(D) Difference between CD8.4- and CD8WT-medi-
ated TCR signaling (CD8.4/CD8WT ratio) in OT-I
Rag2!/! b2 m!/! thymocytes versus t1/2 of a TCR
ligand, predicted by the ‘‘Lck come&stay/signal
duration’’ model. Advantage of increased Lck
coupling (CD8.4) is increasingly apparent at low t1/2.
(E) Comparison of TCR responses induced by
pMHCI and pMHCII ligands in polyclonal prese-
lection DP thymocytes predicted by the Lck co-
me&stay/signal duration model.
See also Extended Experimental Procedures, Fig-
ure S6, and Table S3.
complex scans up to several hundreds of
coreceptors to find one, which carries
catalytically active Lck; subsequently this
recruited kinase phosphorylates ITAMs
and activating tyrosines on ZAP70.
Finding an Lck-loaded coreceptor repre-
sents the first and rate-limiting step in signal initiation, because
only a minority of coreceptor molecules are actually coupled to
active Lck. MHCI-restricted TCRs require antigens with a t1/2
>0.9 s to induce negative selection, while the negative selection
threshold for MHCII-restricted TCRs is t1/2 >0.2 s. A higher fre-
quency of CD4 molecules are coupled to catalytically active
Lck compared to CD8 (2% versus 0.2%); for this reason,
MHCII-restricted receptors have a shorter dwell-time threshold.
Modeling studies revealed that the frequency of Lck-coupled
coreceptors is a critical parameter in establishing the dwell-
time threshold for negative selection. The decrease in the
dwell-time threshold for negative selection seen in CD8.4 OT-I
mice is a consequence of CD8.4’s increased coupling to Lck, re-
sulting in a faster arrival of a coreceptor-pLck complex to an an-
tigen-occupied TCR. CD8.4 mediates an enhanced activation of
proximal TCR signaling pathways and, similar to CD4, allows
negative selection by antigens with short dwell times. It is not
clear whether having a shorter dwell-time threshold for the dele-
tion of MHCII-restricted thymocytes provides an intrinsic advan-
tage or whether this is simply a consequence of the differences
in Lck coupling exhibited by CD4 and CD8. Nevertheless, these
differences illustrate the mechanism, where the dwell-time
threshold is set by the median time required for the antigen
engaged TCR to find an Lck-loaded coreceptor.
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To directly estimate the dwell-time threshold, we attached
monomeric pMHCs to Qdots and observed the binding of mo-
nomeric pMHC to antigen-specific T cells by single molecule
microscopy. The t1/2 for the OT-I threshold ligand (K
b-T4) was
estimated to 0.9 s on thymocytes and 1.3 s on peripheral
T cells, which corresponds well to the dwell-time threshold for
H2-Kd-restricted T1 TCR (0.8–1.5 s), estimated by an on-cell
photoaffinity labeling technique (Naeher et al., 2007; Palmer
and Naeher, 2009). How well does t1/2 measured with soluble
ligand (3D) correspond to antigen binding at the thymocyte/
APC interface? Although the t1/2 was originally viewed as a bio-
physical parameter describing ligand-receptor interactions inde-
pendent of their spatial context (Dustin et al., 2001), several
studies report that koff is accelerated in a planar configuration
(2D) of T cell-APC contacts (Huang et al., 2010; Huppa et al.,
2010). However, other studies showed that pMHC t1/2 measured
using 2D or 3D techniques are similar, consistent with the original
view (O’Donoghue et al., 2013; Robert et al., 2012). Recently,
pMHCI/TCR dwell times were analyzed under tensile force in a
2D setting (Liu et al., 2014). Interestingly, TCR interactions with
potent ligands are stabilized when a moderate force (5–10 pN)
is applied due to the formation of catch bonds. The authors sug-
gest that a tensile force generated at the thymocyte/APC inter-
face contribute to TCR specificity. However, their results show
that both positive and negative selectors can form catch bonds,
so the formation of a catch bond per se does not explain the
negative selection threshold. Nevertheless, the catch bond phe-
nomenon can be easily integrated with our ‘‘Lck come&stay/
signal duration model’’ that provides the signaling mechanism
underlying TCR triggering and discrimination between negative
and positive ligands based on their dwell times.
Interestingly, t1/2 measurements in their system corresponded
well with our on-cell measurements. We determined that the t1/2
of OT-I:Kb-OVA is !10 s, while Zhu and coworkers (Liu et al.
2014) measured the t1/2 for the same antigen as 0.8 s under 10
pN; the!10-fold difference is expected because of the absence
of CD8 engagement in their system (Naeher et al., 2007). How-
ever, it remains unclear why an application of a moderate tensile
force is required in the 2D setting, but not in our on-cell 3D assay,
to measure biologically relevant dwell times of TCR-antigen
interactions.
We generated four mathematical models describing TCR
signaling response in thymocytes, using a combination of our
measurements and published data as input parameters. The
kon (Huppa et al., 2010) was sufficiently high that it hardly limited
the formation of TCR-pMHC bonds in the thymocyte:APC con-
tact area. Ligand concentration and t1/2 had the largest impact
on the quantity of TCR signals generated. To find the most rele-
vant model, we compared the outcome of the models with our
experimental data on TCR signaling in CD8WT and CD8.4 OT-I
DP thymocytes. The ‘‘Lck come&stay/Signal duration’’ model,
which best explains our experimental data, is based on the prin-
ciple of kinetic proofreading (McKeithan, 1995), where Lck
recruitment is the most proximal limiting step. The model as-
sumes that transient CD4-MHCII or CD8-MHCI interactions
allow the TCR-pMHC pair to scan multiple coreceptors via cor-
eceptor exchange before finding a coreceptor carrying catalyti-
cally active Lck. Nika et al. (2010) demonstrated that 38% of Lck
molecules are catalytically active in human CD4+ T cells and
moreover Lck does not undergo further activation upon TCR
stimulation. Murine preselection DP thymocytes have a slightly
lower percentage of active Lck (25%–28%), implying that only
!0.16% of CD8 and !1.8% of CD4 molecules are capable of
initiating a TCR signal. Following the recruitment of catalytically
active Lck, the kinase phosphorylates ITAM tyrosines in the
CD3 complex and subsequently phosphorylates a recruited
ZAP70 kinase. Coreceptor-Lck binding to TCR-pMHC is poten-
tially stabilized via an interaction of Lck’s SH2 domain with a
phosphotyrosine in an ITAM or ZAP70 (Jiang et al., 2011; Straus
et al., 1996). If the TCR-pMHC interaction lasts long enough to
enable Lck-mediated phosphorylation of ZAP70, then ZAP70
generates downstream signals by phosphorylating LAT and
SLP76 for the duration of the TCR-pMHC interaction. The longer
the duration of antigen binding, the more downstreammediators
are generated. Signaling is terminated when the pMHC and sub-
sequently, the coreceptor-Lck disengage from TCR. A thymo-
cyte surveys a single APC for several minutes (Ebert et al.,
2008; Melichar et al., 2013); over this time span, the decision
to initiate negative selection must be made.
We propose that positive- and negative-selecting ligands
induce quantitatively different responses at the level of TCR acti-
vation (i.e., number of TCRs kept triggered) that is transformed to
qualitatively different events in downstream signaling pathways.
Our model is in line with the observation that positive- and nega-
tive-selecting ligands induce distinct patterns of Erk activation
(Daniels et al., 2006). Previous mathematical modeling sug-
gested that only negative-selecting ligands are able to induce
extensive LAT phosphorylation and trigger a feed-forward loop
resulting in the activation of SOS and activation of pErk at the
plasma membrane (Prasad et al., 2009).
The TCR has the unusual property of being able to recognize
antigens with a high degree of sensitivity and an ability to
discriminate between closely related structural variants. As few
as two to four strong ligands within the thymocyte-APC contact
area are able to trigger a strong TCR response and induce nega-
tive selection (Ebert et al., 2008; Peterson et al., 1999). This
sensitivity has been explained by the ability of one pMHC ligand
to trigger several TCRs and amplify the signal. However,
evidence for serial triggering is so far indirect (Valitutti, 2012).
Moreover, a strict serial triggering model does not explain our
experimental data, because it predicts that threshold ligands
(Kb-T4) will engage and trigger similar number of TCRs as long
dwelling ligands (Kb-OVA). Furthermore, serial triggering could
not be detected during direct observation of TCR-pMHC interac-
tions in situ (O’Donoghue et al., 2013). Along this line, we pro-
pose that very few strong ligands are able to keep a few TCRs
continually engaged and triggered; this amplifies the TCR signal
by continuous generation of intracellular signaling intermediates.
Higher numbers of less potent, but above threshold ligands are
required to induce the same effect, while below threshold ligands
are essentially unable to trigger negative selection.
The two models, which employ the Lck multiple visit assump-
tion, are relatively insensitive. These models predict that only
antigens with very long dwell times or present at high concentra-
tions can initiate a TCR signal. For this reason, we do not favor
these models. We also observed that the serial triggering
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strategy poorly discriminates between antigens with differing
median dwell times. On the other hand, the signal duration
mechanism allows the amount of TCR generated signal to reflect
the actual dwell time. Thus, the ‘‘Lck come and stay/signal dura-
tion’’ mechanism allows for antigen recognition, which is both
highly sensitive and discriminatory.
‘‘Lck come and stay/signal duration’’ model uncovers molec-
ular events constituting for a TCR kinetic proofreading mecha-
nism. Highly specific recognition of negative-selecting ligands
by a developing thymocyte is an analogy to a kinetic proof-
reading that provides specificity in DNA, protein, and amino
acid-tRNA synthesis (Hopfield, 1974). These diverse molecular
processes have a built in time delay between a substrate binding
the enzyme and its conversion into a product molecule. A sub-
strate molecule (nucleotide, amino acid, etc.) that binds the
respective enzyme for a longer time is more likely to be the bio-
logically ‘‘correct’’ molecular species. The TCR and coreceptor
operate under a similar principle; a long-lasting antigen binding
event is more likely to be converted into a (negative selection)
signaling event.
Our experimental results and mathematical models explain
how the TCR actually measures antigen affinity to initiate a nega-
tive selection signal. The kinetics of Lck delivery by coreceptors
plays a crucial role in setting the antigen dwell-time threshold for
negative selection. The kinetic proofreading mechanism sug-
gested by our model implies that collisions between hundreds
of coreceptor molecules and a small number of antigen bound
TCRs allow the developing thymocyte to sense the antigen’sme-
dian dwell time and initiate a critical cell fate decision (negative
selection).
EXPERIMENTAL PROCEDURES
Mice
All adult mice were 6–12 weeks old and had a C57Bl/6 genetic background.
OT-I Rag2!/!, OT-I Rag2!/! b2 m!/!, B3K508 Rag1!/!, and B3K506 Rag1!/!
mice were described previously (Daniels et al., 2006; Huseby et al., 2005).
CD8.4 OT-I Rag2!/! b2 m !/! strain was generated by crossing CD8.4
knock-in mouse (Erman et al., 2006) with OT-I Rag2!/! b2 m!/!. Mice were
bred in our colony (University Hospital Basel) in accordance with Cantonal
and Federal laws of Switzerland. Animal protocols were approved by the
Cantonal Veterinary Office of Baselstadt, Switzerland.
Surface Plasmon Resonance
SPR equilibrium binding analysis was performed using a BIAcore T100!
equipped with a CM5 sensor chip. SPR equilibrium analyses were carried
out to determine the KD values for OT-I:H2-K
b-APL interactions at 25"C.
Approximately 300 response units of pMHC or TCR were coupled to the
CM5 sensor chip surface. Analyte was injected at concentrations ranging
from ten times above and ten times below the estimated KD of the interaction.
Flow Cytometry
Live cells were stained with relevant Abs on ice. For intracellular staining, cells
were fixed in 4% paraformaldehyde (15 min, room temperature [RT]), permea-
bilized by 90%methanol (30 min, on ice) and stained with indicated antibodies
at RT. Determination of surface molecule number was performed using satu-
rating concentrations of PE-conjugated Abs and calibration beads. Calcium
mobilization was measured using Indo-1 probe and Calcium response index
was calculated (see Extended Experimental Procedures).
Flow cytometry immunoprecipitation (FC-IP) was done as described
previously (Schrum et al., 2007). Briefly, beads coated with anti-CD4 or anti-
CD8a Abs were used to pull down CD4 or CD8. Subsequently, PE-conjugated
anti-CD4, anti-CD8b, or anti-Lck Abs were used to quantify Lck/CD8 and Lck/
CD4 coupling ratios.
Flow cytometry was carried out with a FACSCantoII (BD Bioscience). Cell
sorting was performed using an Influx sorter (BD Bioscience). Data were
analyzed using FlowJo software (TreeStar).
Determination of Lck Phosphorylation Status
Lck was immunoprecipitated from untreated, or PV- or PP2-treated thymo-
cytes and analyzed by western blotting. Signals from Abs recognizing phos-
phorylated and nonphosphorylated Lck (Y394) were normalized to total Lck
and the percentage of phosphorylatedmolecules was calculated as previously
described (Stepanek et al., 2011).
On-Cell Dwell-Time Measurement
Qdot-pMHCmonomers were added to T cells or thymocytes attached to poly-
lysine-coated borosilicate glass. Binding of Qdot-pMHC monomers was
observed using single molecule microscopy for 2.5 min and the duration of
pMHC binding events wasmeasured. The number of persisting binding events
was plotted versus time and fitted with to a one phase exponential decay func-
tion. See also Extended Experimental Procedures.
FTOC
FTOCs were performed as described (Hogquist et al., 1994). Briefly, thymic
lobes were excised from mice at a gestational age of day 15.5 and incubated
in the presence of particular peptide and, in case of OT-I Rag2!/! b2 m!/!
thymi, exogenous b2 m (5 mg/ml). After 7 days of culture, thymocytes were
analyzed by flow cytometry.
Western Blotting
Samples for western blotting were heated in Laemmli sample buffer (2 min,
95"C), sonicated and analyzed by SDS-PAGE and western blotting, using
AlexaFluor790- or AlexaFluor680-conjugated goat anti-mouse or anti-rabbit
secondary antibodies (Jackson ImmunoResearch). Specific Ab signals were
quantified using an Odyssey Infrared Imaging System (LI-COR Biosciences)
and analyzed by ImageJ software (NIH).
Mathematical Model
The models are composites of Markov chain model describing behavior of
surface molecules, equations describing TCR occupancy, and equations
describing initial catalytic steps in TCR triggering. The models predict either
a number of triggered TCRs within a time interval or a number of occupied
and triggered TCRs in any given time point.
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Supplemental Information
EXTENDED EXPERIMENTAL PROCEDURES
Antibodies and Peptides
Antibodies to following antigenswere used: Lck (clone 3A5), VAV (rabbit polyclonal), SLP76 (rabbit polyclonal, all Santa Cruz Biotech-
nology); Erk1/2 (clone L34F12), ZAP70 (clone L1E5), Erk1/2 pT202/pY204 (clone D13.14.4E), ZAP70 pY319 (rabbit), Src family pY416
(rabbit), Src family non-pY416 (mouse, clone 7G9, all Cell Signaling); TCRz pY142 (clone K25-407.69) (all BD Biosciences);
LAT pY191 (rabbit polyclonal), pTyrosine (clone 4G10, both Merck Millipore); actin (rabbit polyclonal, Sigma-Aldrich); CD3ε (clone
145-2C11), CD8a (clone 53-6.7), CD8b (clone 53-5.8), CD4 (clones RM4-5 and H129.19), TCRb (clone H57-597), TCR-Va2 (clone
B20.1), CD69 (clone H1.2F3) (all BD PharMingen). For flow cytometry, antibodies were conjugated to various fluorescent dyes by
the manufacturer.
Determination of Surface Molecule Numbers
Saturating concentrations of PE–conjugated antibodies were determined (40 mg/ml for CD3ε, CD8a and 10 mg/ml for CD4). 25,000
cells were stained in 25 ml of staining buffer (PBS/2% FCS) for 40 min on ice, washed, and analyzed along with PE calibration beads
(RCP-30-5A, Spherotech Inc., Lake Forest, IL, USA) by flow cytometry. A calibration curve was generated based on the fluorescence
signal from calibration beads to transform the geometric mean of fluorescence intensity (after subtraction of background signal from
antibody stained peripheral B cells) into mean equivalent of PE intensity (MEPE) values. The actual number of surface molecules was
calculated by adjusting the MEPE values to the PE/antibody ratio (determined by absorbance at 560 nm using soluble PE as a stan-
dard). Number of antigens captured by onemolecule of antibody was assumed to be 2 (Davis et al., 1998), except for TCR, where the
results were further corrected for the presence of 2 CD3ε molecules per TCR/CD3 complex.
Flow Cytometric Immunoprecipitation Assay
106 cells were lysed in 50 ml lysis buffer (1%NP-40, 10mMTris pH 7.4, 140mMNaCl, 2mMEDTA, Protease Inhibitor Cocktail (Sigma-
Aldrich)) for 30min on ice. 75,000 CML beads (Invitrogen) coupled to anti-CD4 (clone RM4.4), anti-CD8b (clone 53-5.8), or anti-MHCI
(clone Y3.8) antibodies, as described previously (Schrum et al., 2007), were added to the lysate and incubated for 3 hr at 4!C. Beads
were washed 3x in lysis buffer and stained with different PE-conjugated antibodies to CD4 (clone H129.19), CD8a (clone 53-6.7),
or Lck (clone 3A5) at saturating concentrations (40 min, on ice) and analyzed by flow cytometry. The geometric mean fluorescence
intensities (gMFI) were taken as the measure of the antibody binding. The CD8, CD8.4 or CD4-Lck coupling ratio was calculated as
Lck signal to CD8 or CD4 signal (after subtracting respective background signal measured from control anti-MHCI beads) and
adjusted for the PE/antibody ratio.
Calcium Mobilization
Cells (107/ml in RPMI/10%FCS) were loaded with 0.5 mM Indo-1 (Invitrogen) for 30 min at 37!C. Calcium mobilization was measured
as a ratio of Indo-1 fluorescence intensities elicited by emission wavelengths at 400–500 nm and 500–560 nm (excitation 355 nm).
Baseline Ca2+ mobilization was determined for 30 s after which, cells were stimulated by addition of 2 3 concentrated activators
(tetramers or ionomycin in RPMI/10%FCS). Measurements were continued for 5 min. Calcium response index (Stepanek et al.,
2011) was calculated as the percentage of cells with an intracelluar calcium level, higher than the 90th percentile found in resting cells
during a 10 s time interval prior to stimulation.
Mice
B3K506 Rag1"/" I-A"/" and B3K508 Rag1"/" I-A"/"mice were generated by breeding B3K506 Rag1"/" and B3K508 Rag1"/" with
I-A"/" mice.
Cells
The OT-I hybridoma line expressing CD8b-YFP and TCRz-CFP (Mallaun et al., 2008), and T2-Kb cells (a gift from T. Potter) were culti-
vated in RPMI/10% FBS, 100 U/ml penicillin, 100 mg/ml streptomycin, and 50 mM 2-mercapthoethanol.
Cell Stimulation
DP thymocytes (2 3 108 mil/ml) were preincubated in RPMI (10 min, 37!C) and stimulated by adding an equal volume of 200 nM
tetramers in RPMI. At indicated time points, cells were either fixed in formaldehyde (intracellular staining) or lysed in 2x SDS
PAGE sample buffer (western blotting).
CD69 Upregulation Assay
T2-Kb cells were pre-incubated with varying amounts of peptide for 2 hr before addition of thymocytes. Final concentrations were
63 105 T2Kb cells, 106 thymocytes, and indicated concentration of peptide in 250 ml of RPMI/10%FCS. Thymocytes were examined
by flow cytometry 24 hr later, using antibodies to CD69, CD4, CD8a, and Va2 TCR. The EC50 values for CD69 upregulation were
calculated using nonlinear regression curve (y = a+(b-a)/(1+10^((log(EC50)-x) 3 H))). Aggregate data showing CD8WT/CD8.4 EC50
versus CD8WT EC50 dependency were fitted with log-log line regression (y = 10
^(a 3 log(x)+b)).
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Determination of Lck Phosphorylation Status
Preselection OT-I thymocytes were either treated with 20 mM PP2 (Calbiochem) or 1 mM pervanadate for 10 min or left untreated.
Cells were lysed in a lysis buffer (1% dodecylmaltoside, 1 mM Pefabloc, 5 mM iodoacetamide, 1mM sodium orthovanadate,
100 mM NaCl, 50 mM NaF, 10% glycerol v/v, and 20 mM Tris, pH 7.5) and incubated for 30 min on ice. Nuclei and debris were
removed by centrifugation, and the resulting lysate was subjected to immunoprecipitation with anti-Lck antibody (2 mg/ml) followed
by incubation with Protein G Sepharose (GE Healthcare). Immunoprecipitates were eluted with SDS-PAGE sample buffer and sub-
jected to immunoblotting. Src family pY416 and Src family non-pY416 antibodies were used for the detection of the phosphorylation
state of Lck Y394. Signals from phospho and non-phospho specific antibodieswere normalized to total Lck signal. The percentage of
phosphorylated Lck in untreated cells (P) was calculated using equation:
P=
b2
b1
! 1
b2
b1
! a2
a1
where b and a are signal intensities from non-phospho and phospho specific antibodies, respectively (Stepanek et al., 2011).
The terms 1 and 2 represent untreated and treated conditions, respectively. Percentage of phosphorylated Lck was independently
calculated using either PP2 or PV-treated cells and averaged to obtain a single value for each independent experiment.
Generation of Expression Plasmids
The OT-I TCR a and b chains, H2-Kb heavy chain and human b2 m chain were generated by PCRmutagenesis (Stratagene) and PCR
cloning. Three versions of theOT-I TCRwere generated. Onewith a leucine zipper attached to the C terminus, one with a biotinylation
site on the alpha chain C terminus, and one incorporating human constant domains with an artificial inter chain disulphide to produce
the soluble TCR. These molecules contained residues 1–207 and 1–247 of TCRa and b, respectively (Boulter et al., 2003; Garboczi
et al., 1996). H2-Kb heavy chain (residues 1–248) (a1, a2 and a3 domains), tagged with a biotinylation sequence, and human b2 m
(residues 1–100) were also cloned and used to generate pMHCI complexes. The TCR a and b chains, the H2-Kb a chain and human
b2msequenceswere inserted into separate pGMT7 expression plasmids under the control of the T7 promoter (Garboczi et al., 1996).
Protein Expression, Refolding, Purification
Competent Rosetta DE3 E.coli cells were used to produce the TCR a and b chains, H2-Kb heavy chain and human b2 m in the form
of inclusion bodies following induction with 0.5 mM IPTG as described previously (Cole et al., 2006, 2008; Garboczi et al., 1996).
Biotinylated pMHCI was prepared as previously described (Wyer et al., 1999).
MHC Tetramer and Monomer-Qdot Assembly
Kb-peptide and I-Ab-peptide tetramers were generated by incubating biotinylated pMHC monomers with streptavidin (Jackson
Immunoresearch) or PE-streptavidin (Invitrogen) at a 4:1 ratio on ice. Streptavidin was separately added to pMHC-monomers in
two aliquots. Qdot-labeled pMHCmonomerswere generated bymixing biotinylated pMHCmonomerswithQdot605-streptavidin con-
jugates (Invitrogen) at a 0.5:1 ratio for 20min at 26"C. Free biotin binding sites were subsequently blockedwith an excess of free biotin.
Surface Plasmon Resonance
SPR equilibrium binding analysis was performed using a BIAcore T100! equipped with a CM5 sensor chip as previously reported
(Cole et al., 2007; Gostick et al., 2007; Wyer et al., 1999). Experiments were conducted with H2-Kb variants immobilised on the chip
surface. Two OT-I TCR constructs, one with a leucine zipper attached to the C terminus and one implementing a human constant
domain with an artificial inter chain disulphide, were used in different experiments. SPR equilibrium analyses were carried out to
determine the KD values for OT-I:H2-K
b-APL interactions at 25"C in multiple experiments (representative data shown). In all exper-
iments, approximately 300 response units of pMHC or TCR were coupled to the CM5 sensor chip surface. Analyte was injected at
concentrations ranging from 10 times above and 10 times below the known KD of the interaction (where possible) at 45 ml/min. KD
values were calculated assuming 1:1 Langmuir binding (AB = B*ABMAX/(KD + B)) and data were analyzed using a global fit algorithm
(BIAevaluation! 3.1). A blank flow cell and irrelevant HLA-A*0201-ALWGPDPAAA, or HLA-B*3501-VPLRPMTY monomers were
used as negative controls on flow cell 1. The SPR measurements for B3K506 and B3K508 TCRs were carried out previously at
25"C (Huseby et al., 2006).
Single Molecule Microscopy
LabTek chambers (Thermo Scientific) were precoated with poly-l-lysine at 37"C overnight. 1–2 3 106 lymph node T cells or thymo-
cytes were stained with anti-CD45.2-AlexaFluor488 antibody, washed and resuspended in 200 ml of RPMI (without phenol red)/5%
FCS and added to the chamber. Cells were allowed to attach to the surface for at least 30min. A Nikon A1microscope equipped with
1003magnifying objective (1.49Na), ORCA2 CCD camera (Hamatsu Photonics), and Visiview software (Visitron systems) were used
to acquire images using 50 ms exposure time. One frame consisted of 14 Z-steps with a track radius of 0.65 mm collected over 0.7 s.
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3Dmovies were analyzed using Imaris software (Bitplane). Themeasurements of theQdot-pMHCdwell times on the cell surfacewere
donemanually, excluding first three and last three frames of eachmovie. Only binding events, which began and ended during the time
of the movie and lasted at least 2 frames, were analyzed. The number of persisting binding events was ploted versus time and fitted
with to a one phase exponential decay function: Y = Ymax 3 e
-ln2 3 X/t1/2.
Statistical Analysis
Curve fitting and statistical analysis was performed using Prism version 5.0d (GraphPad Software) and Excel for Mac 2011 version
14.3.9 (Microsoft).
Markov Chain Model
To model the interactions between an engaged TCR (TCR-pMHC) and CD4 or CD8 coreceptors in the membrane, we generated
aMarkov chain model (Figure 6A). The interactions of CD4 and CD8with Lck seem to be very strong, because the majority of Lck mol-
ecules in thymocytes are bound to CD4 or CD8 coreceptors (Van Laethem et al., 2007; Van Laethem et al., 2013). In contrast, the CD4
or CD8 interactions with MHCII or MHCI, respectively, are rather weak and transient (Gao and Jakobsen, 2000; Wyer et al., 1999). For
our model, we assumed that the CD4- and CD8-Lck interactions are stable and there is negligible Lck turnover among the coreceptors
within the time scale of interest (<30 s). In this context, DP thymocytes contain a small fraction of Lck-coupled coreceptors and a larger
pool of empty coreceptors, devoid of Lck (Figure 2). We neglected the role of coreceptor-free Lck in TCR triggering for two reasons,
because it comprises less than 1/3 of total Lck in thymocytes (Van Laethemet al., 2007). Moreover, a significant part of the coreceptor-
free pool is not anchored in the plasma membrane and cannot easily contribute to TCR signaling. (Zimmermann et al., 2010). While a
free Lckmoleculewithin the cytoplasmmight occasionally collidewith a TCR, this occurs in a randomorientation and presumably has a
only a small chance to phosphorylate CD3 and ZAP70. In contrast, coreceptor-bound Lck is recruited to the TCR complex in a more
constrained position under the plasma membrane. In this regard, it has been postulated that orientation of a coreceptor-bound Lck is
constrained to optimize phosphorylation of CD3 chains (Li et al., 2013). This gives an advantage to coreceptor-bound Lck.
The model predicts that the TCR-pMHC (TM) pair typically scans multiple coreceptor molecules before it encounters one coupled
with Lck.
The parameters for theMarkov chainmodels are listed in Table S2. For the case of calculations, we considered that there is just one
TCR-pMHC pair and a proportional number of coreceptors ( = C/A, ca. 3500 in case of CD8) on a 1 mm3 1 mm patch of membrane.
The average distance between the TCR-pMHC and a coreceptor molecule is:
r =
1ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
p3C=A
p (Equation 1)
The average time for a TM to form a pair (close proximity) with a coreceptor is:
t =
r2
D
(Equation 2)
Thus, the kf0 and kf1 finding rates for forming a pair with a coreceptor loaded with (active) Lck (TM+LC) or with a coreceptor devoid of
(active) Lck (TM+C), respectively, are:
kf0 =
1
t0
=
ð1" fÞpCD
A
(Equation 3)
kf1 =
1
t1
=
fpCD
A
(Equation 4)
We assumed a lattice spacing of l = 0.01 mm, meaning that when a coreceptor and TCR-pMHC are in the same lattice site, they can
either diffuse apart or bind with rates kd and kb, respectively. The diffusion coefficient was scaled to a ‘‘hopping rate’’ kd, that de-
scribes the movement of molecules in the lattice grid:
kd =
D
l2
(Equation 5)
The initial state of the Markov chain is a free TCR-pMHC (TM) and the formation of coreceptor-Lck:TCR-pMHC complex was set as
an absorbing end state. A set of 5 ordinary differential equations describe the evolution of probabilities of the various states of the
model with time (see also Figure 6A):
dPTM:C
dt
= " kuPTM:C + kbPTM+C (Equation 6)
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dPTM+C
dt
= kuPTM:C ! ðkd + kbÞPTM+C + kf0PTM (Equation 7)
dPTM
dt
= kdðPTM+C +PTM+ LCÞ ! ðkf0 + kf1ÞPTM (Equation 8)
dPTM+ LC
dt
= kf1PTM ! ðkd + kbÞPTM+ LC (Equation 9)
dPTM:LC
dt
= kbPTM+LC (Equation 10)
These equations were numerically solved (f = 0.014, for other parameters see Table S2 - CD8), showing that the TCR/pMHC
mainly exists as a TM+C pair or eventually in the absorbing LC:TM state shortly after the initial time of TCR-pMHC binding
(Figure S5D).
One of the most difficult parameters to estimate was ku, the off-rate of coreceptor:MHC interaction. For CD8, we took the SPR
data from human CD8aa interaction with HLA-2 (Wyer et al., 1999). The authors determined the dissociation rate to be R 18 s-1.
Because other studies measured a higher CD8:MHCI affinity in the mouse system (indicating slower off-rate) we used ku = 20 s
-1
(close to the lower value) in the model. The affinity of CD4:MHCII interaction is lower than the affinity CD8-MHCI interaction, but as-
sociation and dissociation rates of CD4:MHC binding and unbinding are above the detection limit of SPR (Gao and Jakobsen, 2000;
van der Merwe and Davis, 2003; Xiong et al., 2001). We assumed a similar on-rate for both coreceptors (Artyomov et al., 2010), but a
10-fold higher off-rate for CD4-MHCII (200 s-1). We experimentally determined the number of CD4, CD8, and TCRmolecules on pre-
selection DP thymocytes (Figures S5A and S5B) and diffusion coefficients for CD8 (0.085 mm2 s-1) and TCR (0.13 mm2 s-1) in a hy-
bridoma cell line (Figure S5C). Others reported slightly lower diffusion coefficient for TCR (ca. 0.05–0.06 mm2 s-1) in primary T cells
(Dushek et al., 2008). Based on our and previously published data, we assumed a diffusion coefficient of 0.08 mm2 s-1 for both TCR
and CD8. Remaining parameters were taken from the relevant literature or estimated (Table S2) (Altan-Bonnet and Germain, 2005;
Artyomov et al., 2010).
Equations describing theMarkov statemodel were solved usingMATLAB (MathWorks). We also tested some results of theMarkov
state model with fully stochastic solutions of theMaster equations (data not shown) using a numerical implementation of the Gillespie
method, called Stochastic Simulation Compiler (Lis et al., 2009). The probabilities of Lck delivery to the TCR as a function of timewere
generated for CD4 (MHCII), CD8 (MHCI), and CD8.4 (MHCI) coreceptors using numerical solution of the Markov chain model
(Figure 6B).
Approximate Analytical Solution of the Reduced Markov Chain Model
To obtain an approximate analytical solution, we simplified theMarkov chainmodel. Becausewe saw that the TM+Cand TM+LCpairs
are very infrequent and short-lived (Figure S5D) and approximately constant during the simulation (not shown), we made a pseudo-
steady state assumption and set Equations 7 and 9 to 0. The free TM state is very short-lived, because it rapidly encounters a cor-
eceptor. Thus, we assumed that the initial state of the model is TM:C (PTM:C(0) = 1; PTM:LC(0) = 0) and extended the pseudo-steady
state to the free state (TM) as well. The simplified model consisted of the following equations (Equations 11, 12, 13, 14, and 15):
dPTM:C
dt
= ! kuPTM:C + kbPTM+C (Equation 11)
dPTM+C
dt
= kuPTM:C ! ðkd + kbÞPTM+C + kf0PTM = 0 (Equation 12)
dPTM
dt
= kdðPTM+C +PTM+ LCÞ ! ðkf0 + kf1ÞPTM = 0 (Equation 13)
dPTM+ LC
dt
= kf1PTM ! ðkd + kbÞPTM+ LC = 0 (Equation 14)
dPTM:LC
dt
= kbPTM+LC (Equation 15)
The analytical solution of the reduced model is:
PTM:CðtÞ= e!lt; PTM:LCðtÞ= 1! e!lt (Equation 16)
Where l is the rate of TCR-pMHC:Lck collision mediated by coreceptors.
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l=
kdkf1ku
ðkb + kdÞðkf0 + kf1Þ=
fDku
D+ l2kb
(Equation 17)
The approximate analytical solution showed very similar results to the numerical solution of the full model (not shown).
TCR Occupancy Model
The TCR occupancy model assumes that the number of TCRs occupied by pMHC ligands determines the signal generated in a T cell
or thymocyte. The magnitude of the response (R) can be calculated as:
R=TCRoc =
L
A
+
T
A
+
ln2
kon3 t1=2
#
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi0B@L
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1CA
2
# 4LT
A2
vuuuut
2
3A (Equation 18)
where TCRoc is the number of occupied TCRs in an equilibrium, kon is 2D on-rate of the ligand (Huppa et al., 2010), L and T are
numbers of ligands and TCRs, respectively, in the T cell/APC interface, and t1/2 is the half dwell time of the TCR-pMHC interaction.
We estimated the contact area between the thymocyte and APC to be one third of the total thymocyte surface.
‘‘Lck Come&Stay/Signal Duration Model’’
Thismodel postulates that a TCR signal begins once a TCR-pMHCpair binds a coreceptor loadedwith (active) Lck and the Lck-medi-
ated phosphorylation results in recruitment and phosphorylation of ZAP70. The recruited coreceptor-Lck complex stays catalytically
active for the duration of TCR-pMHC binding and generates additional down-stream signals by maintaining the ZAP70 in the active
state. To calculate the TCR response in this scenario, we combined the Lck recruitment rate with the model of kinetic proofreading
(McKeithan, 1995), that takes into account the Lck catalytic rate and the number of Lck-mediated phosphorylations required for
ZAP70 recruitment and activation:
R=TCRoc3
l
l+ koff
3
"
kp
kp + koff
#n
(Equation 19)
where koff is off-rate of the ligand ( = ln2/t1/2), kp is the Lck catalytic rate, and n is the number of Lck-mediated phosphorylations of
TCRz and ZAP70 required to trigger the TCR (i.e., activate TCR-bound ZAP70). The magnitude of the induced TCR response (R) is
determined by the number of triggered and still occupied TCRs at (pseudo)equilibrium. When accounting for TCR occupancy, the
equation expands to:
R=
L
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T
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(Equation 20)
Because positive selectors do not induce a true synapse formation, the decision to proceed toward negative selectionmust bemade
before the synapse is formed (Ebert et al., 2008; Melichar et al., 2013). For this reason, the ‘Lck come&stay/signal duration’ model
does not assume any significant accumulation of TCRs (nor pMHC) in the thymocyte-APC interface. The parameters are summarized
in Table S3 (Huppa et al., 2010; Ramer et al., 1991).
Since it was previously shown in two independent reports that negative selection can be induced when 2–3 high-affinity an-
tigen molecules are present at the thymocyte/APC interface (Ebert et al., 2008; Peterson et al., 1999), we used this experimental
observation as an assumption in our model; i.e., to initiate negative election,R 2–3 TCRs must be continuously activated up to
the point of generating catalytically active ZAP70 within 5 min. The 5min interval was taken from the observations of Robey
et al., who showed that in the absence of cognate antigen, thymocytes interact with an APC for an average of $5 min (Melichar
et al., 2013).
‘‘Lck Come&Stay/Serial Triggering Model’’
Thismodel differs from the ‘Lck come&stay/signal durationmodel’ by assuming that once a TCR has been triggered by Lck-mediated
activation of ZAP70, there is no further increase in the amount of TCR signal generated by continued ligand occupancy. Thus, short
dwelling ligands benefit because they can trigger additional TCRs or havemore attempts to trigger at least one TCR, while long dwell-
ing ligands are arrested on TCRs that have already been fully triggered. In this model, the magnitude of the induced TCR response (R)
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is expressed as a number of TCRs triggered during a time interval (length of a thymocyte-APC interaction before a decision is made)
and can be calculated as:
R=
L
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T
A
+
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Model of Multiple Lck Visits
This model postulates that repetitive Lck visits are required for TCR triggering. We assumed that an Lck-coupled coreceptor remains
at the TCR/pMHC complex just long enough to enable a single phosphorylation of the TCRz or a recruited ZAP70 molecule. Thus,
accumulation of n Lck visits within the dwell time of TCR/pMHC engagement would eventually lead to the TCR triggering. This model
can be combined with the signal duration model, where the magnitude of the induced TCR response (R) is expressed as a number of
triggered and occupied TCRs in equilibrium:
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or with the serial triggeringmodel, where themagnitude of the induced TCR response (R) is expressed as a number of TCRs triggered
during a time interval:
R=
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Figure S1. SPR Affinity Measurements, Related to Figure 1
(A) Relative frequency of CD8aa and CD8ab thymocytes in B3K508 FTOCs (see Figure 1A). Mean ± range, n = 2. CD8aa cells appeared under conditions of
negative selection and thus, probably represent a nonconventional innate-like T cell lineage (Yamagata et al., 2004). In contrast, a population of CD8ab SPs were
generated in FTOCs exposed to positive selecting ligands; these cells are either immature single positive thymocytes, a transitional stage between double
negative and double positive cells or a population of thymocytes undergoing an atypical positive selection fate; this has been previously described for thymocytes
expressing another MHCII-restricted TCR, 5C.C7 (Yamagata et al., 2004).
(B and C) Ten serial dilutions of OT-I TCR were measured in multiple experiments using different TCR constructs and experimental setups. Representative data
from these experiments are plotted and the mean KD ± SD was calculated. To calculate background binding, OT-I TCR, or H2-K
b–OVA was also injected over a
negative control sample that was subtracted from the experimental data. (Left panel) OT-I TCR with a leucine zipper at the C terminus binding to immobilized H2-
Kb–OVA. (Middle panel) OT-I TCR with a human C terminus binding to immobilized H2-Kb–OVA. (Right panel) H2-Kb–OVA binding to biotin tagged immobilized
OT-I TCR. Two different preparations of H2-Kb-OVA from two different labs gave similar results (EP and AKS).
(D) Ten serial dilutions of OT-I TCRwith C-terminal leucine zipper weremeasured inmultiple experiments using different Kb-OVA peptide variants. MeanKD values
±SDwere calculated and are indicated in the table. NB, not binding. ND, not determined. Our SPR affinitymeasurements of the interaction betweenOT-I TCRand
Kb-OVA or Kb-OVA-derived APLs showedmuch higher KD values and amore pronounced difference between strong and weak ligands than previously published
SPR data on the same TCR (Alam et al., 1999; Rosette et al., 2001). While Alam et al. (1999) determined the KD of OT-I/H-2K
b-OVA and OT-I/H-2Kb-E1 (very weak
ligand) to be 6 mM and 20 mM, respectively, our measurements showed KD !50 mM for Kb-OVA and > 1 mM for ligands even more potent than Kb-E1. We
measured two different H-2Kb-OVA preparations produced in two labs and two different OT-I TCR constructs that were heterodimerized using a non-native
disulphide bond or a leucine zipper. In different experiments, the soluble TCRswere used as analyte or bait ligand. All experiments produced similar results. As the
previous report showed an unexpected decrease in binding dynamics at higher temperature, these data might have been influenced by protein aggregation. The
measurements determined in this work correspond more closely with the distribution of antigen potencies of the various OT-I ligands (Daniels et al., 2006). As the
previously published data have been frequently used for modeling of the TCR response and for arguing against the relevance of SPR measurements in studying
TCR-pMHC interactions, the affinities measured here may resolve some of the discrepancies in the literature.
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Figure S2. Determining Coreceptor-Lck Coupling, Related to Figure 2
(A) Sorted preselection CD3low DP thymocytes from B6mice were analyzed for CD4, CD8a, and TCRb expression levels. Purity of DP thymocytes (left panel) and
TCR levels on sorted DP thymocytes compared to unsorted thymocytes (right panel) are shown.
(B) Mean percentage ± SD of Lck-coupled CD4 molecules in B3K506 Rag1!/! I-A!/!, B3K508 Rag1!/! I-A!/!, and sorted polyclonal DP TCRlow thymocytes is
shown (n = 2–5).
(C) CD8WT and CD8.4 OT-I DP thymocytes were stained with antibodies to CD4, CD8a, and TCRb. Percentage of DP thymocytes (left panel) and TCR levels on
pre-selection DP thymocytes (right panel) are shown.
(D) On cell dwell times of Q4R7monomer on CD8.4 OT-I DP thymocytes were measured by single molecule microscopy and fitted using a one phase exponential
decay curve; t1/2 and R-square values are shown. t1/2 on CD8WT (Figure 1E) and CD8.4 OT-I DP thymocytes are similar.
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Figure S3. CD8.4 Enhances Proximal Signaling in OTI Thymocytes, Related to Figure 4
Thymocytes from CD8WT and CD8.4 OTI Rag2!/!b2 m!/!mice were stimulated with 100 nM Kb-OVA, Kb-Q4R7, or Kb-Q4H7 tetramers or left unstimulated (ns).
(A) Zeta chain phosphorylation was analyzed by flow cytometry. A representative experiment from a total of 6 is shown.
(B) Total phosphorylation of VAV, SLP76, and LATwas analyzed by probing whole cell lysates withmouse anti-pTyr antibody (green) and rabbit antibodies to VAV,
SLP76, LAT, and actin (red) by western blotting. A representative experiment from a total of 4 is shown.
(C) The phosphorylation of specific phosphorylation site was analyzed by probing whole cell lysates with antibodies to LAT pY191, ZAP70 pY319, and Erk pT202/
Y204 by western blotting. Total ZAP70, LAT, and Erk served as the respective loading controls. A representative experiment from a total of 4 is shown.
(D) Tetramer induced increase of Erk1 (at 90 s), ZAP70, LAT, VAV, and SLP76 (at 30 s) phosphorylation was calculated by subtracting normalized basal level of
phosphorylation from the values induced following tetramer stimulation (Figure 4B–4G). For each phosphoprotein, the average ratio of the induced phosphor-
ylation (determined from 4 experiments) observed in CD8.4 and CD8WT thymocytes was calculated (CD8.4/CD8WT). To obtain a broader view of the differences
in early signaling intermediates, the ratios for the induction of the various phosphoproteins were pooled; from these pooled values, the mean and SEM were
plotted. Statistical significance was tested using Student’s t test (2 tailed, unequal variance).
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Figure S4. Gating Strategy, Related to Figure 5
CD8WT and CD8.4 OT-I Rag2!/! b2 m!/! thymocytes were incubated with peptide loaded APCs (T2-Kb cells) for 24 hr and stained with antibodies to CD4, CD8,
and CD69. DP thymocytes were gated using FSClowSSClow/CD4+CD8+. Individual gates are shown.
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Figure S5. Parameters Relevant to Coreceptor Exchange, Related to Figure 6
(A) Sorted preselection polyclonal TCRblow DP thymocytes and control cells (peripheral B cells) were stained with saturating concentration of PE-conjugated
antibodies to CD4, CD8a, or CD3 and analyzed by flow cytometry together with PE calibration beads. Fluorescence signals from stained thymocytes, negative
control (representative negative control for CD3 staining) and calibration beads are shown. The number of mean equivalent soluble PE molecules (MEPE) is
indicated for each peak of the PE calibration beads.
(B) Quantification of the number of TCR, CD8, and CD4 molecules per cell (mean number ± SD from 3 experiments) expressed on polyclonal sorted preselection
DP thymocytes (B6) as well as CD8WT and CD8.4 OT-I Rag2!/! b2 m!/! thymocytes.
(C) Fluorescence recovery after photobleaching (FRAP) CD8b-YFP and TCRz-CFP in OT-I hybridoma cell line was performed using an Olympus IX81 inverted
microscope. Mean normalized fluorescence recovery ± SD (n = 6 for CD8b, n = 7 for TCRz). The points were fitted with an exponential equation y = a3 (1-e^(-K3
x)). Calculated diffusion coefficients are shown.
(D) Probability of various states in the Markov chain model. TM (free TCR-pMHC), TM:C (TCR-pMHC complexed with an Lck-free coreceptor), and TM:LC (TCR-
pMHC complexed with an Lck-bound coreceptor) states are shown. The states TM+C and TM+LC (TCR-pMHC in a close proximity of an Lck-free or Lck-bound
coreceptor, respectively) are very rare (under the resolution of the y axis).
(E) OT-I preselection thymocytes were incubated with 100 nM monomeric Kb-OVA Qdots or Kb-E1 Qdots in PBS/5% FCS at 4"C for 2 hr to establish binding
equilibrium. Subsequently, the cells were diluted 100x with the staining buffer with or without antiCD8b (clone 53.5.8, Biolegend) and/or antiH2-Kb (clone Y3)
antibodies (10 mg/ml). The antiH2-Kb antibody was used to prevent antigen rebinding. The decrease of Qdot fluorescence intensity was monitored by flow
cytometry at 0"C in real time. Kb-E1 Qdots monomers that have undetectable binding to OT-I TCRwere used to determine baseline fluorescence signal. Blocking
free CD8 rapidly accelerated the release of antigen from the thymocytes, providing experimental evidence for the cycling of coreceptors at the TCR-pMHC
complex, as assumed by our Markov chain model. In contrast, preventing of rebinding of monomers to the thymocytes using anti-H2-Kb antibody had only a
modest effect (compare solid and dashed lines). This showed that the effects of CD8 blocking cannot be explained by inhibition of new thymocyte-pMHC in-
teractions due to antigen rebinding. Data were fitted with a one phase exponential decay function.
(F) Quantifying the effect of CD8 blocking on the dissociation of prebound Kb-OVA and Kb-Q4R7 monomers from OT-I T cells. Mean ± SEM n = 2–5. Statistical
significance was tested using Student’s t test (unequal variance, 2 tailed).
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Figure S6. Four Models of TCR Triggering, Related to Figure 7
Graphs show the TCR signal intensity as a function of number of cognate ligands at the thymocyte/APC interface for different ligands (kon = 0.1 mm
2s-1, t1/2 varied).
(A) ‘Lck come&stay/signal duration model’ as in Figure 7Awith x axis scaled up to show the effect of increasing antigen concentration to non-physiological levels.
(B) ‘Lck come&stay/serial triggering model’ for CD8WT OT-I Rag2!/! b2 m!/! and CD8.4 OT-I Rag2!/! b2 m!/! thymocytes.
(C) ‘Multiple Lck visits/signal duration model’ and ‘Multiple Lck visits/serial triggering model’ for CD8WT OT-I Rag2!/! b2 m!/! thymocytes.
See Extended Experimental Procedures.
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